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ABSTRACT  
 
There is increasing evidence that the aberrant expression of cancer-testis (CT) antigens - a family of ca. 
150 proteins that are both autoimmunogenic and mainly restricted to tumours in various types of 
human cancers - makes them attractive immunotherapy targets, as well as possible cancer diagnostic 
markers.  
We carried out a retrospective serological study of primary and secondary autoimmune responses of 
various cohorts of cancer patients prior to and/or following a variety of distinct treatments 
(chemotherapy, radiotherapy and immunotherapy), using a large number of archived human serum 
samples.  Our goals were to develop and validate a novel cancer-testis and -associated antigen 
microarray platform and to then explore its utility and general applicability in the cancer immunology 
field. In addition, we sought to cross-correlate our protein microarray data from specific cohorts with in 
vitro T-cell re-stimulation assays for a selected subset of patients. Furthermore, as a means of 
determining the biological significance of our protein microarray data, we also collected clinical patient 
data where possible.   
The underlying hypothesis of our study was that there were measurable differences in autoantibody 
repertoires towards tumour-specific and –associated antigens between pre- and post-treated cancer 
patient samples (using various trial therapies), potentially augmented by prior chemo- or radiotherapy, 
which would correlate with likelihood of response of individual patients to a given therapeutic 
treatment – including those treatments that aim to generate T-cell responses – and which would also 
correlate with the nature and extent of individual patient responses to treatment.  
Amongst the four cohorts with acceptable patient numbers and recommended achieved statistical 
power, we were able to detect abundant autoantibody titres towards 1) NY-ESO-1 and MAGEB1, 
present in 61% (n = 22/36) and 56% (n = 20/36) of all patients in the kinase inhibitor treatment cohort, 
respectively; 2) SILV/gp100 and p53 Q136X, present in 31% (n = 19/62) and 21% (n = 13/62) of all 
patients in the pre- or post-operative chemotherapy/radiotherapy treatment cohort, respectively; 3) 
NY-ESO-1 and CTAG2/LAGE-1b/LAGE-1L, present in 35% (n = 17/48) and 25% (n = 12/48) of all patients 
in the apoptosis inhibitor treatment cohort, respectively; and 4) NY-ESO-1 and CTAG2 present in 49% (n 
= 48/98) and 46% (n = 45/98) of all patients in the variable treatment cohort, respectively. The 
remaining two cohorts did not have the necessary patient numbers or statistical power, and thus the 
findings obtained could not be statistically supported.  
We showed that we were in fact able to measure differences in autoantibody titres towards tumour-
specific and –associated antigens between cancer patients, both within the same cancer type and across 
      iii 
different cancers, and that these oscillated significantly after distinct treatments, thus supporting our 
initial hypothesis. Although these autoantibody levels showed preliminary evidence of correlation with 
associated T-cell and clinical responses across some of the assayed pilot cohorts, larger focussed studies 
using sufficient patient numbers according to an a priori power calculation estimates are required to 
verify significant and clinically applicable findings.   
In conclusion, we showed that our novel cancer-testis and cancer–associated  microarray platform 
represents a sensitive, high-throughput and readily customizable means to detect and quantify the 
presence of large panels of cancer-specific human autoantibodies in serum, obtaining consistently 
robust, high quality and reproducible data, and demonstrating its potential feasibility and inferred 
biological significance. Applications of this tool include potential use in identifying novel diagnostic, 
disease progression, prognostic, treatment resistant and even predictive biomarkers, which could aid in 
the detection and management of cancer. Most importantly, these could lead to the discovery of novel 
cancer therapeutic targets, patient stratification biomarkers prior to treatment, as well as a means to 
monitor cancer patient responses to treatment.  
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1 INTRODUCTION 
1.1 Global cancer epidemiology 
According to the World Health Organization (WHO) 2012 statistics, the ten leading causes of death 
worldwide were ischemic heart disease (7.4 million deaths, 13.2%), stroke (6.7 million deaths, 11.9%), 
chronic obstructive pulmonary disease (3.1 million deaths, COPD) (5.6%), lower respiratory infections 
(3.1 million deaths, 5.5%), trachea, bronchus and lung cancers (1.6 million deaths, 2.9%), HIV/AIDS (1.5 
million deaths, 2.7%), diabetes mellitus (1.5 million deaths, 2.7%), diarrhoeal diseases (1.5 million 
deaths, 2.7%), road injury (1.3 million deaths, 2.2%) and hypertensive heart disease (1.1 million deaths, 
2%), as indicated below in Fig. 1.1 (http://apps.who.int/gho/data/).   
 
 
 
 
 
 
 
 
 2  
Figure 1.1: Top ten leading causes of death worldwide (percentage contribution to all-cause 
mortality). This pie chart indicates the top ten leading causes of death, with each cause indicated by a 
distinct colour and inserted percentage.  
 
 
Although the top four leading causes of death have remained the same during the past decade, trachea, 
bronchus and lung cancer deaths have increased substantially, resulting in respiratory cancers becoming 
the 5th leading cause of death, a position previously occupied by diarrhoeal diseases. However, these 
values only consider the highest mortality-associated cancer type. When assessing the mortality 
contribution of all cancers combined, malignant neoplasms are responsible for 14.7%, with an estimated 
8.2 million deaths in 2012. When assessing overall contribution to all-cause mortality, malignant 
neoplasms are ranked 2nd, following only cardiovascular diseases that have an estimated 17.5 million 
deaths. These statistics clearly indicate that the majority (68%) of the 56 million global deaths recorded 
in 2012 were caused by non-communicable diseases, such as cardiovascular disease, cancers, diabetes 
and chronic lung disease.  
When considering cancer statistics specifically, the latest data from the most relevant, informative and 
up-to-date source (GLOBOCAN database, IARC) (Bray et al. 2013; Ferlay et al. 2015) indicate that it is 
essential to develop strategies aimed at reducing the global cancer burden. As a means of 
understanding how these mortality rates are distributed across each continent, a global mortality map 
based on ASR rates (weighted mean of the age-specific rates) across all cancer types, excluding non-
melanoma skin cancers, for both genders is illustrated in Fig. 1.2.  
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Figure 1.2: Global mortality ASR for all cancers. This figure indicates the global mortality map 
represented in weighted mean of the age-specific rates (ASR) across all cancer types, with exception of 
non-melanoma skin cancers. A red colour gradient indicates increasing rates, from less to more intense, 
respectively, while grey indicates lack of data. 
 
The darkest red areas indicate the regions of highest mortality (≥116.8), which appear to cluster mainly 
within the Asian, European (mainly Eurasia) and African continents. Interestingly, this includes Southern 
Africa, with a mortality ASR of 117.88, due largely to cancers of the lung, oesophagus, colorectal, liver 
and pancreas.  This indicates that, although most research attention in Southern Africa is focused on 
infectious diseases, cancer accounts for concerning high mortality rates (1426 per 100000 population, 
overall age-standardized rates), relative to global statistics.   
Additionally, in 2012 there were 14.1 million new cancer cases reported globally, with 32.6 million 
people living with cancer within 5 years of diagnosis. As a means of understanding whether regions with 
the highest cancer mortality rates were also those with the highest incidence, a global incidence map 
based on ASR rates across all cancer types, excluding non-melanoma skin cancers, including both 
genders is illustrated in Fig. 1.3.  
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Figure 1.3: Global incidence ASR for all cancers. This figure indicates the global incidence map 
represented in weighted mean of the age-specific rates (ASR) across all cancer types, with exception of 
non-melanoma skin cancers. A blue colour gradient indicates increasing rates, from less to more intense, 
respectively, while grey indicates lack of data. 
 
 
When comparing the mortality (Fig. 1.2) and incidence (Fig. 1.3) global maps, it is evident that the 
highest mortality and incidence regions do not overlap, with the highest incidence regions (darkest blue, 
≥242.9) clustering mainly within the American (mainly North America), European and Australian 
continents: all more developed regions.  These global disparities in cancer mortality and incidence are 
most likely due to differential presence of risk factors (modifiable and non-modifiable), screening 
practices, and/or the availability and use of treatment services (Jemal et al. 2011).  
Regarding gender, incidence rates are almost 25% higher in men, with incidence rates of 205 per 100000 
population compared to 165 per 100000 in women. Male rates vary by almost 5-fold across different 
regions globally. Southern Africa specifically, although a high mortality region, was not a high incidence 
one (incidence ASR of 187.09), with cancers of the lung, colorectal, oesophagus, Kaposi sarcoma and 
stomach dominating. These findings indicate that South African mortality rates should be lower, but are 
perhaps elevated as a function of South Africa’s status as a developing country. Hence, it is of interest to 
verify whether mortality and incidence rates vary greatly between developed and developing countries. 
For this purpose, the mortality and incidence rates across the top 25 cancers for both genders were 
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assessed and grouped by more or less developed regions. The resulting dual multi-bar chart is indicated 
below in Fig. 1.4.  
 
Figure 1.4: Cancer incidence and mortality rates (thousands) by region development. This figure 
indicates a dual multi-bar chart with the incidence and mortality rates represented in thousands across 
the top 25 cancer types for both genders, grouped by more or less developed regions. Blue bars indicate 
incidence rates, whilst red bars indicate mortality rates. 
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Differences amongst both incidence and mortality rates between more and less developed regions are 
evident, with 57% of all new cancer cases and 65% of all cancer deaths occurring in less developed 
regions. When considering gender, less regional variability is seen for mortality rates, with higher rates 
estimated in men (15%) relative to women (8%) in more developed regions. The global cancer 
predictions for 2015 estimate 15.2 million new cases of cancer, with 8.1 million in men and 7.1 million in 
women. Additionally, an estimated 8.9 million cancer deaths are expected in 2015, compared to 8.2 
million deaths in 2012, with 5.1 million of those predicted in men and 3.8 million in women. Predictions 
estimate continued increases in the years to come, more so in low income countries. This further 
highlights the need for cancer research as a means to reducing the cancer burden in such areas and 
worldwide. Intervention measures may include generating awareness of cancer-associated modifiable 
risk factors, such as tobacco use, alcohol consumption, obesity, and lack of physical activity, as well as 
appropriate vaccination (infections agent-related cancers) and vaccine development, treatment, and 
screening programmes, especially in less developed regions (Ferlay et al. 2015).  
1.2 The hallmarks of cancer 
The six hallmarks of cancer describe the biological capabilities that human tumour cells sequentially 
develop during a multistep process (Hanahan & Weinberg 2000; Hanahan & Weinberg 2011). The early 
established hallmarks include 1) sustaining proliferative signalling, 2) evading growth suppressors, 3) 
resisting cell death, 4) enabling replicative immortality, 5) inducing angiogenesis, and 6) activating 
invasion and metastasis, as indicated below in Fig. 1.5. 
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Figure 1.5: An illustration of the originally proposed hallmarks of cancer. This illustration indicates the 
originally proposed hallmarks of cancer which include sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and activating 
invasion and metastasis. [Adapted from (Hanahan & Weinberg 2011).] 
  
 
Cancer cells are able to sustain proliferative signalling, indicating the ability to induce and sustain 
chronic proliferation, by deregulating the previously controlled production and release of growth-
promoting signals, transported mainly by cell-surface receptor binding growth factors, that usually 
control cell number homeostasis to allow normal function and tissue architecture. These growth factors 
usually contain intracellular tyrosine kinase domains, which produce signals that regulate cell cycle 
related progression and cell growth, potentially influencing additional properties like cell survival and 
energy metabolism.  
The ability to evade growth suppressors is another ability of cancer cells, as growth suppressors are 
responsible for negatively regulating cell proliferation, via tumour suppressor genes. These encode for 
example the retinoblastoma-associated and the p53 proteins, which subsequently direct cellular 
proliferation, or activate senescence (a non-proliferative but viable state) or apoptosis (cell death).  
Resisting cell death is perhaps one of the most interesting abilities, as cancer cells are able to achieve a 
multiplicity of apoptosis-avoiding mechanisms, the most common strategy being the loss of p53 tumour 
suppressor function. This acquired ability is said to reflect all apoptosis-inducing signals encountered by 
these cells during their evolution to malignancy.  Most normal cells are only able to undergo a limited 
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number of cell growth and cell division cycles, limitation of which is usually associated with senescence 
and subsequent apoptosis.  
Rarely, cells emerge from a population in apoptosis which exhibit a replicative immortality, another 
characteristic required by cancer cells.  This ability has been linked to the up-regulation of telomerase 
expression or to telomerase maintenance mechanisms, both of which permit cells to maintain 
telomerase DNA length sufficiently to avoid triggering senescence or apoptosis.  
The induction of angiogenesis – the ingrowth of new blood vessels – is a means by which fast-growing 
tumours acquire access to sustenance and waste evacuation. Although angiogenesis is usually only 
ordinarily active during processes such as embryogenesis, wound healing and uterine lining cycling, this 
process becomes abnormally activated during tumour progression.  
Finally, cancer cells are able to activate invasion and metastasis pathways, the least comprehended and 
complex hallmark. This commences with local invasion, followed by transit through the lymphatic or 
haematogenous systems, leading to the formation and growth of micrometastatic lesions into 
macroscopic tumours, a term usually known as colonization (Hanahan & Weinberg 2000; Hanahan & 
Weinberg 2011).  
In addition to the six classical hallmarks described above, recent progress has identified two additional 
emerging ones, 7) reprogramming energy metabolism, and 8) evading immune destruction, as well as 
two enabling characteristics, a) genomic instability and mutation, and b) tumour promoting 
inflammation, as indicated below in Fig. 1.6.    
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Figure 1.6: An illustration of the emerging and enabling hallmarks of cancer. This illustration indicates 
the most recently updated version of the hallmarks of cancer, which now include the emerging and 
enabling hallmarks. [Adapted from (Hanahan & Weinberg 2011).] 
 
 
The acquisition of the classical hallmarks is believed to be dependent on enabling characteristics, such as 
genome instability and mutation. Genome maintenance and repair defects are selectively beneficial for 
tumour progression, accelerating the rate at which developing premalignant cells are able to 
accumulate useful genotypes, thus enabling cancer. Tumour-promoting inflammation is able to enhance 
tumourigenesis and progression, and thus permit the acquisition of hallmark capabilities. In regards to 
emerging hallmarks, reprogramming energy metabolism has shown to be present in cancer cells to the 
equivalent degree of many other cancer-associated traits. The ability of cancer cells to make 
adjustments in energy metabolism is a function of the deregulated control of cell proliferation which 
requires additional energy to fuel cell growth and division. Additionally, evading immune destruction 
appears to be another emerging hallmark and whilst demonstrations of anti-tumour immunity as a 
barrier to tumour formation and progression are still underdeveloped, there are several well-known 
anti-cancer and cancer-permissive mechanisms (Hanahan & Weinberg 2011).  
Hopefully, the full molecular understanding of these key hallmarks will enable a more specific focus on 
the discovery of novel cancer therapeutics to assist in the eradication of the global burden that is cancer.   
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1.3 Cancer diagnosis and treatment 
Cancer may be found early either through regular screening of asymptomatic individuals, process 
facilitated by the existence of cancer type-specific tests (e.g. clinical breast examination and 
mammography for breast cancer screening) and access to the appropriate facilities, or through early 
detection of symptomatic individuals, that is aided by increased awareness of typical cancer signs and 
symptoms (e.g. significant rapid growth of a new mole above 5 mm for suspected melanoma or non-
melanoma skin cancers). Although early detection of cancer is advantageous, because these precursor 
stages when treatment are most successful, this only holds true when linked to effective treatment. It is 
essential that an accurate diagnosis is made, and this may be attained by use of clinical assessment and 
diagnostic testing, such as imaging, histopathology and cytology.  When a suspicious lesion is found, a 
tissue biopsy (core, excisional or subtotal) is commonly performed to assess malignancy. Only once a 
malignant diagnosis is confirmed, can the extent of cancer spread (staging) be investigated, which will 
facilitate treatment planning and the determination of a prognosis (World Health Organization 2002). 
The tumour, node, metastasis staging system (TNM), is one of the most commonly used staging systems, 
and classifies cancer by the size of the primary tumour (T), the absence or presence and extent of 
regional lymph node metastasis (N) and the absence or presence of distant metastasis (M). The use of 
numerical subsets of the TNM components indicates the progressive extent of the malignant disease 
(Edge & Byrd 2010). 
Once an accurate cancer diagnosis and staging is obtained, therapeutic planning can occur with the aim 
to cure, prolong life or improve quality of life of these individuals, depending on the extent of disease. 
There are different types of treatment for patients with cancer, including some that are currently in use 
and are considered to be standard, and others that are in the process of being tested in clinical trials. 
The primary treatment for most cancers at all clinical stages is surgery, when possible, which usually 
includes either partial to total resection of the malignant lesion(s). Additional treatment options include 
chemotherapy and radiotherapy. Chemotherapy aims to stop cancer cell growth, either by inducing 
apoptosis or by inhibiting cell division, whilst radiotherapy uses high-energy x-rays or other types of 
radiation to kill cancer cells or to prevent tumours from spreading. Chemotherapy can be administered 
systemically or regionally, and radiotherapy can be administered externally or internally, depending on 
the type and stage of cancer being treated. Systemic chemotherapy (e.g. dacarbazine for the treatment 
of malignant melanoma) is administered orally or is injected into a vein or muscle, and the drugs enter 
the bloodstream and reach cancer cells throughout the body (Blank et al. 2011). On the other hand, 
regional chemotherapy (e.g. intrathecal administration of cytotoxic chemotherapy for the treatment of 
meningeal leukaemia) is directed solely at the organ or body cavity where the cancer is present, which 
limits negative effects on healthy cells and tissue (Kufe et al. 2003). External radiotherapy (e.g. intensity 
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modulated radiation therapy (IMRT) for the treatment of colorectal cancer) consists of localising 
radiation toward the cancer location, whilst internal radiotherapy (e.g. microspheres containing the β-
emitter yttreium-90 for the treatment of metastatic non-resectable liver tumours) uses radioactive 
substances which are injected directly into or near the cancer (Stubbs et al. 2001) 
(www.ncbi.nlm.nih.gov/pubmedhealth).   
Additional and more recently developed treatment options include biological and targeted therapies. 
Biological therapy, also known as immunotherapy, focuses on the patient’s immune system to fight the 
cancer, utilising naturally occurring endogenous and exogenous substances, as well as chemically 
synthesized substances, which boost, direct or restore the body’s natural defences against cancer. This 
therapy is one of the main focal points of our study, as we will assess the effects of immunotherapy on 
the immune system, amongst other experimental treatments. Targeted therapy, on the other hand, 
uses drugs or other substances to identify and attack specific cancer cells without harming normal cells 
(www.ncbi.nlm.nih.gov/pubmedhealth). Several immunotherapies in use and in development consist of 
attempts to manipulate the patient’s immune system, as a means to activate anti-tumour immunity, 
with the objective of improving currently available cancer treatments by increasing their efficacy and 
reducing their toxicity (Dougan & Dranoff 2009). The most commonly used and researched form of 
targeted therapy is monoclonal antibody therapy, which consists of antibodies which identify and attach 
to cell-surface markers on cancer cells (e.g. cetuximab (targets epidermal growth factor receptor - EGFR), 
for the treatment of colorectal cancer; ipilimumab (targets cytotoxic T-lymphocyte-associated protein 4 
- CTLA-4) and pembrolizumab/nivolumab (targets programmed death-1 receptor - PD-1) for the 
treatment of malignant melanoma) and therefore either kill cancer cells, or inhibit their growth and 
prevent spreading (www.ncbi.nlm.nih.gov/pubmedhealth) (Scott et al. 2012).  
1.4 Cancer immunology 
Both the innate and more specific adaptive immune responses are involved in targeting cancer. 
Components of the innate immune response relative to cancer include soluble factors, such as 
complement proteins, and cellular effectors, such as natural killer (NK) cells, dendritic cells (DCs), 
macrophages, mast cells and granulocytes (neutrophils, eosinophils, and basophils); whilst those of the 
adaptive immune response include B lymphocytes (B-cells) and T lymphocytes (T-cells), which include 
cytotoxic T-cells (CTLs), helper T-cells (Th), suppressor T-cells (Tsupp) or regulatory T-cells (Tregs), and 
natural killer T-cells (NKTs), amongst others (see Fig. 1.7). Specific steps in an immune response include 
antigen presentation and lymphocyte activation, as well as various soluble effector molecules, e.g. 
cytokines such as interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), transforming 
growth factor-β (TGFβ), and colony stimulating factors (CSFs). Immune responses have both humoral 
 12  
and cell-mediated components, for example via antibodies or direct lymphocyte contact, respectively 
(Kufe et al. 2003). 
 
Figure 1.7: Illustration of the main components of the immune response. This illustration indicates the 
main components of the innate and adaptive immune response, and includes visual representations of 
each of these. [Adapted from (Dranoff 2004).] 
 
 
NK cells, particularly important in anti-tumour responses, express two major classes of inhibitory 
receptors for major histocompatibility complex (MHC, or ‘self’) molecules and can recognize cells that 
fail to express MHC class I molecules as abnormal. NK cells are then activated in response to these 
tumour cells, a process which is known as ‘missing-self’ triggering of NK cell activation (see Fig. 1.8) 
(Vivier et al. 2012). They use a number of surface receptors to identify their targets – including tumour 
cells – which they then lyse largely via the perforins/granzymes pathway or via apoptosis-inducing 
ligands. More specifically, NK cells secrete IFN-γ, which aid the killing of tumour cells by 1) inhibiting 
tumour-cell proliferation, 2) enhancing tumour-cell apoptosis, 3) improving tumour antigen 
presentation, and 4) inhibiting angiogenesis (Dranoff 2004).   
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Figure 1.8: Immune recognition of tumour cells by NK cells. This illustration indicates a visual 
representation of NK activation commonly referred to a ‘missing-self’ triggering, indicating immune 
recognition of a tumour cell and subsequent release of cytokines and cytotoxic mediators. [Adapted 
from (Vivier et al. 2012).] 
 
 
DCs, on the other hand, are antigen-presenting cells (APCs), whose role is to take up, process and 
present antigenic peptides to cognate T-cells in the regional lymph nodes in order to activate them (see 
Fig. 1.9). Therefore, APCs play a pivotal role in the induction of functional activity of helper T-cells, and 
are seen as the interface between the innate and adaptive branches of the immune response. 
Macrophages – which are phagocytic cells – remove particulate antigens, participate in the 
inflammatory and healing response, and can lyse tumours by producing nitric oxide and reactive oxygen 
species.  
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Figure 1.9: Immune recognition of tumour cells by DC-activated T-cells. This illustration indicates a 
visual representation of the immune recognition of tumour cells by DC-activated T-cells, indicating 
specifically each step of how the adaptive immune system responds to tumour antigens inside cells.  
[Adapted from (Tindle 2002).] 
 
 
Lymphocytes are responsible for the specific immune recognition of pathogens, and thus for adaptive 
immune responses. All lymphocytes are derived from bone-marrow stem cells, as are cells of the innate 
system, but whilst T-cells then mature in the thymus, B-cells continue to develop in the bone marrow. 
Both B- and T-cells encode surface receptors specific to particular cognate antigens. Having recognized 
this antigen presented by an APC, the B-cell clonally multiplies and differentiates into plasma cells, 
which produce large amounts of the receptor molecule in a soluble form (antibodies) that can be 
secreted and bind to the original activating antigen. There are several different lineages of T-cell, and 
each has a variety of functions. Helper T-cells, for instance, interact with mononuclear phagocytes and 
help destroy intracellular pathogens, while cytotoxic T-cells are responsible for the destruction of host 
cells infected by intracellular pathogens. Although T-cells recognize antigens via their T-cell antigen 
receptors (TCR), this can only occur when these receptors are presented on the surface of MHC 
molecules, i.e. by APCs. T-cells generate their effects either by releasing cytokines that signal other cells, 
or by direct cell-cell interaction (Roitt et al. 2001). More specifically, antibodies are generally known as 
immunoglobulins (Ig), and are one of the most abundant protein constituents present in the blood. 
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These are composed of five different classes - IgA, IgD, IgE, IgG and IgM – which differ in biological 
features, structure, target specificity and distribution. Amongst these, IgG is the major class produced in 
large amounts during secondary immune responses. Numerous forms of antibodies are produced 
exclusively by B-cells, each with a distinct antigen-binding site and associated amino acid sequence. 
Immunoglobulins may be characterized as either soluble antibodies or as membrane-bound antibodies, 
with the production of secreted antibodies and surface-bound B-cell receptors being regulated via 
alternative splicing. An  antibody molecule is usually Y-shaped, with two identical antigen-binding sites 
at the upper ends of the Y with the ability to cross-link antigens and form antibody-antigen complexes, 
and with binding sites for complement components and cell-surface receptors on the lower end of the Y 
(Fig. 1.10) (Alberts et al. 2002).  
 
Figure 1.10: A schematic diagram representing a typical antibody molecule composed of four 
polypeptide chains - two identical heavy chains and two identical light chains. The two identical 
antigen-binding sites are each formed by a N-terminal region of a light chain and a N-terminal region of 
a heavy chain. The tail (Fc) and hinge sites are formed by two heavy chains.  [Adapted from (Alberts et 
al. 2002).] 
 
 
General antibody functions may include neutralisation, agglutination, complement activation, 
opsonisation, and antibody-dependent NK-mediated cytotoxicity. Additionally, the release of early 
soluble inflammatory mediators, such as eicosanoids and histamine, is mediated by activating Fc 
receptor signalling. Furthermore, optimal helper T-cell memory responses require Fc receptor-mediated 
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antibody function for T-cell activation, as there is a decreased memory response in the absence of a 
functional antibody response. B-cells are able to impact T-cell activity by functioning as APCs, secreting 
cytokines such as IFN-γ and IL-10, and thus influencing the cytokine production of other cells (such as 
Tregs). Conversely, B-cells require the aid of helper T-cells activated by the same cognate antigen to 
become adequately activated. When a naive B-cell receives an initial activating signal, its surface 
receptor cross-links with an antigen, which results in antigen ingestion, processing and display by the B-
cell, as well as a migration towards an adjacent T-cell area. However when receiving an additional 
activating signal, the immobilised antigen on its surface binds with a helper T-cell, which results in B-cell 
activation and proliferation, thus forming plasma cells (also known as effector B-cells) for antibody 
production (Roitt et al. 2001). Intuitively, the regulation of antibody production depends on the 
production and maintenance of these plasma cells, which are the long-lived mediators of lasting 
humoral immunity. Plasmablasts (immature rapidly produced plasma cells) on the other hand 
correspond to the short-lived effector cells of the early antibody response. Numerous cellular and 
molecular regulatory mechanisms control this subset of the immune response. Nonetheless, the process 
of B-cell differentiation is controlled by a central gene-regulatory network, and can be modified by 
potential environmental stimuli (Nutt et al. 2015).  
In regards to cancer, there are many mechanisms of tumour cell killing by antibodies, the majority of 
which can be grouped into direct tumour cell killing, immune-mediated tumour cell killing, and vascular 
and stromal cell ablation, which are outlined in Fig. 1.11. Direct tumour cell killing can occur in 
numerous ways, such as 1) Elicited by receptor agonist activity - antibody binding to the tumour cell 
surface receptor, which results in activation and apoptosis, 2) Mediated by receptor antagonist activity - 
antibody binding to a cell surface receptor and as a result blocking dimerization, kinase activation and 
downstream signalling, leading to reduced proliferation and apoptosis, 3) Triggered by antibody binding 
to a specific enzyme, which can lead to neutralization, signalling abrogation and eventually cell death, 
and 4) Drug delivery to tumour cells using conjugated antibodies. Immune-mediated tumour cell killing 
can also occur in a variety of ways, such as 1) Induction of phagocytosis, 2) Complement activation, 3) 
Antibody-dependent cellular cytotoxicity (ADCC), 4) Tumour targeting by single-chain variable fragment 
(scFv) using genetically modified T-cells, 5) T-cell activation via antibody-mediated cross-presentation of 
antigen to DCs, and 6) Inhibition of T-cell inhibitory receptors, such as CTLA-4. Finally, vascular and 
stromal cell ablation can occur via 1) Induction by vasculature receptor antagonism or ligand trapping, 2) 
Inhibition of stromal cells, 3) Toxin delivery to stromal cells, and 4) Toxin delivery to the vasculature 
(Scott et al. 2012).  
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Figure 1.11: Mechanisms of tumour cell killing by antibodies. These illustrations indicate a) Direct 
tumour cell killing; b) Immune-mediated tumour cell killing; and c) Vascular and stromal cell ablation. 
MAC: membrane attack complex; MHC: major histocompatibility complex; NK: natural killer. [Adapted 
from (Scott et al. 2012)] 
 
 
 
Because cancer cells resemble normal host cells in that they display self-MHC, they tend not to be very 
immunogenic. Several factors make it challenging for the immune system to target growing cancers for 
destruction. The literature describes a range of tumour antigens, including tumour-specific antigens 
(TSAs) and tumour-associated antigens (TAAs), but these are typically poorly immunogenic. TSAs (see 
Table 1.1) are unique antigens not found in normal cells that usually result from point mutations in 
genes that are expressed ubiquitously, while TAAs (see Table 1.2) are antigens similar to those found in 
normal cells, but are either modified or produced in greater quantities. Recently, TAAs have been 
further divided into three categories: 1) shared tumour-specific antigens that are expressed in many 
tumours and only in limited normal tissues, 2) differentiation antigens that are expressed in the normal 
tissue of origin of the malignancy, and 3) overexpressed antigens that are expressed across a wide 
variety of normal tissues and overexpressed in tumours (Vigneron et al. 2013). Common examples of 
these tumour antigens are indicated in Tables 1.1 and 1.2, based on the Cancer Immunity Peptide 
Database (www.cancerimmunity.org/peptide).  
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Table 1.1 List of common tumour–specific antigens. This table indicates a selection of common tumour-
specific antigens, and the respective tumour type where they are present [Adapted from the cancer 
immunity peptide database (www.cancerimmunity.org/peptide).] 
Tumour-specific antigens 
Antigen Tumour 
Beta-catenin Melanoma 
BRAF Melanoma 
CDK4 Melanoma 
Elongation factor 2 Lung squamous cell carcinoma 
HLA-A2 Renal cell carcinoma  
K-ras Pancreatic adenocarcinoma 
ME1 Non-small cell lung carcinoma 
Myosin class I Melanoma 
N-ras Melanoma 
p53 Head and neck squamous cell carcinoma 
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Table 1.2 List of common tumour-associated antigens subdivided into shared tumour-specific 
antigens, differentiation antigens and overexpressed antigens. This table indicates a selection of 
common tumour-associated antigens, and the respective tumour type or normal tissue where they are 
present. [Adapted from the cancer immunity peptide database (www.cancerimmunity.org/peptide).] 
Tumour-associated antigens 
Shared tumour-specific antigens Differentiation antigens 
Antigen Antigen Tumour 
BAGE-1 CEA Gut carcinoma 
Cyclin-A1 MART-1/Melan-A Melanoma 
GAGE-1,2,3,4,5,6,7,8 PSA Prostate carcinoma 
LAGE-1/CTAG2 SILV/gp100 Melanoma 
MAGE-A1,A2,A3,A4,A6,A9,A10,A12 Tyrosinase Melanoma 
MAGE-C1,C2 Overexpressed antigens 
Mucin Antigen Normal tissue expression 
NY-ESO-1/LAGE-2 HER-2/neu Ubiquitous (low level) 
SSX-2,4 Cyclin D1 Ubiquitous (low level) 
TAG-1,2 p53 Ubiquitous (low level) 
TRAG-3 Survivin Ubiquitous 
XAGE-1b/GAGED2a VEGF Ubiquitous (low level) 
 
Immune evasion of tumours may occur due to the dysfunction of the immune system, immune 
suppression, cell deletion and immune ignorance, and/or poor immune surveillance. Dysfunction of the 
immune system induced by cancer cells may lead to various immune defects, such as poor DC function 
including antigen presentation, T-cell defects leading to T-cell anergy and resulting in immune evasion 
and loss of T-cell function. Immune suppression occurs when certain enzymes produced by cancer cells 
decrease or increase levels of various cytokines. Cell deletion takes place when developing T-cells 
specific to a tumour antigen are destroyed, thereby preventing an anti-tumour immune response to that 
antigen. Immune ignorance implies that because most cancer cells lack co-stimulatory molecules which 
are present on functional APCs, such as DCs, these cannot activate naive T-cells, either at the site of 
tumourigenesis or via cancer cells/antigens circulating in the spleen (Houghton & Guevara-Patiño 2004). 
Although the immune system may recognize and eliminate the vast majority of emerging cancer lesions 
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via immune surveillance, tumour formation and progression still occurs, indicating that solid tumours 
have either managed to avoid immune detection or have limited the extent  of immunological 
destruction, and thus evading eradication (Kufe et al. 2003; Tabi 2009; Perales et al. 2002; Hanahan & 
Weinberg 2011). In addition to these mechanisms of immune evasion, changes in the expression of MHC 
class I molecules on solid tumours may also affect the recognition of tumour antigen peptides by T-cells, 
which will interfere with the regulation NK cell function, as described above (Garcia-lora et al. 2003). 
Hence, the role of the immune system in resisting or eradicating the formation and progression of 
cancer, from emerging lesions to metastases, is still unknown, with immunoevasion being considered as 
an emerging hallmark, as mentioned above in Section 1.2 (Hanahan & Weinberg 2011).  
Alternatively, tumours may also evade immune responses due to immune tolerance. Immune tolerance 
consists of the failure to generate an immune response towards an antigen, usually due to a lack of 
antigen recognition, and can be subdivided into either ‘self’ tolerance or induced tolerance. ‘Self’ 
tolerance prevents the immune system from attacking its own antigens, and when dysfunctional may 
lead to autoimmune diseases. Alternatively, induced tolerance prevents an immune response against 
external antigens, due to intentional immune manipulation. Immune tolerance may occur towards both 
T-cells and B-cells, and can either be central (within the thymus or bone marrow, respectively) or 
peripheral (outside of the thymus or bone marrow, respectively) (Kimball 1994).  
Central T-cell tolerance occurs before the maturation and circulation of T-cells within the thymus, when 
its receptor is formed, expressed and rearranged on the cell surface. On the other hand, peripheral T-
cell tolerance occurs when mature circulating T-cells are restrained in numbers or in function by 
external antigens that are not present in the thymus. T-cell clonal deletion (negative selection) and 
clonal diversion (Treg differentiation) are the two central tolerance mechanisms, whilst T-cell receptor 
editing or anergy are the two peripheral tolerance mechanisms, which jointly limit the self-reactivity of 
the T-cell repertoire. (Xing & Hogquist 2012). Contrary to T-cells, B-cell tolerance is not as acute, as 
these cannot respond to most antigens without the aid of helper T-cells. Nonetheless, these may also 
become tolerant towards there ‘self’ components during maturation. Central B-cell tolerance occurs 
before the formation and maturation of B-cells within the bone marrow, when its receptor is formed, 
expressed and rearranged on the cell surface. On the other hand, peripheral B-cell tolerance occurs 
when self-reactive B-cells are mediated by the absence of helper T-cells. (Kimball 1994).Of particular 
interest to this Thesis, autoantibodies – potential serum biomarkers in cancer – have the ability to target 
specific TAAs (Shiku et al. 1977; Tan et al. 2009). It is thought that the production of autoantibodies as a 
result of immune surveillance may serve as an early reporter of tumourigenesis, with potential impact 
on disease outcome (Tan 2001; Anderson & LaBaer 2005b). These may be identified or analysed using a 
wide variety of techniques, such as protein microarrays – a high-throughput tool used for the screening 
of immune responses in cancer patients - to identify autoantibody signatures, novel cancer biomarkers 
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for early diagnosis, monitoring of disease progression and response to treatments, and development of 
novel therapeutics (Balboni et al. 2006; Madoz-Gúrpide et al. 2008).  
1.5 Cancer-testis antigens 
The cancer-testis (CT) antigen family are a group of > 90 structurally and functionally unrelated antigens 
usually only expressed in the germ cells in the adult testis or ovary and in the trophoblast of the 
placenta (Scanlan et al. 2002), but which are aberrantly expressed in various cancers in adult somatic 
tissues as a result of disrupted gene regulation. As the testis is an immune-privileged site, aberrant 
expression of these antigens in somatic tissues typically triggers a spontaneous immune response to the 
relevant CT antigen. CT antigens have therefore been exploited as therapeutic tumour vaccines, as well 
as potential prognostic markers in a variety of tumour types (Hunder et al. 2008; Beeton-Kempen et al. 
2014). 
Increasing numbers of clinical trials are evaluating therapeutic cancer vaccines that either target specific 
tumour-associated antigens, such as the CT antigens NY-ESO-1 or MAGEA3, or aim to transiently inhibit 
critical immune check points such as those mediating peripheral tolerance (Ueda et al. 2003). However, 
in many cases, the chronic nature of the disease makes it difficult to gain an early assessment of 
whether an individual patient is generating a therapeutically useful response following vaccination 
(Beeton-Kempen et al. 2014). 
The expression of different CT antigens is known to be associated with many different types of cancer 
(Simpson et al. 2005), but the absence or presence of expression of any one CT antigen is not in itself 
exclusively indicative of any specific cancer (Scanlan et al. 2002). It remains plausible though that 
patterns of CT antigen expression or anti-CT antigen autoantibody titres may prove useful as diagnostic 
markers of specific cancer types or as correlates of disease progression and response to therapy. 
However, to be viable as cancer biomarkers, these signatures should preferably be quantifiable in 
peripheral fluids to avoid unnecessarily invasive treatments and should be highly accurate for diagnostic 
and/or prognostic purposes to allow improved clinical management of patients (Berrade et al. 2011; 
Frank & Hargreaves 2003; Rifai et al. 2006). One way in which this may be achieved, and the particular 
method used in this Thesis, is through the quantitative measurement of correlated anti-CT antigen 
autoantibody signatures – B-cell responses – in serum of cancer patients using protein microarrays  
(Beeton-Kempen et al. 2014). 
1.6 Cancer immunotherapeutics 
Cancer vaccines belong to a class of substances known as biological response modifiers which work by 
stimulating, restoring or beneficially exploiting the immune system’s ability to fight infections and 
 22  
disease. There are two types of cancer vaccines: preventive vaccines, which are intended to prevent 
cancer from developing in healthy people; and therapeutic vaccines, which are intended to treat an 
existing cancer by strengthening the body’s natural defences against the cancer 
(www.ncbi.nlm.nih.gov/pubmedhealth). The ideal therapeutic cancer vaccine should induce a strong 
anti-tumour adaptive immune response (mainly T-cell), and a subsequent clinical response (e.g. solid 
tumour size reduction measured by the response evaluation criteria in solid tumours (RECIST) post-
treatment) in the host, while sparing normal tissue. The two essential factors of a cancer vaccine are 
specificity, such as recognition of a tumour antigen by the T-cell receptor or antibody, and strength of 
the immune response, which is achieved by non-specific or general immunostimulators. The two types 
of molecules that usually boost immunity non-specifically are adjuvants, which are potent but poorly 
understood immunostimulatory agents, and cytokines, which are soluble factors used for signalling by 
immune cells and are often used in conjunction with other treatments (Kufe et al. 2003).  
The different types of therapeutic cancer vaccines include 1) tumour antigen-based vaccines, such as 
tumour antigen DNA vaccines and tumour antigen synthetic peptide vaccines; 2) monoclonal antibody-
based vaccines, such as idiotype vaccines; and 3) cell-based immunotherapy, such as tumour cell-based 
vaccines, DC-based vaccines, T-cell-based vaccines and NK cell-based therapy 
(www.ncbi.nlm.nih.gov/pubmedhealth/)(Kufe et al. 2003).  
Although many DNA vaccines (e.g. transcription factor Fos-related antigen-1 (Fra-1) DNA vaccine (Xiang 
et al. 2008)) initially showed potential in animal models by suppressing tumour growth and metastasis 
through the induction of cell-mediated immune responses, early clinical trials have been disappointing 
with low magnitudes of response (Liu 2011; Schlom 2012). Similarly to DNA vaccines, clinical trials 
assessing idiotype vaccines (e.g. clonal immunoglobulin idiotype, (Bendandi 2009)) have not achieved 
the desired outcomes, although initially showing clinical benefit.  
Tumour antigen synthetic peptide vaccines (e.g. SILV/gp100 (Schwartzentruber et al. 2011), and 
HER2/neu (Disis et al. 2009) peptide vaccines), on the other hand, have shown high magnitudes of 
response upon reaching the clinical trial setting. The SILV/gp100 modified peptide vaccine in particular, 
in combination with IL-2, has shown  improved overall clinical responses and increased survival rates 
across a vast majority of advanced melanoma patients (Schwartzentruber et al. 2011).  
Although the above-mentioned peptide vaccines have several advantages, when considering tumour 
cell-based vaccines, a large meta-analysis across 173 clinical trials has reported that the latter have 
higher response rates (Neller et al. 2008). This increase is most likely related to tumour cells providing a 
broad pool of antigens that may potentially trigger T-cell (CD4+ and CD8+) responses, as well as tumour-
reactive antibodies. However, even though this vaccine type has shown higher response rates, these are 
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still relatively low, and current studies are attempting to increase overall tumour cell vaccine efficacy 
(Andersen & Ohlfest 2012).  
The remaining cell-based vaccines include three distinct cell types – DCs, T-cells and NK cells – all crucial 
players in the immune response towards tumours. DC-based vaccines (e.g. monocyte-derived DC 
vaccine, (Lesterhuis et al. 2011)) have shown to be safe and immune-response inducing across a 
substantial number of cancer patients, although with limited clinical efficacy, an issue that is currently 
being researched by attempts to optimize DC-specific vaccine parameters. T-cell-based vaccines may 
consist in adoptively transferring patient-derived natural occurring or engineered T-cells – after a 
selective in vitro isolation, expansion and activation – back into patients, to effectively eradicate 
tumours by targeting expressed tumour antigens and associated vasculature (Restifo et al. 2012). 
Finally, NK-cell based therapy functions similarly to that described of T-cells, where patient-derived NK 
cells may be isolated from a healthy donor, activated and expanded in vitro, and then infused into the 
cancer patient, as a means of promoting anti-tumour function (Vivier et al. 2012). The possibility of 
editing a cancer patient’s immune system to confer it the ability of triggering a desired substantial anti-
tumour response is one of great interest and relevance, highlighting the true potential of these 
therapeutic cancer vaccines.  
Recent studies indicate that current challenges in designing effective cancer therapeutics targeted at the 
immune system are as follows: antigens need to be specifically selected based on ideal characteristics 
(e.g.  restricted tissue distribution to tumours and relevant to tumour progression based on the timing 
of their cell surface display); selected antigens should to be combined with adjuvants that may 
potentially enhance their immunogenicity and yield strong immune responses; vaccination should be 
timed to anticipate the development of regulatory suppressive immune mechanisms; and specific 
antagonists may be required to enhance immune outcomes, in the advent of suppressive regulatory 
mechanisms arising (Cebon 2010).  
CT antigens are therefore intuitively attractive targets for antigen-specific immunotherapy since they 
are distributed across cancers of many histological types, are immunogenic and show restricted 
expression profiles. As mentioned above (Section 1.5), increasing numbers of clinical trials are 
evaluating tumour-associated CT antigens – such as NY-ESO-1 and MAGEA3 – as potential therapeutic 
vaccines across a variety of different cancer types (Whitehurst 2014).  
In regards to the most commonly reported NY-ESO-1 vaccine, full-length recombinant NY-ESO-1 protein 
formulated with ISCOMATRIX adjuvant, clinical trials have reported the generation of immune 
responses, both humoral and T-cell mediated, as well as reduced risk of disease relapse in melanoma 
patients. However, although clinical responses are obtained in patients with residual disease, this is not 
the case for advanced melanoma patients, which may be due to an overall tumour-induced systemic 
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immune suppression, with a clear correlation between disease progression and an elevated proportion 
of  Tregs in the blood (Nicholaou et al. 2009). Tregs – a T-cell subtype that releases suppressive 
cytokines and serves to silence immune responses – have recently been reported to play a key role in 
the suppression of anti-tumour T-cell immunity, with animal studies showing that when inhibiting or 
removing Tregs an increase in tumour clearance and survival is seen, thus showing that tumours may 
have the ability to create a local immunosuppressive environment by selective recruitment and/or 
expansion of Tregs (Zou 2006; Beyer & Schultze 2006). Hence, clinical trials targeting advanced cancers 
with known well established immunosuppressive networks in place have recently been adapted to 
include a Treg specific cytotoxic agent, as a means of depleting Tregs and bypassing this issue. However, 
these findings also indicate that future vaccine development efforts should rather be directed towards 
early stages of disease, as patient’s with lower tumour volume and extent of immune suppression are 
most likely to receive treatment benefit (Nicholaou et al. 2009).  
MAGEA3-based vaccines, recombinant MAGEA3 protein (RecMAGE A3, MAGRIT trial), have been mainly 
aimed towards melanoma (Kruit et al. 2008) and non-small cell lung cancer (Vansteenkiste et al. 2007). 
In regards to melanoma, MAGEA3 trials have shown T-cell and antibody responses, as well as clinical 
responses (tumour regressions) with correlative gene expression signatures (Ulloa-Montoya et al. 2013). 
Hence, current related trials are being conducted in advanced melanomas (Drake et al. 2014). In non-
small cell lung cancer, the largest phase III trial in this cancer type is currently ongoing and investigating 
the efficacy of relapse prevention of a MAGEA3-based vaccine (Peled et al. 2009). Although results of 
this trial are not yet available, initial trials have demonstrated induction of specific T-cell responses and 
tumour growth inhibition.  
Hence, although current CT antigen vaccines can induce strong immune responses (usually cellular, but 
ideally humoral responses too), conclusive evidence of clinical benefit has been somewhat elusive to 
date. The correlation between an elicited immune response and a succeeding clinical one may assist in 
comprehending the causes of tumour responses and the several mechanisms of tumour escape. Hence, 
patient stratification prior to vaccination based on disease stage, antigen expression or immune profiles 
have been suggested as a means to improve clinical outcomes (Cebon 2010). Additionally, a large 
number of studies continue to investigate the therapeutic applicability of additional CT antigens across 
distinct cancer types, whilst others explore different avenues including agents that may block immune 
checkpoints, such as CTLA-4 and PD-1 (programmed death-1) (Drake et al. 2014).  
To be introduced as a new cancer treatment option and to be approved by the U.S. Food and Drug 
Administration body (FDA), a vaccine must fundamentally be effective (Roitt et al. 2001). Patient 
stratification strategies might be essential to improve the potential effectiveness of a therapeutic 
vaccine, which could lead in turn to an increased probability of gaining regulatory approval in due 
course. Furthermore, recent studies have shown that to obtain improved clinical outcomes during 
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cancer treatment, effective combination therapies should be used (Vanneman & Dranoff 2012). 
Potential combinations may include surgery, chemotherapy or targeted therapies with immunotherapy. 
This finding is supported by evidence that anti-tumour immunity is essential to assure clinical response 
to conventional cancer treatments. For example, a dense amount of tumour infiltrating lymphocytes 
(TILs) within colorectal cancer tumours revealed a strong correlation with improved chemotherapy 
efficacy and a better prognosis, when compared to patients with smaller infiltrates (Halama et al. 2011). 
It has further been reported that surgical resection of primary tumours has shown to reverse in tumour-
derived immunosuppression, indicating that for maximal efficacy immunotherapy should only be 
administered post-operatively (Danna et al. 2004). In regards to the combination of chemotherapy and 
immunotherapy, combining CTLA-4 blockade (ipilimumab) with standard chemotherapy in melanoma 
patients, in a phase II clinical trial setting, resulted in an increase in overall survival rates (Hodi et al. 
2010). Additionally, combining IL-2 and mucin 1 (MUC1) immunotherapy with chemotherapy in 
metastatic non-small cell lung cancer resulted in an increased progression-free survival (Quoix et al. 
2011). When considering the combination of targeted therapies and immunotherapy, a phase I/II clinical 
trial assessed the combination of BRAF inhibitor (vemurafenib) with CTLA-4 (ipilimumab) in patients 
with metastatic melanoma, with the intent of achieving long-lasting responses through immune 
memory induction. This treatment has been shown to affect the immune system by increasing antigen 
expression, such as SILV/gp100 and MART-1/Melan-A, and decreasing tumour secretion of 
immunosuppressive cytokines, resulting in an expected boost in T-cell responses (Boni et al. 2010; 
Sumimoto et al. 2006). Therefore, the promising benefits of combining different cancer therapeutics is 
one of great relevance, indicating that a greater understanding of tumour suppressive mechanisms, 
cancer pathogenesis and protective anti-tumour immunity facilitate the ability to target key molecular 
pathways, and thus increase the likelihood of prolonging patient survival (Vanneman & Dranoff 2012).  
1.7 Cancer biomarkers 
Ideally, a cancer biomarker should have the following characteristics: 1) easy and inexpensive to 
measure to allow easy accessibility in developing countries, 2) measureable in peripheral fluids – such as 
serum – to avoid unnecessarily invasive treatments, and 3) highly accurate for diagnostic and/or 
prognostic purposes to allow improved clinical management of patients (Berrade et al. 2011; Frank & 
Hargreaves 2003; Rifai et al. 2006). However, currently used cancer biomarkers, such as PSA in prostate 
cancer (Prensner et al. 2012) and CEA in colorectal cancer (Nicholson et al. 2014), are not well suited for 
an accurate diagnosis, due to several reported limitations in sensitivity and specificity.  
When considering serum as a target peripheral fluid for cancer diagnosis, the first approach in this 
search would be the identification through serology of a set of candidate serum biomarkers that might 
correlate with disease status. Serological analysis of cancer patient samples could identify and quantify 
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either circulating tumour antigens or autoantibodies to tumour antigens that are aberrantly expressed 
in cancer.  
Of particular interest to this Thesis, the study of autoantibody profiles in cancer patients could lead to 
the discovery of novel biomarkers for early detection of tumours, patient stratification, personalised 
patient treatment, development of improved therapies, and monitoring therapeutic response and 
disease progression (Duarte et al. 2013). This Thesis thus intends to explore the potential of identifying 
novel cancer biomarkers, which could aid in the detection and management of cancer. With use of a 
newly developed proteomic technique, a cancer antigen microarray platform, we aim to comprehend 
and shed light on the interplay between the immune system and tumour responses to treatment, 
including chemotherapy, radiotherapy and immunotherapy. 
1.8 Aims 
1.8.1 Hypothesis 
The underlying hypothesis of this study is that there are measurable differences in autoantibody 
repertoires towards tumour-specific and –associated antigens between pre- and post-treated cancer 
patient samples (using various trial therapies), potentially augmented by prior chemo- or radiotherapy, 
which correlate with likelihood of response of individual patients to a given therapeutic treatment – 
including those treatments that aim to generate T-cell responses – and which would also correlate with 
the nature and extent of individual patient responses to treatment.  
1.8.2 Objectives 
We developed and used novel protein microarrays that contain over 100 cancer antigens to quantify 
broad cancer-related autoantibody profiles in cancer patient serum samples collected pre- and/or post-
chemotherapy, radiotherapy or immunotherapy, the aims being: 
(i)  To identify novel biomarkers that could be used in patient stratification prior to 
chemotherapy/radiotherapy/immunotherapy; 
(ii)  To identify novel biomarkers that could be used in monitoring therapeutic responses in 
patients undergoing chemotherapy/radiotherapy/immunotherapy; 
(iii)  To identify novel diagnostic and/or prognostic biomarkers that could be used in detection 
and management of disease; 
(iv)  To discover whether prior chemo- or radiotherapy significantly altered the pattern of CT 
antigen autoimmune titres , thereby potentially influencing the outcome of any subsequent 
treatment program; 
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(v)  To validate our protein microarray data by conducting sample reproducibility studies; 
(vi)    To correlate our data with patient responder phenotypes; 
(vii)  To correlate our findings to available patient clinical data, with the intent of revealing the 
biological significance and feasibility of our protein microarray platform and generated data. 
1.8.3 Study design 
We carried out a retrospective serological study of primary and secondary autoimmune responses of 
various cohorts of cancer patients prior to and/or following a variety of distinct treatments 
(chemotherapy, radiotherapy and immunotherapy), using a large number of archived human serum 
samples previously collected by the Blackburn Laboratory, our collaborators at the Ludwig institute for 
Cancer Research (LICR, Melbourne, Australia), and our collaborators at the University of Zurich Hospital 
(UZH, Zurich, Switzerland). Our goals were to develop and validate a novel cancer antigen microarray 
platform and to then explore its utility and general applicability in the cancer immunology field. In 
addition, we sought to cross-correlate our protein microarray data from specific cohorts with in vitro T-
cell re-stimulation assays for a selected subset of patients. Furthermore, as a means of determining the 
biological significance of our protein microarray data, we also collected clinical patient data where 
possible.  
This research, which is summarized in a flowchart indicated below in Fig. 1.12, took place in the 
Blackburn Laboratory located in the Division of Medical Biochemistry of the University of Cape Town 
(UCT), the Centre for Proteomic and Genomic Research (CPGR) facilities, the Groote Schuur Hospital 
(GSH), and the Cancer Immunobiology Laboratory (CIBL), located at the LICR. 
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Figure 1.12: Flowchart of study design.  
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2 CLINICAL COHORTS 
2.1 Introduction 
This study included several distinct treatment cohorts, each with a different, unique set of patients in 
either a clinical trial or a standard treatment setting. These cancer treatments include 1) Kinase 
inhibitors (BRAF, BRAF+MEK, BRAF+/-MEK, BRAF/MEK), 2) Pre- or post-operative 
chemotherapy/radiotherapy, 3) Epigenetic modifiers (panobinostat and azacitidine), 4) Apoptosis 
inhibitor (survivin), 5) Internal Radiotherapy (SIRT), and 6) Others. Informed consent was obtained for 
each treatment cohort according to standard clinical trial practice, and our study was conducted after 
review and approval by the Human Research Ethics Committees (UCT HREC 240/2011, UCT HREC 
269/2011). 
The collection of patient clinical information and its addition to experimental data may aid in the 
process of data analysis and interpretation. Demographic information, such as gender and age, could 
provide relevant incidence or prevalence rates, in a disease specific context. Clinical information, such as 
cancer type, stage, treatment undergone and responses thereof, could provide useful details which 
permit grouping of patients into distinct categories and allow for more focused analyses. In conjunction, 
this detailed demographic and clinical information could indicate how homogenous or heterogeneous a 
cohort may be. Consequently, patient cohorts with a great deal of variety amongst them provide 
numerous limitations in the potential data translation.  
For the ability to determine the statistical power of the potential findings of each treatment cohort, i.e. 
the likelihood that a study will detect an effect when there is an effect there to be detected, we 
estimated the need for a minimal sample size of 54 patients. This estimate was generated a priori using 
a size-power calculation (G*Power 3.1.9.2 program, T-test, difference between two dependent means 
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(matched pairs)) with a given probability of error (      ), power (        ) and effect size 
(      ) (Faul et al. 2007; Faul et al. 2009).  
2.2 Methodology 
2.2.1 Kinase Inhibitor cohorts 
The kinase inhibitor treatment cohort included 36 malignant melanoma patients undergoing 1) BRAF 
(dabrafenib, GSK2118436: Study ID 112680; Clinicaltrials.gov Identifier: NCT00880321), 2) Alternative 
BRAF (vemurafenib, RO5185426, Study ID BRIM2/3; Clinicaltrials.gov Identifier: NCT01006980), 3) MEK 
(trametinib, GSK1120212: study ID: MEK113583, Clinicaltrials.gov Identifier: NCT01037127), 4) BRAF + 
MEK (dabrafenib and trametinib, GSK2118436 + GSK1120212: Study ID 113220; Clinicaltrials.gov 
Identifier: NCT01072175), 5) BRAF +/- MEK (dabrafenib and/or trametinib, GSK2118436 +/- 
GSK1120212: Study ID 115306; Clinicaltrials.gov Identifier: NCT01584648) inhibitor treatments. Due to 
limited patient numbers within each four distinct variations of this treatment cohort in regards to 
treatment with BRAF alone (using two distinct BRAF drugs, dabrafenib and vemurafenib), BRAF in 
combination with MEK, or MEK alone, and as a means of obtaining statistically significant data, these 
treatments were joined and treated as a unique cohort of malignant melanoma patients undergoing 
kinase inhibition.  
Serum or plasma was obtained for these patients before (Baseline/D0) and after treatment (Dn), with at 
least one time point post-treatment per patient. This serum or plasma was collected under the 
supervision of our collaborators, Prof. Jonathan Cebon at the Austin Health in Melbourne, and Prof. 
Georgina Long, at the Westmead Hospital in Sydney.  
As part of our ongoing collaboration, a 3-month long research visit was planned and took place at the 
LICR. One of the main objectives of this visit was to obtain access and collect the complete clinical 
profile of the patients included in our cohort from individual patient records. This was possible for all 16 
patients undergoing treatment at the Austin Health, and for all 20 patients being treated at the 
Westmead Hospital.  
2.2.2 Pre- or Post-operative chemotherapy/radiotherapy cohort 
The pre- or post-operative chemotherapy/radiotherapy treatment cohort included 62 colorectal cancer 
patients undergoing chemotherapy/radiotherapy prior- or post-surgical resection of their primary 
tumours.  
Blood samples were previously collected prior to surgical resection of the main tumour(s) by our 
laboratory at the GSH, as part of a local collaboration, and buffy coats with added plasma were 
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prepared. Patients were divided into those who received or did not receive pre-operative 
chemotherapy/radiotherapy. These samples were collected under the supervision of our collaborators, 
Dr. Paul Goldberg at the GSH, and Prof. Raj Ramesar at the Division of Human Genetics, UCT.  
As part of this ongoing collaboration, complete access and collection of clinical profiles of these patients 
was possible.   
2.2.3 Epigenetic Modifier cohort 
The epigenetic modifier treatment cohort included 12 myelodysplasia patients undergoing a 
combination of panobinostat (histone deacetylase (HDAC) inhibitor) with azacitidine treatment (LBH589 
+ 5-AC; Australian and New Zealand Clinical Trial ID: ACTRN12610000924055).   
Serum was obtained for these patients before (Screening) and after treatment (Cycle n), with at least 
one time point post-treatment per patient. This serum was collected under the supervision of our 
collaborator, Prof. Andrew Spencer, at the Alfred Hospital in Melbourne.   
This clinical trial’s progress has been recently published (Tan et al. 2014), and therefore public access 
and collection of the clinical profile of the patients included in our cohort was possible.  
2.2.4 Apoptosis Inhibitor cohorts 
The apoptosis inhibitor treatment cohort included 48 varied cancer (urothelial cancer, colorectal cancer, 
sarcoma, renal cancer, ovarian cancer, adenoid cystic cancer, breast cancer, mesothelioma, melanoma, 
head and neck cancer, non-small cell lung carcinoma (NSCLC), testicular cancer, thymoma, 
neuroendocrine tumour) patients with solid tumours undergoing survivin treatment (EMD640744; 
ClinicalTrials.gov Identifier: NCT01012102).  
Serum was obtained for these patients before (Baseline) and after treatment (Week n), with at least one 
time point post-treatment per patient. This serum was collected under the supervision of our 
collaborator, Prof. Alexander Knuth, at the UZH.  
This clinical trial’s progress has also been recently published (Lennerz et al. 2014), and therefore public 
access and collection of the clinical profile of the patients included in our cohort was possible.  
2.2.5 Internal Radiotherapy cohort 
The internal radiotherapy treatment cohort included 11 primary colorectal cancer patients with 
metastatic non-resectable liver tumours undergoing selective internal radiotherapy treatment (SIRT) 
(ClinicalTrials.gov Identifier: NCT00724503).  
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Serum was obtained for these patients before (D0) and after treatment (Cycle n), with at least one time 
point post-treatment per patient. This serum was also collected under the supervision of our 
collaborator, Prof. Alexander Knuth, at the UZH.  
Access and collection of the complete clinical profile of the patients included in our cohort was not 
possible.  
2.2.6 Other treatment cohorts 
The other treatments cohort included 89 malignant melanoma patients undergoing several distinct 
treatments. Due to the majority of these patients contributing samples at a single time point only, post-
treatment analysis was not possible, and therefore these patients were grouped together as a means of 
conducting a cancer-specific group analysis, focusing on typically expressed antigens and possible 
correlations with disease stage. 
Serum was obtained for these patients at a random time point during their treatment course. This 
serum or plasma was collected under the supervision of our collaborator, Prof. Jonathan Cebon at the 
Austin Health in Melbourne. 
As part of our ongoing collaboration, access and collection of the complete clinical profile of the patients 
included in our cohort was possible.  
 
2.3 Results and Discussion 
The following Section contains all clinical information that could be collected, such as patient IDs, 
gender, age, diagnosis/tumour, karyotype/HLA type, treatment dosage, best response, cycles of 
treatment, overall survival, etc., as well as all treatment-specific information for each cohort analysed in 
this Thesis.   
2.3.1 Kinase Inhibitor cohorts 
The kinase inhibitor treatment cohort included 36 malignant melanoma patients undergoing 1) BRAF, 2) 
Alternative BRAF (aBRAF), 3) MEK, 4) BRAF + MEK, 5) BRAF +/- MEK treatments. Of these, clinical and 
treatment-specific information was available for all 36 patients undergoing treatment.  
Melanoma is a form of skin cancer that originates in melanocytes, cells that produce the skin pigment 
called melanin that is responsible for skin and hair colour. Melanomas can form at any skin site and the 
four major types are: radial spreading (superficial spreading), nodular, lentigo maligna (Hutchinsons’s 
freckle) and acral lentiginous. The development of melanoma is related to sun exposure or ultraviolet 
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radiation and can spread very rapidly, being the leading cause of death from skin disease 
(www.ncbi.nlm.nih.gov/pubmedhealth).  
Metastatic melanoma is known to have a very poor prognosis, with a median overall survival between 9 
to 11 months, or, if brain metastasis are present, between 4 to 5 months instead (Balch et al. 2009; 
Davies et al. 2011). As these tumours are usually unresponsive to standard treatment options, viable 
alternatives are required.  As a result, many researchers are currently investigating the potential of 
kinase inhibitors in treating melanoma. The basis of this selection is that the RAF–MEK–ERK kinase 
pathway is responsible for mediating cellular responses to growth signals, and BRAF, a known 
serine/threonine kinase, is usually activated by somatic point mutation in cancers (Chapman et al. 2011; 
Curtin et al. 2005; Davies et al. 2002; Peyssonnaux & Eychène 2001). Therefore, several distinct kinase 
inhibitor drugs have and are currently still being tested in a clinical trial setting, due to their potential as 
anti-tumour therapeutics, and associated ability to prolong progression-free survival rates for metastatic 
melanoma patients with limited or no alternative treatment options (www.clinicaltrials.gov).  
This treatment cohort in our study includes patients from five distinct kinase inhibition clinical trials, 
each of which will be briefly explained as a means to facilitate data interpretation and analysis.  
The first clinical trial (NCT00880321) consisted of a completed phase I study that investigated the safety, 
pharmacokinetics, and pharmacodynamics of a BRAF inhibitor (dabrafenib, GSK2118436) in subjects 
with BRAF mutated-positive solid tumours that were unresponsive to standard therapies. The study’s 
summarized results found this drug to be safe in patients, and cases of complete and partial tumour 
responses were seen across melanoma, although resistance was noted in the majority of the metastatic 
cases (Falchook et al. 2012).  
The second clinical trial (NCT01006980) consisted of a randomized, open-label, controlled, multicentre, 
global study on progression-free and overall survival in previously untreated patients with unresectable 
metastatic melanoma with the V600E BRAF mutation-positive receiving an alternative BRAF inhibitor 
(vemurafenib, RO5185426) or dacarbazine (chemotherapeutic drug). This study indicated beneficial 
overall results, with improved rates of progression-free survival across patients, and response rates of 
up to 48%, when compared to standard dacarbazine treatment (Chapman et al. 2011; McArthur et al. 
2014).  
The third clinical trial (NCT01037127) consisted of a completed phase II open-label, multicentre study 
that determined the effectiveness of a MEK inhibitor (trametinib, GSK1120212) in BRAF mutation-
positive melanoma previously treated with or without a BRAF inhibitor. This study reported a good drug 
tolerance, and a significant clinical activity in BRAF inhibitor-naïve patients, but a minimal one in those 
previously treated with chemotherapy and/or immunotherapy (Kim et al. 2013).  
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The fourth clinical trial (NCT01072175) consisted of a currently active open-label, dose-escalation, phase 
I/II study that investigated the safety, pharmacokinetics, pharmacodynamics and clinical activity of a 
BRAF inhibitor (dabrafenib, GSK2118436) in combination with a MEK inhibitor (trametinib, GSK1120212) 
in subjects with BRAF mutant metastatic melanoma. This study has already reported a good tolerance of 
the combined drugs, and a significantly improved progression-free survival when comparing 
monotherapy to combination therapy (Flaherty et al. 2012).  
The fifth and final clinical trial (NCT01584648) consisted of a currently ongoing phase III, randomized, 
double-blinded study comparing the combination of a BRAF inhibitor (dabrafenib, GSK2118436) and a 
MEK inhibitor (trametinib, GSK1120212) to dabrafenib and placebo, as first-line therapy in patients with 
unresectable metastatic BRAF V600E/K mutation-positive cutaneous melanoma. This study has reported 
that the combination of these two drugs, when compared with BRAF inhibitor only, improved the 
overall response rates and progression-free survival in these patients (Long et al. 2014).  
The patients included in this treatment cohort were selected from the large number of patients included 
in these five treatment trials, due to all of them displaying interesting responses, ranging from complete 
responses to gaining apparent resistance to treatment. Although this pre-selection enabled the analysis 
of a wide variety of different responses amongst malignant melanoma patients undergoing kinase 
inhibitor treatment, it is essential to note that this introduced significant diversity within this cohort. 
Furthermore, all analyses should take into account this diversity when interpreting any posterior 
findings. Nonetheless, it may be possible to make preliminary assumptions with regards to the benefits 
of treating patients with either BRAF alone or in combination with MEK, although, due to the limited 
number of patients and the heterogeneity amongst them, these may not be of significant statistical 
relevance.   
For the above-mentioned patients, the clinical information that was found most relevant for this 
analysis included patient ID, gender (M: male, F: female), age when treated, treatment undergone, best 
overall response to treatment (SD: stable disease, CR: complete response, PR: partial response, PD: 
progressive disease), and overall survival time in months, as indicated in Tables 2.1 and 2.2. Besides 
from the information included in this Table, the RECIST measurements across time points were 
collected, when available, as a means of further defining a more detailed response status per time point.  
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Table 2.1 Patient demographics of the BRAF, aBRAF and MEK (single inhibitor) cohorts. This table 
includes the complete accessed patient information for the BRAF, aBRAF and MEK (single inhibitor) 
cohorts. M: male; F: female; OS: overall survival; mo: months; SD: stable disease; CR: complete 
response; PR: partial response; PD: progressive disease; +: still ongoing. Dark grey shaded areas 
indicated outstanding clinical information. 
Patient ID Gender Age Treatment Best response 
OS 
(mo) 
KI001: RR M 69 BRAF SD 18 
KI002: TL M 46 BRAF CR 12+ 
KI003: BH M 50 BRAF PR 15 
KI004: DD M 69 BRAF PR 6 
KI005: DBr M 52 BRAF SD 15+ 
KI006: AB M 66 BRAF SD 5 
WMD-006 F 38 BRAF  29 
WMD-007 M 31 BRAF SD 7 
WMD-008 F 61 BRAF PR 62+ 
WMD-009 F 58 BRAF PR 31 
WMD-010 M 31 BRAF SD 6 
WMD-011 M 67 BRAF PR 15 
WMD-012 M 59 BRAF SD 9 
WMD-016 M 62 BRAF PR 10 
WMD-017 F 55 BRAF PR 56+ 
WMD-018 F 29 BRAF PD 3 
WMD-020 M 28 BRAF PR 10 
WMD-021 F 33 BRAF PR 29 
WMD-019 M 69 aBRAF PR 14 
WMD-014 M 29 MEK  5 
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Table 2.2 Patient demographics of the BRAF + MEK and BRAF +/- MEK (dual inhibitor) cohorts. This 
table includes the complete accessed patient information for the BRAF + MEK and BRAF +/- MEK (dual 
inhibitor) cohorts. M: male; F: female; OS: overall survival; mo: months; SD: stable disease; CR: complete 
response; PR: partial response; PD: progressive disease; +: still ongoing. 
Patient ID Gender Age Treatment Best response OS (mo) 
KI007: DR M 26 BRAF + MEK PR 5 
KI008: MC M 44 BRAF + MEK SD 28+ 
KI009: Dbe M 49 BRAF + MEK PD 12 
KI010: NH M 26 BRAF + MEK PR 7 
KI011: GD M 52 BRAF + MEK PR 27+ 
KI012: KM M 59 BRAF + MEK PR 14 
KI013: EB F 31 BRAF + MEK SD 26 
WMD-005 M 37 BRAF + MEK SD 28 
WMD-022 M 41 BRAF + MEK SD 3 
WMD-023 M 39 BRAF + MEK PR 48+ 
WMD-024 M 62 BRAF + MEK CR 46+ 
WMD-015 F 24 BRAF + MEK PR 10 
WMD-013 M 71 aBRAF + BRAF + MEK SD 22 
KI014: KD F 53 BRAF +/- MEK PR 14+ 
KI015: EL F 78 BRAF +/- MEK PR 11 
KI016: DM M 74 BRAF +/- MEK PR 14 
 
The characteristics of these 36 patients included quite an unevenly weighed population, with more 
males (n = 26/36, 72%) than females (n = 10/36, 28%), and a median patient age of 51 years (mean = 49 
years), with ages ranging widely from 24 to 78 years. This population included 20 patients (n = 20/36, 
56%) undergoing single inhibitor treatment (BRAF, aBRAF or MEK), and 16 patients (n = 16/36, 44%) 
undergoing dual inhibitor (BRAF + MEK, aBRAF + BRAF + MEK, or BRAF +/- MEK) treatment. Amongst the 
18 patients with an available overall disease status undergoing single inhibitor treatment subset, one 
achieved a complete response (6%) and ten achieved a partial response (55%), for an overall response 
rate of 61%, while the remaining patients were either stable (n = 6/18, 33%) or had progressive disease 
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(n = 1/18, 6%). For this subset, the median overall survival was 13 months (mean = 18 months). 
However, amongst the 16 dual inhibitor treatment subset, one achieved a complete response (6%), and 
nine achieved a partial response (57%), for an overall response rate of 63%, while the remaining patients 
were either stable (n = 5/16, 31%) or had progressive disease (n = 1/16, 6%). For this subset, the median 
overall survival was 14 months (mean = 20 months). When comparing these two treatment subsets, the 
overall response rates and disease status distributions were very similar, 61% vs 63%, as well as the 
overall survival in months, with only a slightly higher benefit (an additional 2% overall response rate, and 
1 month median survival) for those patients undergoing dual inhibitor treatment. When considering 
these subsets as a one, the overall distribution by disease status included two complete responses (n = 
2/34, 6%), and nineteen partial responses (n = 19/34, 56%), for an overall response rate of 62%, while 
the remaining patients were either stable (n = 11/34, 32%) or had progressive disease (n = 2/34, 6%). 
The median overall survival was 14 months (mean = 19 months) for these patients.   
In regards to the statistical power of these descriptive findings, the number of patients (n = 36) was 
below the a priori estimate (n = 54), indicating that any potential findings would be obtained with lower 
sensitivity than ideally required. Nonetheless, a post hoc estimate was generated to compute the 
achieved statistical power of this cohort (G*Power 3.1.9.2 program, T-test, difference between two 
dependent means (matched pairs), 2-tailed) with a given probability of error (α=0.05), sample size (n = 
36) and effect size (dz=0.5) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an estimated 
power (1-β) of 0.83 (noncentrality parameter σ = 3.00, critical t = 2.03, degrees of freedom = 35), which 
was above the generally recommended and accepted minimum power of 0.8 (Cohen 1988). Therefore, 
when treating the two distinct treatment subtypes (single vs. dual inhibitor treatment) as a whole, the 
probability of this cohort detecting a statistically relevant finding may be acceptable. However, 
comparing findings between the two treatment subtypes does not hold statistical significant relevance. 
Furthermore, although patient selection for each clinical trial was conducted following the necessary 
pre-stipulated statistical design, the patients that were posteriorly included in this analysis cohort were 
not selected based on a pre-determined study design, but rather on a variety of distinct clinical 
responses, as a means to aid in comprehending why malignant melanoma patient responses to the 
same treatment differ substantially. As a consequence, this cohort was quite heterogeneous regarding 
patient demographics, namely age and gender, which may further limit the achieved statistical power of 
potential findings.   
2.3.2 Pre- or Post-operative chemotherapy/radiotherapy cohort 
The pre- or post-operative chemotherapy/radiotherapy treatment cohort included 62 colorectal cancer 
patients undergoing chemotherapy/radiotherapy prior- or post-surgical resection of their primary 
tumours.  
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Colorectal cancer originates in the large intestine (colon) or the rectum (end of the colon), and usually 
begins as a noncancerous polyp, which develops in the lining of the colon or rectum. There are several 
types of colon and rectal cancers, but adenocarcinomas account for more than 95% of all colorectal 
cancer, whilst other less common types include carcinoid tumours, gastrointestinal stromal tumours, 
lymphomas and sarcomas. As with most cancers, an early diagnosis is critical to obtain as successful 
treatment outcome and reduced chance of recurrence (www.ncbi.nlm.nih.gov/pubmedhealth). 
When possible, the primary treatment for colorectal cancer is surgery, and the additional treatment 
options include chemotherapy and radiotherapy. In this specific treatment cohort, systemic 
chemotherapy, usually 5-fluorouracil (5FU) and leucovorin (LV), was administered orally or via injection, 
and external radiotherapy was administered localised toward the cancer location. Several studies have 
researched the effects of pre- or post-operative chemotherapy/radiotherapy in rectal cancer, and whilst 
some studies show that pre-operative therapy is beneficial in regards to the reduction of local re-
occurrences, others state that this beneficial effect is obtained whether the therapy is administered pre- 
or post-operatively (Sauer et al. 2004; Kapiteijn et al. 2001; Bosset et al. 2006).  
The 62 patients included in this treatment cohort were selected based solely on sample availability 
(single time point per patient), emerging from a previous sample collection effort within our group, 
without following a pre-established patient selection or study design. These patients were undergoing 
standard cancer treatments (surgery, chemotherapy and radiotherapy) based on an individually defined 
personal treatment plan by their oncologist, as well as personal preference to undergo treatment. It is 
essential to note that these patients were not involved in a particular clinical trial, and that these 
samples were analysed here with the intent of conducting a retrospective analysis on whether pre- or 
post-operative therapy was most beneficial, and on how this therapy significantly altered the pattern of 
cancer-associated antigen autoimmune titres in these patients, thereby potentially influencing the 
outcome of any subsequent treatment. Whether or not potential findings may be of significant 
statistical relevance would depend on the heterogeneity of the resulting cohort. For these patients, the 
clinical information that was found most relevant for this analysis included patient ID, gender, age at 
diagnosis, colorectal cancer type (sporadic or HNPCC: hereditary non-polyposis colorectal cancer), stage, 
location and site (rectum, RSJ: recto-sigmoid junction, DC: descending colon, TC: transverse colon, SC: 
sigmoid colon, AC: ascending colon, PDC: proximal descending colon, HF: hepatic flexure), presence or 
absence of pre-operative chemotherapy or radiotherapy, risk factors (HT: hypertension, S: smoking 
history, fCRC: familial history of CRC, AC: alcohol consumption, O: Obesity), and recurrence information, 
as indicated in Table 2.3.  
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Table 2.3 Patient demographics of the pre- or post-operative chemotherapy/radiotherapy cohort. This 
table includes the complete accessed patient information for the pre- or post-operative 
chemotherapy/radiotherapy cohort. CRC: colorectal cancer; Pre-op CT/RT: pre-operative 
chemotherapy/radiotherapy; M: male; F: female; HNPCC: hereditary non-polyposis colorectal cancer; -: 
none; RSJ: recto-sigmoid junction; DC: descending colon; TC: transverse colon; SC: sigmoid colon; AC: 
ascending colon; PDC: proximal descending colon; HF: hepatic flexure; Y: yes; N: no; HT: hypertension; S: 
smoking history; fCRC: familial history of CRC; AC: alcohol consumption; O: Obesity. Dark grey shaded 
areas indicated outstanding clinical information. 
Patient 
ID 
Gender Age CRC type Stage Location Site 
Pre-op 
RT/CT 
Risk 
factors 
Recurrence 
CRC002 M 67 Sporadic II Distal Rectum Y - N 
CRC003 M 70 Sporadic III Distal RSJ N HT Y 
CRC004 F 44 HNPCC III Proximal Caecum N S, fCRC N 
CRC005 M         
CRC006 F 23 Sporadic III Distal Rectum Y - N 
CRC007 M 52 Sporadic III Distal Rectum N HT, AC Y 
CRC008 M 61 Sporadic III Distal Rectum N HT, S, AC N 
CRC009 F 64 Sporadic III Distal Rectum N  N 
CRC010 M 63 Sporadic III Distal DC N - Y 
CRC011 M 84 Sporadic I Proximal TC N S N 
CRC012 M         
CRC013 F 46 HNPCC II Proximal Caecum N - N 
CRC014 M 80 Sporadic IV Distal SC N - N 
CRC015 M 74 Sporadic II Distal Rectum N S, AC N 
CRC016 M 76 Sporadic I Proximal AC N - Y 
CRC017 M 79 Sporadic III Distal SC N - N 
CRC019 F 62 Sporadic I Distal Rectum Y - N 
CRC020 F 26 HNPCC  Proximal Caecum N -  
CRC021 F 61 Sporadic III Distal Rectum N HT, O N 
CRC022 M 49 Sporadic III Distal Rectum Y - N 
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Patient 
ID 
Gender Age CRC type Stage Location Site 
Pre-op 
RT/CT 
Risk 
factors 
Recurrence 
CRC024 M 42 Sporadic III Distal Rectum Y - N 
CRC025 F 67 Sporadic I Distal Rectum Y - N 
CRC026 F 73 Sporadic I Distal Rectum Y HT, S, fCRC Y 
CRC028 M 79 Sporadic II Distal Rectum Y - N 
CRC029 M 73 Sporadic III Distal Rectum Y HT N 
CRC031 F 54 Sporadic I Distal Rectum Y - N 
CRC032 F 52 Sporadic III Proximal Caecum N  N 
CRC033 F 69 Sporadic III Distal Rectum N HT, S N 
CRC034 F 70 Sporadic III Distal Rectum N - Y 
CRC035 M 68 Sporadic II Distal Rectum Y - Y 
CRC036 F 67 Sporadic III Distal Rectum Y  N 
CRC037 M 49 Sporadic III Distal PDC N - N 
CRC038 M 49 Sporadic I Distal Rectum Y  N 
CRC039 F 51 Sporadic II Distal Rectum Y O  
CRC040 F 47 Sporadic II Distal Rectum Y - N 
CRC041 F 71 Sporadic II Distal Rectum N HT, O N 
CRC042 M 37 Sporadic II Distal Rectum Y  Y 
CRC043 F 67 Sporadic II Distal Rectum Y - N 
CRC044 M 36 Sporadic III Proximal Caecum N - N 
CRC045 F 36 Sporadic II Distal Rectum Y - Y 
CRC046 F         
CRC047 M 25 HNPCC III Distal DC Y S, fCRC N 
CRC048 M 37 Sporadic IV Distal Rectum N O N 
CRC049 F 50 Sporadic  Distal RSJ Y  N 
CRC050 F 60 Sporadic I Distal Rectum Y  Y 
CRC051 M 47 Sporadic II Distal Rectum Y - Y 
CRC052 F 42 Sporadic II Distal Rectum Y  N 
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Patient 
ID 
Gender Age CRC type Stage Location Site 
Pre-op 
RT/CT 
Risk 
factors 
Recurrence 
CRC053          
CRC054 M 60 Sporadic    N -  
CRC055 M 64 Sporadic III Distal DC N - Y 
CRC056 F 54 Sporadic III Distal RSJ N fCRC N 
CRC057 M 45 Sporadic III Distal RSJ N S N 
CRC058  71 Sporadic II Distal Rectum Y - N 
CRC059 F 79 Sporadic II Distal Rectum Y - Y 
CRC060 M 65 Sporadic II Distal RSJ N fCRC N 
CRC062 F 40 Sporadic II Distal Rectum Y - N 
CRC063 F 78 Sporadic II Proximal HF N fCRC N 
CRC064 F 69 Sporadic II Distal Rectum Y - N 
CRC065 M 73 Sporadic III Distal Rectum Y - N 
CRC066 F 59 Sporadic III Distal Rectum Y - N 
CRC067 M 64 Sporadic III Distal Rectum N - N 
CRC068 F 76  II Proximal Caecum N  N 
 
The available characteristics of these 62 patients included quite an equally weighed population, with an 
equal number of males (n = 30/60, 50%) and females, and a median patient age of 62 years (mean = 59 
years), with ages ranging widely from 23 to 84 years. The majority of these patients presented with 
sporadic colorectal cancer (n = 53/57, 93%), whilst only a few types were HNPCC (hereditary non-
polyposis colorectal cancer, n = 4/57, 7%). Amongst this population, a great deal of patients presented 
with stage III (n = 25/55, 45%), followed by stages II (n = 20/55, 36%), I (n = 8/55, 15%) and IV (n = 2/55, 
4%). In regards to tumour location, most cancers occurred in a distal location (n = 48/57, 84%), with only 
a few cases located proximally (n = 9/57, 16%). Interestingly, the three most common cancer sites 
amongst the nine were in the rectum (n = 37/57, 65%), caecum (n = 6/57, 11%) and recto-sigmoid 
junction (n = 5/57, 9%). Of the 58 patients for which pre-operative chemotherapy/radiotherapy 
information was available, exactly half (n = 29/58, 50%) underwent pre-operative therapy, and the other 
half did not. However, when considering disease recurrence, the majority of these patients did not have 
recurrent disease (n = 42/55, 76%), whilst a small subset did (n = 13/55, 24%). Amongst the patients that 
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did not have disease recurrence, exactly half underwent pre-operative therapy (n = 21/42, 50%), and the 
other half did not. When assessing the recurring patients (n =13/55, 24%) in regards to presence or 
absence of pre-operative therapy, patient numbers were limited, thus preventing further analysis.  
In regards to the statistical power of these findings, the number of patients (n = 62) was above the a 
priori estimate (n = 54), indicating that any potential findings would be obtained with higher sensitivity 
than ideally required. A post hoc estimate was generated to compute the achieved statistical power of 
this cohort (G*Power 3.1.9.2 program, T-test, difference between two dependent means (matched 
pairs), 2-tailed) with a given probability of error (      ), sample size (n = 62) and effect size 
(      ) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an estimated power (   ) of 
0.97 (noncentrality parameter σ = 3.94, critical t = 2.00, degrees of freedom = 61), and therefore the 
probability of this cohort detecting a statistically relevant finding surpassed the initial ideal estimate. 
Thus, when conducting analysis within this treatment cohort, findings are of statistical relevance, 
whereas when dividing this cohort into those that received pre-operative chemotherapy/radiotherapy 
and those who did not, patient numbers are limited and do not permit statistically worthy 
considerations to be made. Furthermore, although the inclusion of patients in this study cohort was not 
according to a pre-established study design, this cohort was homogenous and equally weighed 
regarding demographics such as gender. However, a wide age range was obtained, which may reduce 
the estimated sample number-based power, although not significantly.  
2.3.3 Epigenetic Modifiers cohort 
The epigenetic modification treatment cohort included 12 myelodysplasia patients undergoing a 
combination of panobinostat (HDAC inhibitor) with azacitidine treatment, of which clinical and 
treatment-specific information was available (Tan et al. 2014).   
Epigenetics, one of the most promising and expanding fields in cancer research,  is currently defined as 
the study of heritable changes in gene expression, that are not due to any DNA sequence alterations 
(Holliday 1987; Esteller 2008). Cancer is known to have aberrant epigenetic regulation and, due to the 
possibility of reversing these alterations, unlike with mutations, epigenetic therapies showed great 
potential as a cancer therapy (Esteller 2008). This aberrant regulation is usually characterized by global 
changes in DNA methylation and altered histone modification patterns, both which are being targeted 
by the epigenetic therapies used in this cohort, which could lead to epigenetic silencing of tumour 
supressing genes (Jones & Laird 1999; Rodríguez-Paredes & Esteller 2011). This epigenetic inactivation, 
which is associated with dense CpG-island promoter hypermethylation and the appearance of 
repressive histone markers, can be partially modified using epigenetic drugs, by way of removing 
inactivation markers (DNA methylation) and inducing the presence of active markers (Histone 
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acetylation), which explains the rationale of using this dual epigenetic targeting as a potential cancer 
therapeutic (Esteller 2008).  
Myelodysplastic syndrome (MDS) is a type of cancer where blood stem cells, immature cells resulting 
from the bone marrow, do not become healthy red blood cells, white blood cells or platelets, dying 
instead either in the bone marrow or shortly after reaching the blood 
(www.ncbi.nlm.nih.gov/pubmedhealth). MDS can evolve into acute myeloid leukaemia (AML), 
depending on the associated risk-based categorical cytogenetic subgroups (Good: normal, del(5q) only, 
del(20q) only, -Y only; Intermediate: +8, single miscellaneous, double abnormalities; Poor: complex with 
 3 anomalies or chromosome 7 abnormalities). Additionally, MDS can be scored using the International 
Prognostic Scoring System (IPSS), which provides relevant survival and AML evolution predictions based 
on an aggregate prognostic score of bone marrow blasts (%), karyotype (normal, complex or 
intermediate) and cytopenias (Greenberg et al. 1997). The resulting scores for each risk group are low 
(0), Int1 (0.5 – 1.0), Int2 (1.5 – 2.0) and high ( 2), which is usually represented as part of the MDS 
diagnosis, such as MDS-low, for example.  
Azacitidine, a hypomethylating agent, was the first FDA-approved drug (5-azacytadine, Vidaza) for the 
treatment of MDSs that showed improvement of overall survival rates and delayed progression to AML 
(Vigil et al. 2010). Panobinostat, a potent HDAC inhibitor, has shown great promise as an anti-
proliferative and cytotoxic clinically efficient therapeutic in hematologic and solid tumours (Atadja 
2009).  Both therapeutic options are categorized as epigenetic modifiers, and are widely studied in the 
epigenetics field.  
This clinical trial  in particular, an open-label phase Ib/II study, conducted at the Alfred, Princess 
Alexandra and Austin hospitals in Australia, aimed to clinically evaluate the safety and efficacy of 
combining panobinostat with azacitidine in patients with high-risk MDS or AML that were unsuitable for 
standard induction chemotherapy (ACTRN12610000924055). Usually, limited therapeutic options and 
poor treatment outcomes are common for older patients with AML, mainly due to the high treatment-
related mortality risk. Therefore, this potential treatment alternative was investigated with the intent of 
prolonging their median survival and quality of life. To assess the clinical efficacy of this treatment, 
patients were given an injection with azacitidine (75 mg/m2) on days 1-5, followed by an oral dose of 
panobinostat (10, 20, 30 and 40 mg) three times a week on days 5-28 for seven doses of each 28-day 
cycle. Clinical responses to treatment were measured using bone marrow assessments after cycles 1, 3 
and 6, and patients were classified accordingly as having a complete response (CR), a partial response 
(PR), progressive disease (PD) or being resistant (R) to treatment (Tan et al. 2014).   
The 12 patients included in this treatment cohort were selected by our collaborators amongst the 39 
patients treated in this clinical trial, as a means of assuring the provision of a full range of observed 
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responses to treatment. Although this pre-selection enabled the analysis of a wide variety of different 
responses amongst myelodysplasia patients undergoing dual epigenetic modification treatment, it is 
essential to note that this resulted in a very limited number of patients. Furthermore, all analyses should 
take this limitation into account when interpreting any posterior findings.  
For these patients, the clinical information that was found most relevant for this analysis included 
patient ID, gender, age when treated, attributed diagnosis and karyotype, baseline white blood cell 
(WBC) levels, treatment dosage, best overall response to treatment, cycles of treatment undergone and 
overall survival time in months, as indicated in Table 2.4. Besides from the information included in this 
Table, time point-specific patient assessments were collected based on clinician’s patient notes, as a 
means of further defining a more detailed response status per time point.  
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Table 2.4 Patient demographics of the epigenetic modification cohort. This table includes the complete 
accessed patient information for the epigenetic modification cohort. M: male; F: female; WBC: white 
blood cell count; Pano: panobinostat; OS: overall survival; mo: months; MDS: myelodysplastic 
syndrome; AML: acute myeloid leukaemia; MRC: myelodysplasia-related changes; HI-E: major 
hematologic improvement with erythroid response; HI-N: major hematologic improvement with 
neutrophil response; HI-P: major hematologic improvement with platelet response; CR: complete 
response; PR: partial response; PD: progressive disease; #co-existent severe co-morbidities; 1prior MDS; 
2prior myelofibrosis (MF); 3prior chronic myelomonocytic leukaemia (CMML). 
Patient ID Gender Age Diagnosis Karyotype 
Baseline 
WBC 
(10
9
/L) 
Pano 
dose 
(mg) 
Best response Cycles 
OS 
(mo) 
001-0001 M 68 MDS- Int2  Complex 4.4 10 CR, HI-E 16 16 
001-0002 M 70 AML MRC
1
 Normal 4.3 10 PR 7 8 
001-0003 F 72 MDS- Int2  Normal  3.3 10 CR 30 34+ 
001-0004 M 61 MDS- high  del(20q) 10.8 10 PD 5 6 
001-0006 F 43 MDS- Int2  t(3;3) 3.2 20 CR, HI-E 18 32 
001-0007 F 73 AML MRC
1
 Normal  27.5 20 Resistant 7 7 
001-0008
#
 M 58 AML MRC
2
 Normal  37.1 20 Resistant 7 7 
001-0011 M 65 AML MRC
1
 7- 2.8 20 Resistant 12 16 
001-0012 M 73 AML MRC
3
 Normal  1.9 20 PR 14 13 
001-0013 F 67 MDS- Int2  Complex 3.6 30 SD, HI-N 6 12 
001-0016 M 36 MDS- Int2  7- 4.6 30 PD 6 11 
001-0018 F 60 MDS- high  Normal  38.8 30 PR, HI-E,P 23 23+ 
 
The characteristics of these 12 patients included quite an equally weighed population, with slightly more 
males (58%) than females (42%), and a median patient age of 66 years (mean = 62 years), with ages 
ranging widely from 36 to 73 years. This population included 7 patients with high-risk MDS and 5 
patients with acute myeloid leukaemia (AML), with half of the population (n = 6/12, 50%) displaying a 
normal karyotype. Amongst the 7 patients with MDS, three achieved a complete response (43%) and 
one achieved a partial response (14%), for an overall response rate of 57%, while the remaining patients 
were either stable (n = 1/7, 14%) or had progressive disease (n = 2/7, 29%). However, amongst the 5 
patients with AML, two achieved a partial response (40%), for a lower overall response rate of 40%, 
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while three became resistant to treatment (60%), with no patient exhibiting a complete response or 
remaining stable. The median overall survival (OS) was 16 months for patients with MDS, and 8 months 
for patients with AML.  
In regards to the statistical power of this treatment cohort, the number of patients (n = 12) was well 
below the a priori estimate (n = 54), indicating that any potential findings would be obtained with much 
lower sensitivity than ideally required. Nonetheless, a post hoc estimate was generated to compute the 
achieved statistical power of this cohort (G*Power 3.1.9.2 program, T-test, difference between two 
dependent means (matched pairs), 2-tailed) with a given probability of error (α=0.05), sample size (n = 
12) and effect size (dz=0.5) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an estimated 
power (1-β) of 0.35 (noncentrality parameter σ = 1.73, critical t = 2.20, degrees of freedom = 11), which 
was well below the generally recommended minimum power of 0.8 (Cohen 1988). Therefore, the 
probability of this cohort detecting a statistically relevant finding was not acceptable. Furthermore, 
although patient selection for this clinical trial was conducted following the necessary pre-stipulated 
statistical design, the patients that were posteriorly included in this analysis cohort were not selected 
based on a pre-determined study design, but rather on a variety of distinct clinical responses, and as a 
result very limited patients sample numbers were obtained, thus limiting our analysis substantially. 
Nonetheless, it may be possible to make very preliminary assumptions regarding comprehending why 
AML and high-risk MDS patients respond differently to dual epigenetic modification, which could 
provide insight into patient stratification or even likelihood of a desired response. 
2.3.4 Apoptosis Inhibitor cohorts 
The apoptosis inhibitor treatment cohort included 48 varied cancer (urothelial cancer, colorectal cancer, 
sarcoma, renal cancer, ovarian cancer, adenoid cystic cancer, breast cancer, mesothelioma, melanoma, 
head and neck cancer, non-small cell lung carcinoma (NSCLC), testicular cancer, thymoma, 
neuroendocrine tumour) patients with advanced solid tumours undergoing survivin treatment, of which 
clinical and treatment-specific information was available (Lennerz et al. 2014).  
Several cancer types were included in this treatment cohort, as solely a metastatic or locally advanced 
survivin-expressing solid tumour was required, rather than a specific cancer type.  
Survivin, also known as baculoviral IAP repeat containing protein 5 (BIRC5), is a unique member of the 
inhibitor of apoptosis (IAP) family, and is critically required for the suppression of apoptosis and to 
ensure normal cell division, being a key apoptosis inhibitor/cell cycle regulator (Ambrosini et al. 1997; 
Tamm et al. 1998; Li et al. 1998; Shin et al. 2001)(www.uniprot.org). Although survivin expression is 
developmentally regulated in normal tissues, it has found to be aberrantly overexpressed across a 
variety of cancers, from premalignant to metastatic lesions, which is most likely related to the 
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suppression of apoptosis that contributes to carcinogenesis (Ambrosini et al. 1997; Thompson 1995). In 
cancer, the evasion of cell cycle checkpoints that would normally induce apoptosis may contribute 
towards aberrantly prolonging the cell life span, which could potentially facilitate the accumulation of 
harmful gene mutations and a growth factor-independent cell survival, which could promote patient 
resistance towards immune-based cytotoxicity (Thompson 1995; Tamm et al. 1998). These features, 
along with the reported association with increased tumour recurrence and poor prognosis, make this 
protein a very attractive anti-cancer immunotherapy target (Islam et al. 2000; Swana et al. 1999; Altieri 
2003). Therefore, several studies have assessed whether the disruption of survivin activity in cancer cells 
could sensitize them to subsequent therapeutic interventions, and have found decreased cell 
proliferation and increased apoptosis without any apparent toxicity to healthy tissues (Fukuda & Pelus 
2006).  
This cohort in particular is derived from a randomized first-in-man phase I study with a cocktail of 
survivin-derived and 5 partially modified HLA class I-restricted peptides in the oil adjuvant, montanide 
ISA (EMD640744), conducted at 5 medical centres in Switzerland, that aimed to compare three dosages 
with respect to immunologic efficacy, safety, tolerability, and clinical activity in patients with different 
types of metastatic or locally advanced solid tumours (NCT01012102). Although multiple HLA class I-
binding peptides of survivin have been identified, previous trials have only tested single survivin 
peptides associated with a restricted number of common HLA alleles (clinicaltrial.gov). The therapeutic 
cocktail of this study included five multiepitope short peptides, based on the amino acid sequence of 
different regions of the survivin protein, shown to bind HLA-A01/A02/A03/A24/B07 peptides, due to a 
wider HLA type distribution and T-cell stimulatory activity. Therefore, this treatment was investigated 
with the intent of maximizing the number of patients with survivin-expressing tumours that could 
benefit from receiving this vaccine. To assess the immunological efficacy of this treatment, patients 
were given an injection with EMD640744 (30 µg, 100 µg or 300 µg) reconstituted and emulsified with 
montanide ISA for an 11-week initiation therapy (8 treatments), followed by 13-week maintenance 
therapy (4 weekly treatments). Clinical benefit (complete response, partial response, or stable disease) 
was assessed by imaging, physical examination, nuclear scanning, and/or serum tumour markers 
established for the given tumour entity. Immunologic efficacy was assessed by ELISpot and pHLA-
multimer staining before and until week 17 after vaccination, until tumour progression or unacceptable 
toxicity was seen (Lennerz et al. 2014). 
The 48 patients included in this treatment cohort were selected by our collaborators amongst the 53 
patients treated in this clinical trial, based on sample availability. Although this pre-selection enabled 
the analysis of a large amount of patient responses undergoing apoptosis inhibitor treatment, it is 
essential to note that these included a variety of tumour types, which introduces a substantial amount 
of clinical diversity amongst this cohort. Furthermore, all analyses should take into account this diversity 
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when interpreting any posterior findings. Nonetheless, it should still be possible to make preliminary 
assumptions with regards to the benefits of treating patients with apoptosis inhibitors, although, due to 
the broad range of cancer types, these may not be of large significant statistical relevance.   
For these, the clinical information that was found most relevant amongst what was available for this 
analysis included patient ID, gender, age, tumour type, HLA type, treatment dosage, best overall tumour 
response to treatment (PD: progressive disease, SD: stable disease) and presence of a post-vaccination 
immunological response. This data was grouped according to each medical centre of treatment (C01, 
C02, C03, C04 and C05), and is indicated in Tables 2.5, 2.6, 2.7, 2.8 and 2.9. The above-mentioned clinical 
data was available for all but two patients, C01P005 and C02P008.  
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Table 2.5 Patient demographics of the apoptosis inhibition cohort C01. This table includes the 
complete accessed patient information for the apoptosis inhibition cohort C01. M: male; F: female; PD: 
progressive disease; SD: stable disease; Y: yes; N: no; Dark grey shaded areas indicated outstanding 
clinical information. 
Patient ID Gender Age Tumour HLA type 
Dose 
(µg) 
Best 
response 
T-cell 
response 
C01P002 M 56 Urothelial cancer A01, A03, B07 30 PD Y 
C01P005        
C01P007 F 67 Colorectal cancer A03 100 PD Y 
C01P009 F 67 Colorectal cancer A01, A02 30 SD Y 
C01P012 M 62 Colorectal cancer A02 300 SD Y 
C01P013 M 36 Sarcoma A02 100 PD Y 
C01P015 M 51 Renal cancer B07 30 PD N 
C01P016 F 28 Ovarian cancer A02 300 PD Y 
C01P017 F 63 Adenoid cystic cancer A01 30 SD N 
C01P018 F 55 Breast cancer A01, A02 100 PD N 
C01P024 M 79 Colorectal cancer A01 300 SD N 
C01P027 M 60 Mesothelioma A03 300 SD Y 
C01P028 F 44 Ovarian cancer A01, A03, B07 30 PD Y 
C01P029 F 67 Ovarian cancer A02, A03 100 PD N 
C01P032 F 69 Ovarian cancer A02 30 PD Y 
C01P033 F 51 Melanoma A02 100 SD N 
C01P035 M 58 Head and neck cancer A02, A24 30 PD Y 
C01P037 F 58 Ovarian cancer A02 300 PD Y 
C01P040 M 45 Mesothelioma A02 30 PD N 
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Table 2.6 Patient demographics of the apoptosis inhibition cohort C02. This table includes the 
complete accessed patient information for the apoptosis inhibition cohort C02. M: male; F: female; PD: 
progressive disease; Y: yes; N: no; Dark grey shaded areas indicated outstanding clinical information. 
Patient ID Gender Age Tumour HLA type 
Dose 
(µg) 
Best 
response 
T-cell 
response 
C02P003 M 62 Melanoma A01, A02 30 PD N 
C02P007 F 53 Melanoma A03 300 PD Y 
C02P008        
C02P010 F 43 Melanoma A02 30 PD Y 
 
Table 2.7 Patient demographics of the apoptosis inhibition cohort C03. This table includes the 
complete accessed patient information for the apoptosis inhibition cohort C03. M: male; F: female; SD: 
stable disease; PD: progressive disease; NE: not evaluable; Y: yes; N: no. 
Patient ID Gender Age Tumour HLA type 
Dose 
(µg) 
Best 
response 
T-cell 
response 
C03P001 M 65 Sarcoma A24, B07 100 SD N 
C03P002 F 49 NSCLC A03 30 PD Y 
C03P005 M 51 NSCLC A02, B07 30 SD Y 
C03P009 F 20 Melanoma A02 300 PD Y 
C03P012 M 71 Colorectal cancer A01, A24, B07 100 NE N 
C03P014 F 53 Breast cancer A02 100 PD Y 
C03P015 M 65 Colorectal cancer A02 100 SD Y 
C03P016 M 71 Colorectal cancer A01, A02 30 NE Y 
C03P017 M 38 Testicular cancer A01, A02 100 PD Y 
C03P019 M 34 Sarcoma A02 300 SD Y 
C03P020 M 55 Melanoma A01, A02 100 PD N 
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Table 2.8 Patient demographics of the apoptosis inhibition cohort C04. This table includes the 
complete accessed patient information for the apoptosis inhibition cohort C04. F: female; M: male; PD: 
progressive disease; NE: not evaluable; SD: stable disease; Y: yes; N: no. 
Patient ID Gender Age Tumour HLA type 
Dose 
(µg) 
Best 
response 
T-cell 
response 
C04P004 F 68 Mesothelioma A02, B07 300 PD N 
C04P005 M 60 NSCLC A02, A03, B07 100 PD Y 
C04P007 M 58 Mesothelioma A03 100 PD Y 
C04P012 F 64 NSCLC A02, A24 100 NE N 
C04P013 M 52 Melanoma A01, A03 300 PD N 
C04P014 M 68 Thymoma A02, A03, B07 30 SD Y 
C04P015 M 80 Adenoid cystic tumour A02 100 SD Y 
C04P016 F 59 Colorectal cancer A02 300 PD N 
 
Table 2.9 Patient demographics of the apoptosis inhibition cohort C05. This table includes the 
complete accessed patient information for the apoptosis inhibition cohort C05. F: female; M: male; NE: 
not evaluable; SD: stable disease, PD: progressive disease; Y: yes; N: no. 
Patient ID Gender Age Tumour HLA type 
Dose 
(µg) 
Best 
response 
T-cell 
response 
C05P002 F 61 Ovarian cancer A01, A03 100 NE N 
C05P005 F 63 Ovarian cancer A01 300 NE N 
C05P011 M 51 Neuroendocrine tumour A24 300 SD Y 
C05P012 M 61 Melanoma A01, A24, B07 300 PD Y 
C05P014 M 47 Melanoma A01, A02 300 PD Y 
C05P017 M 63 Neuroendocrine tumour A01, A02 300 SD Y 
 
The characteristics of these 46 patients included quite an equally weighed population, with slightly more 
males (57%) than females (43%), and a median patient age of 59 years (mean = 57 years), with ages 
ranging widely from 20 to 80 years. This population included patients with a wide range of advanced 
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solid tumours, the most frequent tumours being melanoma (n = 9/46, 20%), colorectal cancer (n = 8/46, 
17%), and ovarian cancer (n = 7/46, 15%). Patients expressed one to three of the alleles HLA-A01, HLA-
A02, HLA-A03, HLA-A24 and HLA-B07, with the most commonly expressed allele being HLA-A02 (n = 
29/46, 63%), followed by HLA-A01 (n = 17/46, 37%), HLA-A03 (n = 12/46, 26%), HLA-B07 (n = 10/46, 
22%), and lastly HLA-A24 (n = 6/46, 13%). Amongst the 46 patients and in regards to best overall tumour 
responses, the majority had progressive disease (n = 27/46, 59%), or remained stable (n = 14/46, 30%), 
whilst five patients were not evaluable due to safety concerns (11%). Hence, as progressive disease was 
not an inclusion criterion, stable disease as best response cannot be considered a clinical benefit. 
Immunological benefit, T-cell responses against survivin peptides measured by ex vivo and/or in vitro 
ELISpot and/or pHLA-multimer staining, was detected post-vaccination in 29/46 (63%) patients, the 
majority of which were not present at baseline, providing evidence for de novo induction. No dose-
dependent effects of the treatment were observed.  
In regards to the statistical power of this treatment cohort, the number of patients (n = 48) was below 
the a priori estimate (n = 54), indicating that any potential findings would be obtained with lower 
sensitivity than ideally required. Nonetheless, a post hoc estimate was generated to compute the 
achieved statistical power of this cohort (G*Power 3.1.9.2 program, T-test, difference between two 
dependent means (matched pairs), 2-tailed) with a given probability of error (      ), sample size (n 
= 48) and effect size (      ) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an 
estimated power (   ) of 0.92 (noncentrality parameter σ = 3.46, critical t = 2.01, degrees of freedom 
= 47), which was well above the generally recommended minimum power of 0.8 (Cohen 1988). 
Therefore, the probability of this cohort detecting a statistically relevant finding was acceptable. 
Furthermore, although patient selection for each clinical trial was conducted following the necessary 
pre-stipulated statistical design, the patients that were posteriorly included in this analysis cohort were 
selected based on sample availability, which excluded 5 patients from the original clinical trial. When 
considering the demographic and clinical characteristics of this cohort, the diversity amongst patient 
ages and tumour types may limit the achieved statistical power of potential findings. Nonetheless, this 
cohort may aid in comprehending how patient responses to the same treatment differ amongst distinct 
cancer types.  
2.3.5 Internal Radiotherapy cohort 
The internal radiotherapy treatment cohort included 11 primary colorectal cancer patients with 
metastatic non-resectable liver tumours undergoing selective internal radiotherapy treatment (SIRT).  
Secondary or metastatic liver tumours – metastasis resulting from an alternative primary site (most 
likely colon cancer) – are much more common rather than primary liver tumours, and are usually 
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treated as a means of either increasing survival or removing metastasis-related blockages or discomfort, 
when possible (www.ncbi.nlm.nih.gov/pubmedhealth). Selective internal radiotherapy is a very 
attractive and effective therapy used in these circumstances, as it permits a high-dose internal 
radiotherapy delivery with little damage to healthy liver tissue, through use of microspheres containing 
radioactive yttrium (Stubbs & Wickremesekera 2004). These microspheres are delivered via a trans-
femoral hepatic artery catheter, lodging in the blood vessels supplying tumours, as a means of impeding 
blood flow and therefore oxygen and nutrient supply to the tumours, a technique known as 
radioembolisation.  
This clinical trial in particular, a randomised multi-centre comparative study of standard systemic 
chemotherapy  regimen of FOLFOX - combination of 5-fluorouracil, leucovorin and oxaliplatin – in 
combination with SIR-spheres microspheres containing the β-emitter yttrium-90 (FDA approved) versus 
chemotherapy alone, as first line treatment in patients with non-resectable liver metastases from 
primary colorectal carcinoma (NCT00724503). Although this therapy is used often, its efficacy is yet to 
be tested on a large scale, which will hopefully be done by this trial (Gibbs et al. 2014). However, these 
results are yet to be officially reported.   
The patients included in this treatment cohort were selected by our collaborators from the large 
number of patients included in this clinical trial, based only on sample availability. It is essential to note 
that this resulted in a very limited number of patient samples. Furthermore, all analyses should take this 
limitation into account when interpreting any posterior findings. Unfortunately, patient clinical 
information was not available for this treatment cohort, and therefore only the treatment and cancer 
type, as well as the patient and corresponding samples distribution before and after treatment were 
available.  
The lack of accessible clinical information for these patients limited the possible data analysis, as the 
clinical relevance of our findings could not be assessed. Hence, solely the presence or absence of an 
immune response as a result of selective radiotherapy treatment could be analysed here.  
In regards to the statistical power of this treatment cohort, the number of patients (n = 11) was well 
below the a priori estimate (n = 54), indicating that any potential findings would be obtained with much 
lower sensitivity than ideally required. Nonetheless, a post hoc estimate was generated to compute the 
achieved statistical power of this cohort (G*Power 3.1.9.2 program, T-test, difference between two 
dependent means (matched pairs), 2-tailed) with a given probability of error (      ), sample size (n 
= 11) and effect size (      ) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an 
estimated power (   ) of 0.32 (noncentrality parameter σ = 1.66, critical t = 2.23, degrees of freedom 
= 10), which was well below the generally recommended minimum power of 0.8 (Cohen 1988). 
Therefore, the probability of this cohort detecting a statistically relevant finding was not acceptable. 
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Furthermore, although patient selection for this clinical trial was conducted following the necessary pre-
stipulated statistical design, the patients that were posteriorly included in this analysis cohort were not 
selected based on a pre-determined study design, but rather on sample availability, which resulted in 
very limited patient sample numbers, thus limiting our analysis substantially. Nonetheless, it may be 
possible to make very preliminary assumptions regarding comprehending how colorectal cancer 
patients with non-resectable liver metastasis respond to selective internal radiotherapy, which could 
provide insight into patient stratification or even likelihood of a desired response. 
2.3.6 Other treatment cohorts 
The other treatment cohort included 88 malignant melanoma patients undergoing either no treatment 
or one of several distinct treatments. Due to the majority of these patients contributing samples at a 
single time point only, post-treatment analysis was not possible, and therefore these patients were 
grouped together as a means of conducting a cancer-specific group analysis, focusing on typically 
expressed antigens and possible correlations with disease stage. 
The primary treatment for melanoma, cancer type described above in Section 2.3.1, is surgery when 
possible, and the additional treatment options include chemotherapy and radiotherapy. In this specific 
treatment cohort, three distinct chemotherapeutic drugs are administered, and these include 
gemcitabine, vinorelbine and dacarbazine. Immunotherapy, also known as biological therapy, focuses on 
the patient’s immune system and utilises naturally occurring endogenous and exogenous substances, as 
well as chemically synthesized substances, which boost, direct or restore the body’s natural defences 
against cancer (www.ncbi.nlm.nih.gov/pubmedhealth). Also in this specific treatment cohort, five 
distinct immunotherapeutic drugs are administered in a clinical trial setting, and these include NY-ESO-
1/ISCOM, BRAF + MEK, ipilimumab, vaccinia melanoma oncolysate, and A2/IL-12. These treatments will 
not be discussed in detail, as we were not assessing responses to treatment, as done in previous 
cohorts, due to sole access to single time point samples across the majority of these patients.  
The 88 patients of this treatment cohort were selected based solely on sample availability (mainly single 
time points per patient, collected by the LICR), and these patients were undergoing a variety of distinct 
cancer treatments (surgery, chemotherapy, radiotherapy, immunotherapy or none), either in a clinical 
trial setting or not, based on an individually defined personal treatment plan by their oncologist, as well 
as personal preference to undergo treatment. Although this selection enabled the analysis of a large 
malignant melanoma cohort, it is essential to note that this introduced significant diversity within this 
cohort. Furthermore, all analyses should take into account this diversity when interpreting any posterior 
findings. Nonetheless, it may be possible to conduct a retrospective analysis, as a means of verifying 
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potential diagnostic or prognostic biomarkers with significant statistical relevance, as well as to assess 
whether and how different therapies significantly alter autoimmune titres.  
For these patients, the clinical information that was found most relevant for this analysis included 
patient ID and number of samples, gender, age at the time of sample collection, disease stage, date at 
which samples were collected and matching treatment at the time, as well as deceased information, as 
indicated in Table 2.10. 
 
Table 2.10 Patient demographics of the melanoma cohort undergoing other treatments. This table 
includes the complete accessed patient information for the melanoma cohort undergoing other 
treatments. -: none; NY-ESO-1/ISCOM, BRAF + MEK, Ipilimumab, VMO (vaccinia melanoma oncolysate), 
A2/IL-12: immunotherapeutic drugs; Gemcitabine, Vinorelbine and DTIC (Dacarbazine): 
chemotherapeutic drugs; RXT: radiotherapy. Dark grey shaded areas indicated outstanding clinical 
information. 
Patient ID Gender Age Stage Sample date Treatment Deceased 
581576  M 
54 
III 
10/Feb/2000 Surgery 
N 
59 17/Mar/2005 NY-ESO-1/ISCOM follow on-study (2003) 
578172 M 
58 
II 
04/Nov/1999 Surgery 
N 
64 20/Oct/2005 - 
579634 M 
69 
III 
24/Nov/2005 
NY-ESO-1/ISCOM follow on-study (2004) N 
70 16/Feb/2006 
825325 F 
33 
IV 
20/Jul/2006 
- 
Y 
37 
02/Sep/2010 
21/Oct/2010 Ipilimumab 
756870 M 
77 
IV 
22/Sep/2000 VMO, NY-ESO-1/ISCOM 
Y 
83 26/Oct/2006 NY-ESO-1/ISCOM follow on-study (2003) 
773298 F 
60 
III 
04/Jul/2002 Surgery  
Y 
68 
16/Mar/2010 - 
30/Sep/2010 Ipilimumab 
707903 F 
45 
IV 
10/Jun/1998 - 
Y 
46 01/Nov/1999 A2/IL-12 
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Patient ID Gender Age Stage Sample date Treatment Deceased 
2044549 M 26 IV 
28/Mar/2011 
BRAF + MEK Y 
22/Jul/2011 
811116 F 71 III 21/Jun/2005 Surgery Y 
806076 M 47 III 20/Oct/2005 - Y 
819515 M 75 II 03/Mar/2006 - N 
827874 M 47 IV 12/Oct/2006 - Y 
532958 F 81 IV 09/Nov/2006 Surgery N 
045723 F 87 IV 08/Nov/2007 Surgery Y 
018615 M 78 I 12/Jun/2008 - Y 
859616 F 48 III 31/Jul/2008 - Y 
189526 F 64 IV 07/Aug/2008 - Y 
115092 M 48 III 18/Mar/2010 - Y 
556868 F 62 IV 22/Apr/1998 - Y 
558959 M 66  02/Jun/1998 Gemcitabine, Vinorelbine Y 
555751 M 48 IV 06/Jun/1998  Y 
540994 F 37 IV 06/Jul/1998 - Y 
068526 F 54  15/Dec/1998  N 
568788 F 32 II 18/Feb/1999 - N 
570397 F 39 II 08/Apr/1999 - N 
560261 F 39  10/May/1999  Y 
574156 F 51 III 15/Jul/1999 Surgery Y 
318133 F 74 III 29/Jul/1999 Surgery, VMO Y 
570369 M 21 III 01/Apr/1999 - Y 
228343 F 48 III 24/Jun/1999  Y 
577323 F 55 III 30/Sep/1999 Surgery Y 
X228302 M 77  03/Dec/1999  N 
574184 F 50 IV 22/Jul/1999 -  
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Patient ID Gender Age Stage Sample date Treatment Deceased 
574971 F 64 IV 05/Aug/1999 - Y 
576503 F 63 III 02/Sep/1999 DTIC Y 
735678 F 40 III 25/Nov/1999 - Y 
579655 F 59 IV 09/Dec/1999 - Y 
081308 M 30 IV 16/Dec/1999 RXT N 
581512 F 55 III 27/Jan/2000 -  
739201 M 25 III 18/Jan/2001 - N 
739649 M 72 IV 30/Jan/2001 Surgery Y 
739648 M 72 III 30/Jan/2001 Surgery Y 
760422 M 39 IV 08/Mar/2001 - Y 
588383 F 45 III 15/Mar/2001 - N 
739555 M 60 IV 29/Mar/2001 - Y 
739586 F 59 II 21/Jun/2001 - Y 
766755 M 62 IV 04/Oct/2001 DTIC Y 
557856 M 42 IV 08/Jun/2000 DTIC Y 
567297 M 63 III 29/Jun/2000 - Y 
739492 F 45 III 30/Nov/2000 - Y 
592455 M 49 IV 14/Dec/2000 - Y 
760600 M 31 III 24/May/2001 - Y 
766181 M 54 III 09/Aug/2001 - N 
767120 F 36 III 01/Nov/2001 - N 
739657 F 44 III 15/Mar/2002 - N 
h310975 F 54 III 31/May/2002 Surgery  Y 
773301 M 55 III 04/Jul/2002 - N 
790406 M 39 III 28/Nov/2002 - Y 
175175 M 66 III 05/Dec/2002 Surgery  N 
783776 F 44 IV 06/Mar/2003 Surgery  Y 
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Patient ID Gender Age Stage Sample date Treatment Deceased 
792319 F 58 II 17/Apr/2003 - Y 
793139 M 55 III 22/May/2003 - Y 
785265 M 68 II 22/May/2003 - Y 
793393 M 76 II 26/Jun/2003 Surgery  Y 
788768 F 71 IV 14/Oct/2003 - Y 
584653 M 51 IV 23/Oct/2003 Surgery, RXT Y 
584655 M 54 IV 22/Apr/2004 Surgery  N 
733506 M 45 III 02/Jun/2004 Surgery  Y 
539105 F 69 I 24/Jun/2004  N 
802701 F 67 III 14/Oct/2004 - N 
163149 M 77 II 18/Nov/2004 - Y 
642244 M 42 III 25/Nov/2004 Surgery  Y 
702850 M 62 IV 11/Dec/2004 - Y 
566332 F 58 IV 10/Feb/2005 Surgery, RXT (CR) N 
583239 M 40 III 16/Mar/2000 - N 
773823 M 72 III 01/Aug/2002 - Y 
541666 F 31 IV 13/May/2004 - N 
801733 M 32 IV 19/Aug/2004 - Y 
694790 M 76 IV 30/Sep/2010 Ipilimumab  
775519 M 55 IV 21/May/2010 Ipilimumab Y 
386412 M 76 III 15/Mar/2005 NY-ESO-1/ISCOM N 
535907 M 57  06/May/1997   
AP 28/09/2007 M 50 IV 28/Sep/2007 Ipilimumab Y 
C 6/3/1996    06/Mar/1996   
CIBL1 M      
2052357 M 49 IV 04/Oct/2011 BRAF + MEK Y 
2052508 M 26 IV 19/Oct/2011 BRAF + MEK Y 
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Patient ID Gender Age Stage Sample date Treatment Deceased 
2050349 M 38 IV 21/Sep/2011 BRAF + MEK Y 
 
The characteristics of these 88 patients, for which clinical information was available, included an 
unevenly weighed population, with more males (n = 50/87, 57%) than females (n = 37/87, 43%), and a 
matching median and mean patient sample age of 54 years, with ages ranging widely from 21 to 87 
years. Amongst this population, the majority of these patients presented with stage III (n = 35/81, 43%) 
and IV (n = 35/81, 43%), and then the remaining stages II (n = 9/81, 11%) and I (n = 2/81, 3%). In regards 
to the treatment undergone, the majority of these patients, for whom treatment information was 
available, received no treatment (n = 47/89, 53%), followed by immunotherapy (n = 18/89, 20%), 
surgery only (n = 17/89, 19%), chemotherapy (n = 4/89, 5%) and radiotherapy (n = 3/89, 3%). Based on 
the available deceased information, the majority of these patients were deceased (n = 58/82, 71%), 
whilst a smaller subset was still alive (n = 24/82, 29%), which was in agreement with the larger number 
of patients with a more advanced stage of disease.   
In regards to the statistical power of this treatment cohort, the number of patients (n = 88) was well 
above the a priori estimate (n = 54), indicating that any potential findings would be obtained with higher 
sensitivity than ideally required. A post hoc estimate was generated to compute the achieved statistical 
power of this cohort (G*Power 3.1.9.2 program, T-test, difference between two dependent means 
(matched pairs), 2-tailed) with a given probability of error (      ), sample size (n = 88) and effect 
size (      ) (Faul et al. 2007; Faul et al. 2009). This calculation indicated an estimated power (   ) 
of 0.996 (noncentrality parameter σ = 4.69, critical t = 1.99, degrees of freedom = 87), and therefore the 
probability of this cohort detecting a statistically relevant finding surpassed the initial ideal estimate. 
However, as sample collection was based only on availability, a very heterogeneous cohort undergoing a 
variety of different or no treatments was obtained, which may substantially and differentially alter 
patient antibody repertoires, thus limiting the achieved statistical power of potential findings.  
Nonetheless, this is the treatment cohort with the largest number of patient samples, which is of great 
use when attempting to verify potential diagnostic or prognostic biomarkers with significant statistical 
relevance.  
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3 PROTEIN MICROARRAY 
DEVELOPMENT 
3.1 Introduction 
The following Section will discuss in detail our protein microarray assays, from prototypical protein 
microarray principles to our patient sera assays, covering all relevant topics which will enable a 
complete understanding of this topic.  
Protein microarrays have many potential applications in biomarker discovery and the systematic, 
quantitative analysis of protein function. This technology addresses several biological questions via the 
high-throughput analysis of biochemical and/or biological interactions between the arrayed proteins 
and other biomolecules contained in complex sample solutions, thereby generating significant volumes 
of proteomic information for analysis (Hardiman 2003; Duarte et al. 2013). 
 Fundamentally, protein microarray technology is based on the immobilisation of multiple proteins onto 
a surface (typically glass, gold or plastic) in a spatially defined array for use as capture probes. The 
techniques of immobilisation are important both for effective concentration and orientation of 
immobilised proteins on the surface and also to preserve their folded conformations. There are two 
categories of protein immobilisation methods, covalent and non-covalent. The covalent immobilisation 
method is based on a covalent coupling to a cross-linker attached to the surface. By contrast, the biotin–
streptavidin methodology used by our group is a non-covalent immobilisation method based on the high 
affinity of the biotin and streptavidin interaction. This method links biotinylated macromolecules to a 
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surface that was previously derivitised with streptavidin via a single point of attachment (see Fig. 3.1) 
(MacBeath & Schreiber 2000; Büssow et al. 2001; Duarte et al. 2013). 
 
Figure 3.1: Schematic of single-step immobilisation/purification route to array fabrication. The array 
surface is intrinsically ‘nonstick’ with respect to proteinaceous material but has a high affinity and 
specificity for biotinylated proteins. Crude cellular lysates containing the recombinant biotinylated 
proteins can then be printed onto the surface in a defined array pattern (step a) and all non-biotinylated 
proteins removed by washing (step b), leaving the recombinant proteins purified and specifically 
immobilised via the affinity tag in a single step. [Adapted from (Duarte et al. 2013).] 
 
 
 
One of the main goals in protein microarray experiments is the quantitation of interactions between the 
probes immobilised on the slide surface and target analytes contained in the sample solution. To permit 
detection of this typically bimolecular interaction, molecules with specific interaction properties are 
labelled with either fluorescent, photochemical or radioisotope tags. The choice of one detection 
method over another depends on the need to reach a low signal-to-noise ratio at an affordable cost for 
the specific assay in question. Since the vast majority of target analytes are not naturally coloured, 
fluorescent, bioluminescent or radioactive, detection of the molecular interaction on a protein 
microarray usually requires that some detectable molecule (a ‘label’) be included in the assay, either by 
direct conjugation to the analyte molecule itself or by conjugation to some secondary detection agent 
(e.g. an antibody) that can also bind to the analyte once it is specifically captured onto the array surface. 
Label-free biosensors (e.g. surface plasmon resonance- and quartz crystal microbalance-based 
biosensors) circumvent this problem, but in most manifestations are not yet truly compatible with 
medium- to high-density protein microarrays, plus they struggle to match label-based methods in terms 
of assay sensitivity (i.e. limit of detection). The choice of potential labels is wide: Chemiluminescence is a 
highly sensitive label-based detection method, but it has a relatively limited dynamic range; 
radioactivity-based methods are much less frequently used today because of safety concerns; 
 62  
fluorescent labelling is still therefore currently the most widely used detection method for protein 
microarray experiments since it is highly sensitive, stable, safe and effective and can be archived for 
future imaging. However, the direct labelling of analyte molecules might affect their ability to interact 
with their respective binding partners (Klein & Thongboonkerd 2004; Hall et al. 2007; Schweitzer et al. 
2003). In the context of antigen microarray-based assays to measure human autoantibody profiles, the 
simplest mode of detection is thus via use of a fluorescently labelled antihuman IgG as a secondary 
detecting agent, since this will bind with high affinity to all human autoantibodies captured onto the 
antigen array surface, removing the need to label each target analyte in every biological sample (Duarte 
et al. 2013).  
This technology thus enables the high throughput, parallel analysis of a number of different molecular 
interactions under uniform assay conditions (Wolf-Yadlin et al. 2009; Boutell et al. 2004; Kodadek 2001; 
Predki 2004; Zhu et al. 2000; Zhu et al. 2001; Michaud et al. 2003; Fang et al. 2003), albeit not typically 
yielding robustly quantitative data, and in principle therefore enables identification of novel disease-
specific serological markers that are not readily accessible by other proteomic technologies (Matarraz et 
al. 2011; Sanchez-Carbayo 2011; O’Kane et al. 2011). 
Upon commencement of this study, the initial prototype of the CT antigen array platform (CT100) had 
been assessed and defined as poorly reproducible, with non-workable intra-array CVs, and rudimentary 
data analysis software. Additionally, no data was available regarding limits of detection or linearity of 
response. Therefore, the first goal of this Thesis was to systematically develop and validate a robust, 
quantitative CT antigen array platform with expanded content. This process is thoroughly described in 
this protein microarray development Chapter.  
3.2 Methodology  
3.2.1 In-house streptavidin coated surfaces 
In-house streptavidin-coated array surfaces were developed, based initially on a protocol published by 
our group (Blackburn et al. 2012), with a focus on significantly improving uniformity and reproducibility 
of surface coatings.  
A vial containing 100 mg of streptavidin lyophilisate (Prospec, 100 mg, #PRO-283) was equilibrated to 
RT, and then dissolved in 10 mL of 1x spotting buffer (100 mM KCl, 0.01% Triton X-100, 25 mM HEPES, 
pH 8.5 in dH2O), with constant vortexing for 30 min. A 10 mL streptavidin solution at a final 
concentration of 1 mg/mL was prepared in the 1x spotting buffer. Nexterion H slides (Schott, 25 slides, 
#1070936) were removed from -20 °C storage and equilibrated to RT for 1 h to avoid condensation. A 
processing chamber was put together to allow for the assay steps to occur fluidly, as indicated in Fig. 
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3.2. The following steps took place in a plastic chamber wrapped in foil placed on an orbital shaker at RT 
with gentle shaking (20-40 rpm). Each slide was immersed in the sequential chambers as follows: 1) 
Derivitising in streptavidin solution for 1 h, 2) Blocking in blocking buffer (50 mM Ethanolamine in 0.1 M 
Potassium phosphate buffer (PPB) pH 8.0) for 1 h, 3) three washes in wash buffer (0.1 M PPB pH 8.0) for 
5 min each, 4) one final wash in dH2O, 5) drying in a falcon tube using the centrifuge at 483 x g at RT. 
This process was repeated until obtaining a pre-determined amount of streptavidin coated H slides. 
Slides were then stored in an appropriate light blocking container, labelled with batch details, and 
stored at -20 °C.  
  
Figure 3.2: Flowchart of in-house streptavidin coating of Nexterion H slides.  
 
QC tests were performed for each batch to determine whether the coating across the slide surface was 
homogenous. For this purpose, the last slide of the batch was immersed in a 5 ng/µL concentration of 
Cy5-biotin-BSA (provided by the CPGR) for 30 min at RT in a container wrapped in foil placed on an 
orbital shaker with gentle shaking. The slide was then washed three times in PBST (1x phosphate 
buffered saline (PBS), 0.1% Tween-20) for 5 min each, and once in dH20 for 5 min. After drying, the slide 
was scanned using a Tecan LS Reloaded fluorescence microarray scanner (Tecan Group, Mäannedorf, 
Switzerland). Using the ArrayPro data extraction and analysis software (Media Cybernetics, Rockville, 
MD), the CVs were calculated using spots, blocks and whole slide area overlaid grid settings. The main 
intent was to obtain a homogeneity measure of solely the printing/assay area, as the whole slide area 
CV could be misleading. Finally, a QC report was prepared, as a means of being able to refer back to 
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these details after performing assays. A CV of < 5% for the slide assay area was required, to ensure good 
quality coating for subsequent assays.  
3.2.2 Cloning cancer-testis antigen genes 
The following cloning was carried out by Dr. Aubrey Shoko from the CPGR. 
A parental insect cell expression vector was constructed essentially according to previously published 
methods (Blackburn & Shoko 2011). The E. coli biotin carboxyl carrier protein (BCCP) domain, amino 
acids 74–156 of the E. coli accB gene (Athappilly & Hendrickson 1995; Chapman-Smith & Cronan 1999) 
was cloned 5′ to a c-Myc epitope in an E. coli transfer vector, pAS1, derived from pTriEx-1.1 (Novagen, 
Merck Millipore, Johannesburg, South Africa). cDNA clones for each CT antigen of interest were 
obtained from Origene (Rockville, MD, USA), Open Biosystems (Thermo Scientific, Waltham, MA, USA) 
or GeneService (Source BioScience, Nottingham, UK). PCR primers were designed from the coding 
sequence of each cDNA such that the stop codon would be removed, enabling cloning into the pAS1 
transfer vector 5′ to and in-frame with the 3′-BCCP tag via ligation-independent cloning methods (all 
primers were synthesized by IDT, Glasgow, UK) (Yang et al. 1993). Each resulting recombinant transfer 
vector thus encoded an individual CT antigen fused to a C-terminal c-Myc-BCCP tag. Successful PCR 
amplification of each antigen was confirmed by gel electrophoresis, while successful cloning was 
determined by Sanger sequencing. All sequences were verified against the RefSeq database 
(www.ncbi.nlm.nih.gov/refseq). Recombinant baculoviral vectors were prepared for each cDNA clone 
and these were then transfected into Sf21 cells, using a system we previously adapted from the work of 
Prof Ian Jones (Reading University, UK) (Blackburn & Shoko 2011; Zhao et al. 2003). Based on the 
intended array layout, size restrictions and necessary spot spacing, a total of 123 full length antigens 
were cloned and expressed in insect cells as N-terminal fusions to the Escherichia coli BCCP protein 
domain (Athappilly & Hendrickson 1995; Chapman-Smith & Cronan 1999) for printing on the CT100+ 
array. These were compiled based on a broad literature search of relevant cancer-related antigens, 
some of which have been previously described as potential biomarkers or therapeutic targets (CT 
antigen database: www.cta.lncc.br; Cancer Immunity Peptide Database: 
www.cancerimmunity.org/peptide; Protein database: www.uniprot.com). It was intended that these 
were not specific to a single cancer type, as a means of assuring potential applicability across a variety of 
cancers, and that these included TAAs and TSAs. Of the 123, 79 were CT antigens, which were 
thoroughly described in Section 1.5, while the remaining 44 were other cancer-associated antigens, such 
as protein kinases, p53s, cytochrome P450s and oncoproteins (see Table 3.1). 
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Table 3.1 List of the 123 antigens included on the CT100+ array.  
ID Name ID Name ID Name ID Name ID Name 
001 BAGE2 026 LEMD1 051 SGY-1 076 CDK7 101 5T4/TPBG 
002 BAGE3 027 LIP1 052 SILV 077 FES 102 XAGE1B 
003 BAGE4 028 MAGEA1 053 SPAG9 078 FGFR2 103 SOX2 
004 BAGE5 029 MAGEA10 054 SPANXA1 079 MAPK1 104 ACVR2A 
005 CCDC33 030 MAGEA11 055 SPANXB1 080 MAPK3 105 ACVR2B 
006 CEP290 031 MAGEA2 056 SPANXC 081 PRKCZ 106 ITGB1 
007 COL6A1 032 MAGEA3 057 SPANXD 082 RAF 107 MAP9 
008 COX6B2 033 MAGEA4v2 058 SPO11 083 SRC 108 PIM1 
009 CSAG2 034 MAGEA4v3 059 SSX1 084 CALM1 109 TKTL1  
010 CT47.11 035 MAGEA4v4 060 SSX2A 085 CDC25A 110 SPATS1 
011 CT62 036 MAGEA5 061 SSX4 086 CREB1 111 DPPA2 
012 CTAG2 037 MAGEB1 062 SYCE1 087 CTNNB1 112 SOX1 
013 CXorf48.1 038 MAGEB5 063 SYCP1 088 p53 S6A 113 ROPN1A 
014 DDX53 039 MAGEB6 064 THEG 089 p53 C141Y 114 CEACAM 1 
015 DSCR8 040 MART-1 065 TPTE 090 p53 S15A 115 POU5F1 
016 FTHL17 041 MICA 066 TSGA10 091 P53 T18A 116 NANOG 
017 GAGE1 042 NLRP4 067 TSSK6 092 p53 Q136X 117 BORIS B0 
018 GAGE2A 043 NXF2 068 TYR 093 p53 S46A 118 DPPA4 
019 GAGE4 044 NY-CO-45 069 XAGE-2 094 p53 K382R 119 DPPA3 
020 GAGE5 045 NY-ESO-1 070 XAGE3av1 095 p53 S392A 120 GDF3 
021 GAGE6 046 OIP5 071 XAGE3av2 096 p53 M133T 121 LAGE-1b 
022 GAGE7 047 p53 072 ZNF165 097 p53 L344P 122 CAMEL 
023 GRWD1 048 PBK 073 AKT1 098 CYP450 3A4 123 NY-ESO-1 ORF2 
024 HORMAD1 049 RELT 074 CDK2 099 CYP450 red   
025 LDHC 050 ROPN1 075 CDK4 100 EGFR   
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3.2.3 Expression of cancer-testis antigens 
The following protein expression was carried out by Dr. Aubrey Shoko from the CPGR. 
Recombinant CT antigens were expressed in Sf9 insect cells using a previously published protocol 
(Blackburn & Shoko 2011). The soluble, crude protein extracts were collected, the protein 
concentrations were determined by Bradford assay (Bradford 1976) and the extracts were stored at -80 
°C before array printing. Expression of each antigen was assessed by western blot using a 1:5000 
dilution of monoclonal anti-c-Myc antibody produced in mouse (Sigma-Aldrich, 2 mL, #M5546) followed 
by a 1:25000 dilution of anti-mouse IgG (H+L) horseradish peroxidase (HRP) conjugate produced in goat 
(KPL, 1 mg, #074-1806). Biotinylation of each antigen was assessed by western blot using a 1:40000 
dilution of streptavidin-HRP conjugate probe (KPL, 0.5 mg, #14-30-00). 
3.2.4 Fabrication and optimization of the cancer-testis antigen (CT100+) 
microarray   
Crude lysates of each antigen were diluted 1:1 in printing buffer (1x PBS, 20% sucrose) and 40 µL of the 
diluted crude protein extract for each BCCP-tagged protein was transferred to individual wells of a 384-
well V-bottom plate. The plate was centrifuged at 1000 x g for 2 min at 4 °C to pellet any residual cell 
debris and then kept at 4 °C before and during the microarray print run. Each CT100+ array was printed 
on a previously thawed streptavidin-coated microarray slide using a QArray2 robotic arrayer equipped 
with 8 x 300 µm flat-tipped solid pins. Each array was printed in eight grids of 8 x 8 spots (i.e., 480 
discrete protein spots per array) with a spot-to-spot spacing of 562 µm. In principle, this format enables 
up to 170 individual protein types, including controls, to be printed in triplicate in each array field. The 
printing procedures were performed at RT, while the source plate was kept at 4 °C and the print 
chamber humidity was maintained at ~50%. The arrays were printed using the settings indicated in 
Table 3.2. 
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Table 3.2 CT100+ microarray printing settings used for each print run.  
Arraying pattern 8 rows x 8 columns of spots per grid  
Maximum stamps per ink 1 
Number of stamps per spot  1 
Stamp time  0ms 
Inking time   500 ms 
Print depth adjustment   150 microns 
Number of touch offs  0 
Water washes  60 s wash and 0 s dry 
Ethanol wash   10 s wash and 1 s dry 
 
Replica CT100+ arrays were printed in a four-plex format (i.e., four replica arrays per slide) using the 
previously loaded samples. Each of the 123 CT antigens and cancer-associated antigens was printed in 
triplicate within each array. The positive controls consisted of 10 ng/µL of biotinylated human IgG 
(Rockland Immunochemicals, 1 mg, #009-0602), which serves as a confirmation that detection antibody 
was added to the assay and was able to bind to the antigen under the assay conditions; 100 ng/µL of 
biotinylated anti-human IgG antibody produced in goat (Sigma-Aldrich, 1 mL, #I5260), which bind to IgG 
present in patient sera and thus serves as a confirmation that sera was added to the assay and was able 
to interact with the antibody under the assay conditions. In addition, three concentrations of 
biotinylated Cy5-BSA (5, 10 and 15 ng/µL) were included in each sub-array for slide orientation and 
signal normalization purposes, which also serve as a confirmation that the protein microarray print run 
was successful. The negative controls comprised of control buffer only; BCCP-myc tag only; and insect 
cell “empty vector” lysate, to ascertain any background fluorescence or non-specific immunochemical 
interactions. The array design is shown in Fig. 3.3. These printing parameters and the array layout, 
including the location of individual antigens, were recorded in a .gal file output from the arrayer. After 
printing had concluded, each slide was kept in the microarrayer for at least 30 min, as a means of 
assuring a humid environment to prevent evaporation and facilitate protein-surface interactions. Each 
slide was then stored in an upright light-protected container at 4 °C until use. 
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Figure 3.3: CT100+ array design printed four times (4-plex) across each slide. This image indicates a 
single slide with 4 replica arrays, with focus on the complete representation and localisation of the 
printed antigens across a single CT100+ array, with antigens indicated by their ID number, and controls 
indicated by name. Positive controls are indicated in red across the array.  
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3.2.5 Development of the CT100+.jar bioinformatic tool 
We developed a bioinformatic pipeline for pre-processing and quality control of custom protein 
microarray data, which was automated in Java. A prototype version of this program suitable for the first 
version of our platform (CT100 array) was created previously by a previous student in the Blackburn 
Laboratory, Mr. Jean-Michel Serufuri (Safari Serufuri 2010). The following processing steps were 
included in this original bioinformatic tool:  
1) the local background signal – mean intensity of local corners – for each spot was replaced 
by its neighbourhood background (i.e. median value of the mean background intensities of 
the surrounding  8 (3 x 3 window)  neighbourhood spots,  see Fig. 3.4) (Zhu et al. 2006);  
2) The net intensity for each spot was calculated by subtracting its neighbourhood 
background from its foreground signal; 
3) All spots containing a net intensity of less than two standard deviations of the background 
(noise threshold) thereof were removed from analysis;  
4) The mean net intensities for each set of replicates were calculated, and replicates 
containing a CV of > 20% (user-defined) were removed;  
5) Whole arrays were filtered to remove any exhibiting a CV > 20% (user-defined) across the 
array for a chosen control (we used 5, 10 or 15 ng/µL Cy5-biotin-BSA). Any resulting whole 
arrays with unsatisfactory CV values were discarded and indicated as a required repeat; 
6) Sub-arrays within each array were normalized with respect to each other to minimize any 
effects of pin-to-pin variation; 
7) Whole arrays were then normalized with respect to each other to minimize any effects of 
slide-to-slide variation.  
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Figure 3.4: Visual illustration of the local background correction method. The local background of the 
centre spot is replaced by a median of the local backgrounds of surrounding neighbourhood spots (3 x 3 
spot window), as a means of avoiding skewed background intensities due to artefacts or dust particles. 
The corrected net intensity is measured by the centre spot’s raw intensity minus corrected background 
intensity. Green spot: neighbourhood spot: Red spot: centre spot; Brown diamond: local background 
[Adapted from (Zhu et al. 2006).]. 
 
 
In regards to the normalization of the pin-to-pin and array-to-array variation, a novel composite 
normalization method combining both quantile and total intensity normalization modules was used 
(Duarte et al. 2013). This method aimed to make more efficient, effective and robust usage of a 
relatively small number of positive controls to correct for systematic bias in pin-to-pin and array-to-array 
variations. Robustness is the ability of the method to cope with the flagging of some positive controls, 
while still being based on sound biological principles. The normalisation assumption was that our 
positive control spots shared a common underlying distribution across the chips (block, arrays, etc.) on 
which they were printed. This perspective provided greater flexibility than assuming that the individual 
positive control spots maintained the same intensities across the chips. Thereafter, our composite 
normalisation method corrects for systematic bias among the chips, while providing more robustness 
when dealing with flagged positive control spots (Causton et al. 2004)(Bolstad et al. 2003). These 
modules are thus described below in detail.  
i) Quantile-Based Module 
Since the positive control spots (Cy5-biotin-BSA) are replica spots across different arrays, it 
seemed reasonable to assume that they share an underlying distribution across arrays, and the 
quantile approach can be used to identify the corresponding housekeeping spot intensities 
based on their intensity distributions. 
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Bolstad et al. described an algorithm to carry out spot identification within the same quantile according 
to the following steps, where     is the intensity of a positive control spot   on chip  : a) load the positive 
control spot intensities       into an     matrix  , b) sort the spot intensities in each column   of   to 
get       and c) Take the means across each row   of       and get  ̅   
  ̅  is considered the underlying distribution of the positive control spot intensities across chips (Bolstad 
et al. 2003). This reorganisation enabled more flexibility in handling outliers or flagged spots within the 
positive control data set. 
ii) Total Intensity-Based Module 
This module assumed that post-normalisation, all arrays had a common total intensity value of their 
positive control spots (i.e. the sum of all the positive control spot intensities on each array should be 
constant), given by ∑  ̅ 
      
   . The normalisation factor    to normalise array   is then given by  
    
∑  ̅ 
      
   
∑  ̅  
      
   
 
where ∑  ̅  
      
    is the total intensity of all the positive control spots on array   prior to normalisation 
(Causton et al. 2004; Quackenbush 2001). This scaling normalisation method assumes that different 
arrays share a common total intensity of their housekeeping spots, while taking into account the 
potential existence of flagged spots within the housekeeping spots. Importantly, if a given positive 
control spot is identified as an outlier on one array (i.e. it is flagged for some reason), the corresponding 
positive control spots across all arrays are identified in the quantile module above and are then also 
flagged across all arrays prior to normalisation; the net consequence of this is to ensure that the same 
number of positive control spots are considered across all arrays during normalisation. 
This prototype program was rigidly designed for the CT100 array exact antigen layout, which initially 
comprised only 100 cancer-associated antigens and original controls. Therefore, if any additional 
antigen was added to this layout, this tool was not able to function correctly, which accentuated the 
need for a dynamic version of this program, that could function with any antigen layout (read from the 
.gal file) that was provided. Additionally, when interpreting the program’s code itself, several bugs were 
identified, which required immediate attention. For example, when saturated spots were observed, 
these were flagged, and set to zero, which led to the loss of data from our highest detected 
autoantibody titres. A solution to this issue would be to scan each slide using an automatic gain control 
(AGC) mode, which would automatically adjust the scanning gain setting to a level where no saturation 
was observed. As our program includes normalization steps, these values would later be adjusted, and 
no signals would be lost. An additional error included averaging the mean net intensities of triplicate 
spots for a given antigen. When one of the replica spots was discarded based on a previous filtering 
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condition, the program automatically set that titre to zero. This led to the loss of real autoantibody titres 
for certain antigens, which was not ideal. A solution to this issue would be when only two out of the 
three autoantibody titre replicas for a given antigen are available and similar (i.e. where the duplicate 
means have low CV values), a mean should still be calculated and utilised in the final consolidated data 
file. Therefore, together with the assistance of a current colleague, Mr. Ryan Goosen, we adapted and 
improved this prototype tool to accommodate the numerous changes our protein microarray platform 
has undergone since then (CT100+ array).  
Besides from the above-mentioned adaptations, the following parameters were also included: 
1) A user-defined adjustable noise threshold; 
2) A more descriptive program output, which includes CV  information per antigen and array, 
as a means of allowing the user to verify why an array has been discarded from analysis; 
3) Whole array CV discarding automatically calculated for each Cy5-biotin-BSA control, but all 
processing that follows conducted using the user-selected control. This addition would 
permit the user to verify which control is best used for this purpose, without having to 
conduct three separate program runs; 
4) Autoantibody titre  replicates should only be considered if two or three of the replicates 
were available and similar, which would assure that skewed means were not calculated if 
one of the three replicas was either too high or too low, and that titres towards an antigen 
were not flagged as high CV and unnecessarily set to zero due to one unusable replicate. 
This addition would avoid us from obtaining skewed means and from losing relevant 
autoantibody signals; 
5) A less cluttered output file, which only includes the consolidated files, before and after 
averaging, the user-defined settings and processing steps used, the whole array discarded 
lists per Cy5-biotin-BSA control, user-friendly program interface (see Fig. 3.5 and 3.6) and 
understandable output. 
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Figure 3.5: CT100+.jar program interface settings selection. After selection of the raw data, this user-
friendly interface allows the user to indicate which settings should be used for analysis, such as mean or 
median intensity, whole array filtering control selection and CV threshold, replica CV threshold and 
noise filter threshold.   
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Figure 3.6: CT100+.jar program interface processing steps selection. After the selection of analysis 
settings, this interface allows the user to select which methods should be used for processing.  
 
 
Additionally, to account for issues such as spot running, missing spots (pin sticking), washing artefacts, 
dust particles, and faded arrays, a visual assessment and discarding of each array image was essential 
(Duarte et al. 2013). When evaluating the quality of an array image, there are many considerations that 
should be taken into account, such as: 
1) Spot-to-spot variation – when looking at the signal of triplicate spots, one should expect a 
similar signal across all replicas, as well as uniform spots across the whole slide. Variations which 
may occur include a) spot running (2 or more spots run into each other due to close proximity 
between spots or inappropriate spotting buffer, compromising the signal of all affected spots); 
b) pin sticking or erroneous pin calibration (inadequate cleaning of the arrayer pins and 
printhead between print runs could lead to the failure to print some or all intended spots, as 
well as non-reproducible printed spots); and c) washing artefacts and speckles (inadequate 
washing steps throughout the assay could lead to large washing artefacts which appear as 
negative spots or random additional smaller spots across the slide) on the array surface; 
2) Spot homogeneity – when looking at the signal of an individual spot, one should expect a 
homogenous signal across all pixels within that spot. Variations which may occur include a) the 
‘doughnut’ effect (inadequate pin height during print run and liquid residues on the pin body 
when immersing pin head in source plate could lead to uneven spot distribution); b) dust 
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particles (inadequate storage and handling of slides during assays could lead to the presence of 
dust particles on spots of interest, which appear as high-intensity pixels and skews the real 
signal) on the array surface; and c) temperature and humidity conditions (increased 
temperature/decreased humidity may lead to the evaporation of printed spots, and humidity 
above 75% may lead to condensation, which would account for an uneven intensity within 
spots). The homogeneity between replica spots can be measured by calculating the coefficient 
of variation (CV), which is the ratio between the standard deviation (SD) of all pixel intensities 
within a spot and the mean intensity as a percentage; 
3) Background variation – when looking at several spots across an array, one should expect low 
variation of the background between the neighbourhood spots. Variations which may occur 
include dust particles (inadequate storage and handling of slides during assays could lead to the 
presence of dust particles around spots of interest, which results in high local background for a 
specific spot and difficulty distinguishing between real signal) on the array surface; 
4) Signal-to-noise ratio – when looking at several spots across an array, one should expect the spot 
intensity to be greatly above its local or neighbourhood background. Variations which may occur 
include washing artefacts and speckles (inadequate washing steps throughout the assay could 
lead to large washing artefacts which appear as negative spots or random additional smaller 
spots across the slide) and dust particles (inadequate storage and handling of slides during 
assays could lead to the presence of dust particles around spots of interest, which results in high 
local background for a specific spot and difficulty distinguishing between real signal) across the 
array surface. To be confident that the net spot intensity (i.e. foreground intensity minus 
background intensity) is significantly above background, a signal-to-noise ratio of at least 2 is 
used for quality assurance, with ‘noise’ defined as the standard deviation of the background 
pixels. 
 
Therefore, a list of all computationally or visually discarded arrays was compiled, and the respective sera 
samples re-assayed. These adaptations increase the possibility of obtaining more robust resulting data 
and associated conclusions in a rapid automated setting, which removes chances of human error and 
time-consuming processing when dealing with large amounts of data. 
3.2.6 Linearity and dynamic range microarray assays 
Prior to commencing the array experiments, robust linearity and dynamic range experiments were 
carried out to determine the optimal serum and anti-human IgG antibody dilutions for detection of 
antibody-antigen binding. 
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3.2.6.1 Linearity and dynamic range microarray fabrication 
A single NY-ESO-1 crude lysate was diluted 1:2 in lysis buffer (25 mM HEPES, 50 mM KCl, 20% glycerol, 
0.1% Triton X-100, 1 mM DTT in dH20), and 30 µL was transferred to an individual well of a 384-well V-
bottom plate (Separations, #MD-X7022), along with 30 µL of lysis buffer only (negative control), and 30 
µL of Cy5-bioitn-BSA (16 ng/mL, positive control). On each array, a 6 x 6 grid was printed on a previously 
thawed streptavidin-coated microarray slide using a QArray2 robotic arrayer (Genetix, Berkshire, UK)) 
equipped with a single 300 µm flat-tipped solid pin. The printing procedures were performed at RT, 
while the source plate was kept at 4 °C and the print chamber humidity was maintained at ~50%. The 
arrays were printed using the settings indicated in Table 3.3. 
 
Table 3.3 Linearity and dynamic range microarray printing settings used for each print run. 
Arraying pattern 6 rows x 6 columns of spots per grid  
Maximum stamps per ink 1 
Number of stamps per spot  1 
Stamp time  0 ms 
Inking time   500 ms 
Print depth adjustment   150 microns 
Number of touch offs  0 
Water washes  60 s wash and 0 s dry 
Ethanol wash   10 s wash and 10 s dry 
 
Replica arrays were printed in a 16-plex format (i.e., 16 replica arrays per slide) using the previously 
loaded samples. Each antigen and control had six replica spots printed within each array. These printing 
parameters and the array layout, including the location of individual antigens, were recorded in a .gal 
file output from the arrayer. After printing had concluded, each slide was kept in the microarrayer for at 
least 30 min, as a means of assuring a humid environment. The printed slide was then stored in an 
upright light protected container at 4 °C until use. 
3.2.6.2 Linearity and dynamic range assay 
An initial linearity assay was performed in duplicate using serial dilutions of a single serum sample 
(P117, day 483) at 1:50, 1:100, 1:200, 1:400, 1:800, 1:1,600, 1:3200 and 1:6400 dilutions in PBST. A 
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previously printed slide was immersed in blocking buffer (50 µM biotin in lysis buffer) and incubated on 
ice for 1 h, in a plastic chamber wrapped in foil with gentle shaking. The slide was then washed three 
times for 5 min in lysis buffer, and then placed in a falcon tube and centrifuged at 483 x g for 5 min at RT 
to dry. A 16-chamber silicone gasket (Flexwell incubation chamber; Grace Bio-Labs, OR) and a 16-
chamber metal gasket (ProPlate slide chamber system; Grace Bio-Labs) were assembled over the slide. A 
serum volume of 45 µL was added to each gasket chamber and incubated at RT for 1 h, after which each 
chamber was washed independently with PBST. Alexa Fluor 546 (Cy3 equivalent) Goat anti-Human IgG 
(H+L) (Invitrogen, Life Technologies, 2 mg/mL, #A21089; 1:100 dilution in PBST) was added to each 
chamber and incubated for 1 h at RT. The gasket was removed and the slide was washed in PBST, dried 
and scanned at various gain settings on an LS Reloaded fluorescence microarray scanner.  
An additional linearity assay was performed using serum dilutions 1:200 and 1:2400 (P117, day 483), 
with each serum dilution (45 µL) added to a separate individual array on a previously blocked and 
washed slide. After incubation as above, each array was washed independently and Alexa Fluor 546 
Goat anti-Human IgG (45 µL diluted in PBST to final concentrations of 1.25, 2.5, 5, 10, 15, 20, 30 and 40 
µg/mL) was incubated on duplicate individual arrays for 1 h at RT. The slide was then washed, dried and 
scanned. 
A dynamic range assay was similarly performed in duplicate using serial serum dilutions (1:1000, 1:2000, 
1:4000, 1:8000, 1:16000, 1:32000, 1:64000 and 1:128000) and a fixed concentration of Alexa Fluor 546 
goat anti-human IgG (20 µg/mL).  
The complete assay design is summarized in the flowchart indicated below in Fig. 3.7.    
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Figure 3.7: Flowchart of the linearity and dynamic range assay design. 
 
3.2.6.3 Linearity and dynamic range data extraction 
Using GenePix Pro Acquisition and Analysis Microarray software (Molecular Devices Inc., USA), a grid 
was autoaligned over the individual spots on each scanned image file and manually configured across 
the whole array surface. The raw data of each feature on the array was then analysed and a report was 
generated containing the median fluorescence and background pixel intensities per sample spot. This 
data was then used for further processing and analysis. 
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3.2.6.4 Linearity and dynamic range data processing and analysis 
A manual analysis of protein array raw data was carried out as follows: (1) Any spots which displayed 
saturation were removed from analysis; (2) The net intensity (RFU values) for each spot was calculated 
by subtracting its median background from its median fluorescent intensity; (3) All spots in each grid 
containing a net intensity of less than two median standard deviations of the background were removed 
from analysis; (4) The mean net intensities for each set of replica spots were calculated across the array, 
and replicates containing a CV of above 30% were removed from analysis. No pin-to-pin normalization 
was necessary as the printing design only used a single pin. No slide-to-slide normalization was 
necessary as each assay was contained within a single printed slide. GraphPad Prism software 
(GraphPad Software, Inc. – Version 4.0, Radioligand Binding Analysis) was used to generate saturation 
binding curves and Scatchard plots. 
3.2.7 Quantification of the absolute array detection limit for cancer-testis 
antigens 
To estimate the absolute detection limit of our CT antigen microarray platform, three further assays 
were performed using the same serum sample used for the linearity assays: a Bradford assay, a Sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)-based densitometry assay, and a 
protein microarray assay.  
Firstly, the absolute total protein concentration of the serum sample was determined by extrapolation 
of a standard curve obtained by conducting a typical Bradford protein assay, using BSA standards 
(Bradford 1976).  
Secondly, a 7.5 % SDS-PAGE gel was prepared and analysed according to standard methodology 
(Ausubel et al. 1999). The protein molecular weight marker used was the PageRuler prestained protein 
ladder (Thermo Scientific, # 26616). The SDS-PAGE gel was then stained using AcquaStain (Vacutec) for 
10min and rinsed in dH2O, as no destaining was required. A densitometry analysis (Gene Tools; Syngene, 
Cambridge, UK) was then performed to determine the proportion of total protein corresponding to total 
IgG. 
Thirdly, a protein microarray assay was performed to determine the proportion of total IgG 
corresponding to anti-NY-ESO-1. This last assay was performed in quadruplicate as follows: replica 16-
plex arrays of the serum sample (1:800 dilution in 1 M PPB pH 8.0 containing  15% glycerol) were printed 
on an un-derivitised Nexterion H slide using a single 300 µm flat-tipped solid pin, unreacted NHS esters 
were blocked for 1 h in blocking buffer (50 mM ethanolamine in chilled 50 mM PPB), and 45 µL anti-
human IgG (100 ng/mL), NY-ESO-1-BCCP crude insect cell lysate (1:20 dilution), insect cell “empty 
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vector” lysate (ICL) (1:20 dilution), or buffer-only control were incubated on discrete replica arrays for 1 
h at RT. Each array was washed independently with PPB, and Cy5-labelled streptavidin (GE Healthcare, 
0.5 mg/mL, # PA45001; 1:500 dilution in PBST) was incubated on each replica array for 1 h at RT, after 
which the slide was washed, dried, scanned and analysed as before. 
3.2.8 Standard CT100+ array quality controls  
As a means of assessing whether each protein microarray print run met the defined robust quality 
standards, three distinct assays were performed routinely for each print run. These included verifying 
that the 123 printed antigens were bound successfully to the array, that a pooled cancer patients 
sample gave rise to a positive array with several autoantibody titres towards cancer-related antigens 
being detected, and that a pooled healthy patients sample gave rise to a negative array with no 
autoantibody titres towards cancer-related antigens being detected.  
3.2.8.1 Verification of the immobilization of BCCP-tagged proteins to array surface 
A c-Myc assay was conducted to verify that all antigens were immobilized on the array surface, following 
a successful microarray print run, as each protein contains both a BCCP-tag and a c-Myc tag. An 
individual array per print run was incubated with 100 µL of Monoclonal anti-c-Myc-Cy3 Clone 9E10 
(Sigma, 1.3 mg/mL, #C6594; 1:50 dilution in PBST) for 30 min at RT. This assay differs from that indicated 
previously in Section 3.2.5.2 only in regards to adding c-Myc antibody instead of detection antibody, and 
by not including a serum sample incubation step. Additionally, the array was scanned using both the Cy3 
and the Cy5 laser (dual scan), as a means of detecting all Cy5-biotin-BSA control spots and all antigens 
which have a c-Myc tag. Both anti-human IgG and human IgG spots are not detected in this assay, as 
their signal is sera and detection antibody dependent.  The resulting data was extracted and processed 
as indicated previously. 
3.2.8.2 Verification of array specificity for cancer 
As a means of verifying the array’s specificity for cancer, two control groups, cancer and healthy 
patients, were defined. All sera samples gathered for each group were later pooled together, creating a 
cancer control pool and a healthy control pool, respectively. Two individual arrays were incubated with 
either control pool per print run, and the assay proceeded as a typical CT100+ patient assay. It is 
expected that the array incubated with the cancer control pool would display several cancer-specific 
antibody signals, and that the healthy control pool would display solely the standard positive controls, 
with no cancer-associated antibody signals. The resulting data was extracted and processed as indicated 
above. 
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3.2.9 Reproducibility studies 
As a means of validating the resulting array data, a number of different assays and parameters were 
considered, such as the linearity and dynamic range assays, the standard quality control assays, the 
biotinylated Cy5-BSA controls, the replicate spots, and the pre- and post- optimized CT100+ runs. These 
assays would inform us on how reproducible and consistent our resulting data was.  
 
3.3 Results and Discussion 
This Section presents and discusses the complete set of results obtained whilst optimizing the CT100+ 
array, as well as the resulting data.  
3.3.1 In-house streptavidin coated slides 
In order to determine optimal conditions for uniform coating of microarray slides with streptavidin, 
several methods were tested ranging from no shaking to gentle or vigorous shaking. QC tests using each 
of these shaking methods were conducted, and spots, blocks and whole slide area CVs were obtained 
using median raw intensity/RFU and SD values, as a measure of coating homogeneity. When comparing 
whole slide area CVs, it was found that a gentle shaking method was best (13.3%) versus the no shaking 
(14.6%) and vigorous shaking (27.0%) methods. As mentioned in Section 3.2.1, the CV for the 
printing/assay area of the slide, i.e. the spots and blocks CVs, provides a more useful measure of slide 
coating homogeneity, as our quantifiable signals are located there, and should therefore be considered 
instead. When comparing blocks and spots CVs, it was also found that a gentle shaking method was best 
(blocks: 2.1%, spots: 2.2%) versus the vigorous (blocks: 4.4%, spots: 3.0%) and no shaking (blocks: 7.6%, 
spots: 7.4%) methods. Additionally, when visually inspecting the resulting QC slides, it was apparent that 
gentle shaking was certainly the preferred method, as seen indicated below in Fig. 3.8.  
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Figure 3.8: Comparison of QC slides testing distinct shaking methods. This figure includes the resulting 
scanned images of three distinct slides, each testing a distinct shaking method: left: vigorous shaking; 
middle: gentle shaking; right: no shaking. Fluorescent intensity is indicated in red.  
           
 
Vigorous shaking led to the appearance of several bubbles in the streptavidin solution during the coating 
procedure, which was also apparent in the resulting QC slide (Fig. 3.8 on left) as several black spots are 
visible across the slide. A swirl pattern is also seen across this slide, as a result of the rapid movement of 
the coating solution. No shaking led to non-optimal washing of the slide, as a distinct washing artefact is 
apparent on the resulting QC slide (Fig. 3.8 on right). Hence, based on both CV and visual data, the 
gentle shaking method was the most optimal one, and was therefore used for all subsequent coating 
procedures. Furthermore, when comparing the initial and improved coating procedures, as indicated 
below in Fig. 3.9, it was very evident that an improved coating procedure was obtained.  
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Figure 3.9: Comparison of QC slides testing initial and improved method. This figure includes the 
resulting scanned images of two distinct slides, each testing a distinct coating method: left: initial 
procedure; right: improved procedure. Fluorescent intensity is indicated in red.  
      
 
When comparing whole area CVs, a decrease in CV from 27.6% (initial procedure) to 13.3% (improved 
procedure), and therefore an increase in slide coating homogeneity, was evident. Visually, saturation 
due to lifterslip-associated uneven coating (Fig. 3.9 on left) was completely eliminated with the 
immersion technique (Fig. 3.9 on right), and a more homogenous coating was obtained. Furthermore, it 
was shown that the streptavidin solution was reusable, as no change in overall coated intensity was 
apparent after multiple re-use.   
3.3.2 Cloning and expression of cancer-testis antigens 
The following cloning expression results were obtained by Dr. Aubrey Shoko from the CPGR. 
Recombinant gene cloning methods were used to insert a total of 79 CT antigen and 44 non-CT antigen 
genes into a baculoviral expression vector as N-terminal fusions to an E.coli-derived biotin-carboxyl 
 84  
carrier protein (BCCP) tag carrying a c-Myc tag (see Table 3.1 for the full list of antigens). The BCCP-tag is 
biotinylated in vivo, enabling single-step immobilization and purification of folded, BCCP-tagged 
recombinant proteins by printing crude lysates directly onto streptavidin-coated, PEG-derivitised 
microarray surfaces under native conditions; the very high affinity (Kd ~10
-15 M) (Boutell et al. 2004) and 
specificity of the streptavidin-biotin interaction combined with the intrinsic resistance of PEG surfaces to 
non-specific protein adsorption (Zheng et al. 2005) enabled avoidance of laborious pre-purification of 
each recombinant protein under denaturing conditions (O’Kane et al. 2011). 
In the absence of any pre-purification step, it might be expected that host cell proteins that are 
endogenously biotinylated and observed in western blots would compete with the biotinylated 
recombinant proteins for available streptavidin-binding sites on the array surface. However, under 
native conditions we have observed that these endogenous biotinylated proteins do not compete 
efficiently with biotinylated recombinant proteins for binding  (Koopmann & Blackburn 2003), probably 
because in such endogenous proteins the biotin moiety is typically buried (Choi-Rhee & Cronan 2003) 
and therefore not physically available to bind streptavidin under native conditions. 
Western blotting using a monoclonal anti-c-Myc antibody was used to confirm expression of each 
antigen, and a representative image for a subset of 12 antigens is indicated in Fig. 3.10, courtesy of Dr. 
Aubrey Shoko. These antigens include GAGE1, GAGE2A, GAGE4, GRWD1, HORMAD1, LDHC, LIPI, 
MAGEA1, MAGEA10, MAGEA11, MAGEA3, MAGEA4, and adequate control. In this western blot, good 
levels of expression were obtained for all antigens across a range of unrelated proteins, with the 
exception of HORMAD1, LIPI and MAGEA11. Similarly, the expression of all of the remaining antigens, 
123 in total, was also confirmed. The recombinant insect cell expression used approach was found to 
give a > 95% success rate from cloned, sequence-verified transfer vector to expressed, folded and 
biotinylated proteins suitable for array fabrication; this compares favourably with the lower success 
rates observed when attempting to express mammalian proteins in E. coli (Terwilliger et al. 2009). Any 
antigen that was not initially produced (< 5%) was repeated until successful. Western blotting using a 
streptavidin-HRP conjugate probe was used to confirm biotinylation of the expressed recombinant 
proteins, and a representative image for the same subset of 12 antigens is indicated in Fig. 3.11, 
courtesy of Dr. Aubrey Shoko. The addition of free biotin to the growth medium was observed to 
increase the extent of biotinylation of the recombinant BCCP fusion proteins despite the absence of a 
co-expressed E. coli biotin ligase. Antigen expression was further confirmed by assaying printed arrays 
for the c-Myc tag using a c-Myc assay, which will be discussed below in Section 3.3.7.2. 
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Figure 3.10: Western blot confirming the expression of a subset of 12 antigens.  1-GAGE1, 2-GAGE2A, 
3-GAGE4, 4-GRWD1, 5-HORMAD1, 6-LDHC, 7-LIPI, 8-MAGEA1, 9-MAGEA10, 10-MAGEA11, 11-MAGEA3, 
12-MAGEA4, 13-control. Molecular weight marker is indicated on left. Western blot was done using 
crude insect cell lysates and developed using a monoclonal anti-c-Myc antibody. Good expression levels 
were observed across a range of unrelated proteins, with the exception of HORMAD1, LIPI and 
MAGEA11. 
 
 
Figure 3.11: Western blot confirming the biotinylation of a subset of 12 antigens.  1-GAGE1, 2-
GAGE2A, 3-GAGE4, 4-GRWD1, 5-HORMAD1, 6-LDHC, 7-LIPI, 8-MAGEA1, 9-MAGEA10, 10-MAGEA11, 11-
MAGEA3, 12-MAGEA4, 13-control. Molecular weight marker is indicated on left. Western blot was done 
using crude insect cell lysates and developed using a streptavidin–HRP conjugate probe. Good 
biotinylation levels were observed across a range of unrelated proteins, with the exception of 
HORMAD1, LIPI and MAGEA11. 
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All recombinant proteins were expressed under the same conditions, with no attempt made to 
maximize expression levels. We estimated there to be a limiting number of available biotin-binding sites 
on the streptavidin-coated microarray surface, and the high affinity of the streptavidin-biotin interaction 
means that the surfaces saturate with antigen even at low antigen expression levels. This provides a 
crude normalization of protein loading without the need to pre-adjust the concentrations of the 
individual crude lysates to compensate for differences in expression levels before array fabrication 
(Boutell et al. 2004). 
3.3.3 Fabrication and optimization of the cancer-testis antigen (CT100+) 
microarray   
In the process of improving the first version of our platform (CT100), which contained 100 cancer-
associated antigens, to the current augmented version (CT100+), which contains 123 cancer-associated 
antigens, several issues arose, resulting in a relatively high assay repeat rate of ~40%, even when using a 
relatively high CV threshold (40%). These included spot running and associated carryover, as a result of 
reduced spacing between spots on each array, and variable spot size, as a result of differences in buffer 
composition between antigens of interest and positive controls (Cy5-biotin-BSA), as seen below in Fig. 
3.12. These indicated that additional development was required, as a means of assuring data 
reproducibility.   
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Figure 3.12: Array printing settings comparison. This figure includes the resulting scanned CT100+ array 
images of two distinct arrays, each utilising distinct printing settings and assay conditions: above: CT100+ 
array using previous settings; below: CT100+ array using improved settings. The array below indicates 
red and green spots, due to the uses of two distinct fluorescent tags – Cy3 and Cy5 – solely with the 
intent of verifying if spot carry-over was occurring.  
 
 
 
As a means to resolve these, several printing settings and buffer compositions were tested, and the 
most advantageous ones were implemented. Namely, the number of pin stamps onto the slide per spot 
was reduced from 2 to 1, which reduced spot size and thereby increased spacing between spots to an 
acceptable level, and a standard printing buffer was stipulated for all samples, which now included 
sucrose to increase surface tension and thereby allow for an increased spot consistency. As seen in Fig. 
3.12, these alterations eliminated the issues stated above, resulting in well-defined consistently sized 
spots, with no spot running or carry-over, exemplified by use of two distinct fluorophores, Cy3 and Cy5 
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equivalents, amongst samples. When re-running these samples, a drastic reduction in repeat rate to 
~6% was obtained, even when using a more stringent CV threshold (20%).  
Additionally, as a means of resolving previous issues related to E. coli expression vector-based non-
specific signal, all antigens were now expressed using insect cells, which removed all unwanted non-
patient-specific signals, which was confirmed by a consistent lack of signal in our “empty lysate” 
negative control across assays.  
Each print run was cohort size-dependent, with each run including all patient samples along with 3 
arrays reserved for quality control assays (c-Myc assay, cancer pool and health pool assay). On each 
slide, 4 replica CT100+ protein microarrays were printed in a 4-plex format, with each spotting event 
delivering ~10 nL sample, allowing for 4 patient samples to be assayed per slide. Due to the very small 
volumes required, each 50 µL aliquot of harvested expression cells provided enough recombinant 
protein to print 25 replica slides in four-plex format, with each protein printed in triplicate in each array. 
Therefore, one 3 mL baculovirus culture yielded sufficient expressed protein to fabricate 700 replica 
arrays, or >2000 replica spots of each protein, thereby aiding reproducibility.  
3.3.4 Development of the CT100+.jar bioinformatic tool 
 As a means of demonstrating the usefulness of the CT100+.jar bioinformatic tool, the background 
correction and the normalization methods were tested for a selected print run.  
As described above in Section 3.2.5, the background correction method smooths the local background 
by reducing the effect of artefacts and noise in the background, thus enabling calculation of more 
accurate net intensities by subtracting the corrected neighbourhood background value from the median 
local foreground pixel intensity. As a means of exemplifying this correction, the net intensities (RFU 
values) of Cy5-biotin-BSA control spots at 5, 10 and 15 ng/µL of a selected array were plotted before and 
after background selection, as is indicated below in Fig. 3.13. 
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Figure 3.13: Quantitative illustration of the local background correction method. The local background 
of each Cy5-biotin-BSA spot is replaced by a median of the local backgrounds of surrounding 
neighbourhood spots (3 x 3 spot window). The corrected net intensity is measured by each spot’s raw 
intensity minus corrected background intensity. Red line: mean net intensities before background 
correction; Blue line: mean net intensities after background correction.  
 
 
It was evident that there were differences between the pre- and post-corrected net intensities, 
accentuated at some times more than others. As expected, net intensities before background correction 
appear to be slightly skewed due to noisy local background signals. Once this background was replaced 
by neighbourhood local backgrounds, the net intensities increased slightly to a more representative 
intensity, without local background bias. Hence, it was apparent that this method is most relevant, as it 
permits a larger amount of confidence in the generated array data.   
In regards to the pin-to-pin and array-to-array normalization methods, the novel composite 
normalization method combining both quantile and total intensity normalization modules was used, as 
described above in Section 3.2.5, enabling more flexibility in the presence of outliers of flagged spots 
and ensuring that an adequate number of positive controls are available for normalization. As a means 
of exemplifying this normalization, the net intensities (RFU values) of Cy5-biotin-BSA control spots of a 
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selected slide – four distinct arrays – were plotted before (see Fig. 3.14) and after (see Fig. 3.15) 
normalization, as is indicated below. 
 
Figure 3.14: Quantitative illustration pre-composite normalization method. This graph indicates the 
Cy5-biotin-BSA average net intensities across four distinct arrays of a single slide prior to conducting pin-
to-pin and array-to-array normalization.  
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Figure 3.15: Quantitative illustration post-composite normalization method. This normalization 
method combines both quantile and total intensity normalization modules to account for inter- and 
intra-array variability. This graph indicates the Cy5-biotin-BSA average net intensities across four distinct 
arrays of a single slide after conducting pin-to-pin and array-to-array normalization.  
 
 
By comparing the average RFU values of the positive controls across four arrays – one single slide – 
before and after inter- and intra-array normalization, it was evident that there were differences 
between the pre- and post-normalized net intensities across the whole graph, although these may not 
be visible at first glance. The most evident difference seen was that for each control post-normalization, 
the range of values across the four arrays is smaller when compared to the same control pre-
normalization.  For example, in Fig. 3.14, the first set of Cy5-biotin BSA controls at 5 ng/µL ranges from 
~3800 RFU to ~6200 RFU (2400 RFU variation), whilst the same set after normalization in Fig. 3.15 
ranges instead from ~4600 RFU to ~5800 RFU (1200 RFU variation), thus indicating that the variability 
for that set of controls across all arrays was halved. Additionally, it was also evident that the average 
RFU values appear slightly lower after normalization, with the maximum intensity lowering from ~18200 
RFU to ~16600 RFU (1600 RFU difference). 
Hence, this normalization method proved highly beneficial, guaranteeing to reduce bias caused by 
problematic spots or arrays amongst the obtained data. Furthermore, by normalizing results between 
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arrays, it is possible to compare different time points for a single patient with confidence, thus enabling 
autoimmune comparisons between time points.  
3.3.5 Linearity and dynamic range microarray assays 
Robust linearity and dynamic range experiments were performed to determine the optimal serum and 
anti-human IgG antibody dilutions for the detection of antibody-antigen binding. All data generated by 
the protein arrays for these assays were pre-processed and analysed as described in Methodology. No 
data points were excluded by the data filtering steps, indicating that the arrays were of good quality. 
An initial linearity assay was performed using a range of serial dilutions (1:50, 1:100, 1:200, 1:400, 1:800, 
1:1,600, 1:3200 and 1:6400) of a randomly chosen serum sample (P117, Day 483) using a fixed 
secondary Ab concentration (20 µg/mL) (Fig. 3.16). After analysing the resulting array image, a classic 
saturation binding curve was obtained (Fig. 3.17) which indicated that at serum dilutions of ~1:50 of a 
randomly chosen serum sample demonstrating a high response to NY-ESO-1 (P117, day 483), the 
available NYESO-1 binding sites on the microarray were saturated (maximum number of binding sites 
(Bmax) = 55370 RFU), with half-maximal binding occurring at ~1:1250 dilution. This corresponds with 
the known high immunogenicity of NY-ESO-1 (Nicholaou et al. 2006). Therefore, an optimal serum 
dilution was selected at 1:800 and used in all further assays.  
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Figure 3.16: Array image (16-plex) obtained from the Initial linearity assay using a series of serum 
dilutions of a randomly chosen patient sample (P117, Day 483) to measure saturation binding of 
patient autoantibodies to the NYESO-1 antigen on the array surface, using 20 µg/mL secondary Ab for 
detection. This figure includes the resulting overlapped array images of a dual-scanned (Cy3 and Cy5 
lasers) single slide. Positive control spots consisting of Cy5-biotin-BSA (10 ug/mL) are indicated in red on 
image. Negative control spots consisting of lysis buffer only did not display any non-specific 
fluorescence. NY-ESO-1 autoantibody signals obtained are in green on image, across a range of serum 
dilutions (1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200 and 1:6400) from top to bottom and a fixed 
detection antibody concentration . Fluorescent intensity is indicated in red (Cy5) or green (Cy3).  
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Figure 3.17: Saturated binding curve obtained for the initial linearity assay using a series of serum 
dilutions of a randomly chosen patient sample (P117, Day 483) to measure saturation binding of 
patient autoantibodies to the NYESO-1 antigen on the array surface, using 20 µg/mL secondary Ab for 
detection. Insert: Scatchard plot of the same data. 
 
 
To exclude the possibility that the observed saturation binding occurred due to limiting secondary 
antibody availability, an assay was performed using two different serum dilutions (1:200 and 1:2400) 
and a range of secondary antibody concentrations (Fig. 3.18). After analysing the resulting array images 
at both serum dilutions, saturation of secondary antibody binding was obtained at ~10 µg/mL (Bmax = 
58936 RFU; Fig. 3.19), with a calculated binding affinity (Kd) of the primary–secondary antibody 
interaction on the array surface of ~2 µg/mL. This confirmed that the data in Fig. 3.17 reflected the 
saturation binding of the serum autoantibodies to the immobilized antigens, rather than a limiting 
quantity of secondary antibody. Therefore, 20 µg/mL of secondary antibody was used in all further 
assays. 
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Figure 3.18: Array images (16-plex) obtained from the second linearity assay using two serum 
dilutions (1:200 and 1:2400) of the same patient sample and a range of secondary Ab concentrations 
to determine the dynamic range of secondary Ab binding. This figure includes the resulting scanned 
images of a single slide scanned twice, using the Cy5 (image on left) and the Cy3 (image on right) lasers. 
Array on left: Positive control spots consisting of Cy5-biotin-BSA (10 ug/mL) indicated in red on image. 
Negative control spots consisting of lysis buffer only did not display any non-specific fluorescence. Array 
on right: NY-ESO-1 autoantibody signals obtained in green on image, across a 1:200 (left panel of image) 
and 1:2400 (right panel of image) dilutions. Detection antibody concentrations of 40, 30, 20, 15, 10, 5, 
2.5, 1.25 ug/mL were used for both dilutions from top to bottom, respectively. Fluorescent intensity is 
indicated in red (Cy5) or green (Cy3). 
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Figure 3.19: Saturation binding curves of the second linearity assay using two serum dilutions (1:200 
and 1:2400) of the same patient sample and a range of secondary Ab concentrations to determine the 
dynamic range of secondary Ab binding.  
 
 
To assess the linear range of this platform, a dynamic range assay was performed using serial serum 
dilutions (1:1000, 1:2000, 1:4000, 1:8000, 1:16000, 1:32000, 1:64000 and 1:128000) and a fixed 
secondary Ab concentration (20 µg/mL) (Fig. 3.20). This assay revealed a linear response over greater 
than three orders of magnitude (Fig. 3.21) and no evidence of signal limitation was observed at the 
serum dilutions tested. Even at the highest tested dilution (1:128000), a measurable signal was still 
detectable well above the median background values. 
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Figure 3.20: Array images (16-plex) obtained from the dynamic range assay indicating the linear range 
of the platform. This figure includes the resulting scanned images of a single slide scanned twice, using 
the Cy5 (image on left) and the Cy3 (image on right) lasers. Array on left: Positive control spots 
consisting of Cy5-biotin-BSA (10 ug/mL) indicated in red on image. Negative control spots consisting of 
lysis buffer only did not display any non-specific fluorescence. Array on right: NY-ESO-1 autoantibody 
signals obtained in green on image, across a range of serum dilutions (1:1000, 1:2000, 1:4000, 1:8000, 
1:16000, 1:32000, 1:64000 and 1:128000) from top to bottom and a fixed detection antibody 
concentration (20 ug/mL). Fluorescent intensity is indicated in red (Cy5) or green (Cy3). 
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Figure 3.21: A dynamic range assay indicating the linear range of the platform. The limit of detection 
(1:1000000 serum dilution) is where the data intersects with the signal cut-off level (two standard 
deviations of the background; indicated here as the dashed line). 
 
By extrapolation of the linear range to the lower limit and assuming a noise threshold of two standard 
deviations (SD) of the background, the detection limit was estimated to be ~1:1000000 serum dilution. 
3.3.6 Quantification of the absolute array detection limit for cancer-testis 
antigens 
To estimate the absolute detection limit of our CT antigen microarray platform, three assays were 
performed using the same serum sample used for the linearity assay.  
Firstly, a Bradford protein assay was successfully conducted using BSA standards, with the intent of 
obtaining an absolute total protein concentration of the serum sample. By extrapolation of the standard 
curve (                         ), a concentration of 63.7 mg/mL was obtained, which is in 
agreement with the reported total protein range in serum of 60-80 mg/mL (Merrell et al. 2004).  
Secondly, a SDS-PAGE densitometry analysis was conducted on the same sample, as a means of 
determining what proportion of total proteins corresponded to total IgG. A 7.5% polyacrylamide gel was 
prepared, and 1.0, 1.5 and 2.0 µg of serum were loaded in triplicate, along with a protein molecular 
weight marker. The SDS-PAGE gel was electrophoresed accordingly, and the gel obtained is indicated in 
Fig. 3.22. Increasing band intensities were seen with increasing loaded amounts of serum, with several 
bands appearing from 25 to 170 kDa. Serum albumin (66.5 kDa) was present as expected and was 
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consistently the most abundant protein, as well as the anticipated IgG heavy (55 kDa) and light (25 kDa) 
chains.  
 
Figure 3.22: SDS-PAGE protein gel of serum (1.0, 1.5 and 2.0 µg) using AcquaStain. This image indicates 
the resulting stained gel with indications on left of molecular weights, and on right of relevant protein 
band identification.  
 
 
A densitometry analysis was performed on this gel using Gene Tools, and all existing bands were 
identified automatically. Each band was attributed an automated molecular weight, after indicating the 
protein ladder used, and each band was assigned a raw volume. Using the three lanes loaded with 2.0 
µg of serum, a proportion of each band was indicated in the form of a percentage, utilising the sum of all 
bands as the total proportion and removing the background volume. After adding the IgG heavy and 
light chains, the IgG proportion corresponded to 5.7% of the total serum, slightly below the normal IgG 
regular range (7.5 – 22 mg/mL). This difference is most likely due to the fact that the serum used was 
collected from a potentially immunosuppressed advanced melanoma patient, and therefore, IgG levels 
were not within the usually reported healthy range. The proportion of serum albumin, on the other 
hand, was 64.3%, well within the reported range (57-71%), validating these results (Merrell et al. 2004). 
Considering that the sum of all bands equated to the absolute total protein concentration of 63.7 
mg/mL (measured above via Bradford assay), a rough concentration of IgG was determined, obtaining 
3.63 mg/mL.  
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Thirdly, a protein microarray assay was performed to determine the proportion of total IgG 
corresponding to anti-NY-ESO-1. The assay was performed as indicated above in Section 3.2.6, and the 
resulting data was analysed accordingly. When incubating anti-human IgG, NY-ESO-1-BCCP crude insect 
cell lysate, ICL and buffer-only control on the previously printed serum spots, and after adding detecting 
antibody (Cy5-labelled streptavidin) on this inverted array format, the intensities obtained 
corresponded to levels of total IgG, anti-NY-ESO-1, non-specific binding to the insect cell vector, and 
non-specific binding to the assay buffer, respectively. Non-specific binding to the assay buffer was not 
detected, indicating that solely the ICL values should be deducted from the anti-NY-ESO-1 levels, as the 
NY-ESO-1-BCCP crude lysate was expressed in this vector. The 48 replicas of each of these were 
averaged, and a single median net intensity value was obtained, as indicated in Table 3.4. 
 
Table 3.4 Average net intensity values of IgG, anti-NY-ESO-1, ICL and buffer only measured by a 
protein microarray assay. 
 Average Net intensity 
IgG 22346.94  
anti-NYESO1 1418.25 
ICL 266.10 
 
Assuming that each anti-human IgG molecule had one biotin attached to it, and knowing that each NY-
ESO-1-BCCP crude lysate was also attached to one biotin, IgG and anti-NY-ESO-1 were at a 1:1 ratio. 
Hence, the proportion of anti-NY-ESO-1 in IgG was of 5.6%. Considering that the rough concentration of 
IgG was 3.63 mg/mL, as determined above via densitometry analysis, the concentration of anti-NY-ES0-1 
was therefore 0.19 mg/mL in the neat serum sample. Based on the estimated detection limit of 
~1:1000000 serum dilution by extrapolation of the linear range graph indicated in Fig. 3.21 using the 
same serum sample, the detection limit could thus be quantified, obtaining an autoantibody titre of 
~190 pg/mL. 
Herein, we have shown that our CT antigen microarray platform can detect and quantify specific human 
autoantibodies in serum with a detection limit in the pg/mL range—equating to a million-fold serum 
dilution, and with linearity over at least three orders of magnitude, representing a significant advance in 
the field compared to ELISA or other protein microarray platforms.  
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3.3.7 Standard CT100+ array quality controls  
3.3.7.1 Verification of the immobilization of controls to array surface 
As part of each standard microarray print run, great attention was given towards assuring that a robust 
quality was obtained. All positive, negative and assay controls were plotted per print run, as seen below 
in Fig. 3.23, for a selected print run. 
 
Figure 3.23: Positive, negative and assay controls for a selected print run. This graph indicates the 
complete set of negative (buffer, ICL, BCCP-myc) and positive (Cy5-biotin-BSA at 5, 10 and 15 ng/µl, 
biotin-hIgG 10ng/ul and biotin-αhIgG) controls included on the CT antigen array for a selected print run 
with associated average RFU values.  
 
 
Based on the plot indicated above, all negative controls which included buffer only (“Buffer”), insect cell 
“empty vector” lysate (“ICL”) and BCCP-myc tag only (“BCCP-myc”) displayed either very low or no 
intensities, which indicated that all signals arising from these were negligible, and therefore non-specific 
binding and associated fluorescence did not occur. Additionally, besides from the standard noise 
threshold – two standard deviations (SD) of the background – an additional threshold stipulated as the 
median of all negative controls per array (usually below 1000 RFU) was measured for each assay, and 
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autoantibody intensities were only considered if above this value. The biotinylated Cy5-BSA controls 
(“Cy5 BSA 5ng/ul”, “Cy5 BSA 10ng/ul”, “Cy5 BSA 15ng/ul”) displayed a gradual increase in intensity as a 
function of an increasing concentration, with relatively stable signals amongst each, which indicated 
that the print run was successful, and that all slides used had a satisfactory homogeneous streptavidin 
coating. It is also important to note that these controls would still be present and available for use, 
independent of a successful subsequent assay. The biotinylated human IgG controls (“biotin-hIgG 
10ng/ul”) displayed relatively high intensities across all arrays, which indicated that detection antibody 
was added to all, and that these antibodies were able to bind to the serum autoantibodies.  Lastly, the 
biotinylated anti-human IgG controls (“biotin-αhIgG”) also displayed high, but quite variable, intensities, 
which indicated that serum was added to all arrays, and that the available autoantibodies were able to 
bind to respective antigens on the array. Furthermore, this parameter displays the high variability of 
total IgG levels amongst patients, which are most likely true fluctuations as a result of treatment, rather 
than varying overall serum concentrations.  Each print run conducted per treatment cohort roughly 
matched this expected pattern, which indicated successful print and assay runs, eliminating the need for 
any high-scale repeats. 
3.3.7.2 Verification of the immobilization of BCCP-tagged proteins to array surface 
Since all arrayed antigens should also carry a c-Myc tag, an anti-c-Myc assay was conducted per print 
run, as a means of reconfirming that all antigens were successfully expressed, and that all spotted 
antigens had successfully bound to the array, as seen below in Fig. 3.24, for a selected print run. 
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Figure 3.24: c-Myc assay for a selected print run. This image indicates a dual scanned array of a c-Myc 
assay, with Cy5-biotin BSA controls indicated with red fluorescence (independent of c-Myc assay) and 
antigens indicated with green fluorescence.  
 
 
Based on the image indicated above, it was apparent that all spotted recombinant proteins of interest 
(green spots) were indeed successfully expressed and bound to the array. Due to the higher sensitivity 
achieved with protein microarrays when compared to western blot assays, we verified that for the very 
few antigens where expression could not be confirmed via western blot, expression was in fact verified 
via this c-Myc assay. Furthermore, it also confirms that the printing and assaying conditions and 
parameters were optimal, as no spot running, variable spot size, carry-over or even washing artefacts 
were seen on the array. These findings provide great assurance that the obtained data derived from 
robust quality arrays. These results were obtained consistently across all print runs, serving as a clear 
indication of the high reproducibility of the array.  
3.3.7.3 Verification of array specificity for cancer 
Array specificity was tested using the cancer and healthy patient pools on the array. For a selected print 
run, the resulting scanned array for the pooled cancer patient samples is displayed below in Fig. 3.25. 
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Figure 3.25: Cancer control pool scanned array for a selected print run. This image indicates a scanned 
array assaying the cancer pooled sample, and thus indicating the presence of multiple cancer-specific 
autoantibody responses besides from the positive controls. Red boxes highlight triplicate CTAG2 (above) 
and NY-ESO-1 (below) positive signals. 
 
 
This resulting array image clearly indicated that many cancer-specific autoantibodies were abundant 
amongst these patients, resulting in a positive array with several above noise quantifiable signals. This 
was certainly expected as a result of pooling a variety of different cancer patients, due to the well-
known patient-specific autoimmune diversity. As a means of facilitating interpretation of the visual 
array, this data was plotted in Fig. 3.26, indicated below.  
 
 
 
 
 
 
 
 
 
CTAG2 
 
 
 
NY-ESO-1 
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Figure 3.26: Cancer control pool plotted data for a selected print run. This graph indicates the resulting 
quantitative data when assaying the cancer control pool for a selected print run with associated average 
RFU values.  
 
This graph indicated signals according to the controls mentioned above, along with several autoantibody 
titres to antigens of interest, including NY-ESO1, CTAG2 and MAGEA4, amongst others. This assay was 
deemed successful, and suggested that all existing autoantibody signals should be effectively detectable 
and quantifiable. Additionally, healthy patient pooled samples were also assayed per print run, and a 
resulting scanned array is shown in Fig. 3.27 for a selected print run. 
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Figure 3.27: Healthy control pool scanned array for a selected print run. This image indicates a scanned 
array assaying the healthy pooled sample, and thus indicates the absence of cancer-specific 
autoantibody responses, besides from the positive controls. 
 
 
 
This resulting array image clearly indicated that, aside from the expected positive controls, no cancer-
specific autoantibodies were present amongst these patients, resulting in a negative array with no 
quantifiable signals. This was certainly expected, as healthy patients should certainly not display any 
cancer-specific signals. As a means of further deciphering all signals on this array, the data was plotted 
in Fig. 3.28, indicated below.  
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Figure 3.28: Healthy control pool plotted data for a selected print run. This graph indicates the 
resulting quantitative data when assaying the healthy control pool for a selected print run with 
associated average RFU values.  
 
 
This graph confirmed that solely the positive controls were detected, with all cancer-specific signals 
falling below the noise threshold, with low non-specific binding to the arrayed antigens in healthy 
controls. This assay was also therefore deemed successful, emphasizing that all detected autoantibody 
signals are indeed cancer-specific. Both these cancer and healthy pooled samples were assayed per print 
run, with consistently satisfactory results, similar to those indicated above.  Therefore, all resulting 
patient data was obtained with high confidence and quality, which was according to our pre-established 
necessary standards.  
3.3.8 Reproducibility studies 
During the linearity and dynamic range assays, it was evident that given the ability to produce the 
above-mentioned data (Section 3.3.5) using the same randomly selected sera sample, our CT100+ 
protein microarray platform was a means to repeatedly obtain consistent data.  
Whilst performing the standard array quality controls assays (Section 3.3.7), it was evident that lack of 
data reproducibility was not a concern, as the routinely conducted c-Myc, cancer control and healthy 
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control pools assays gave rise to highly constant results, even amongst arrays from distinct print runs. 
Moreover, the biotinylated Cy5-BSA controls repeatedly gave rise to stable signals within and across 
arrays. This was guaranteed with the low CV requirement of 20% amongst replicates within each array, 
which discarded any array that did not display steady signals across replicates.  
Additionally, when considering inter-array reproducibility, such as reproducibility amongst replicate 
spots, it was evident that the majority of all signals showed consistent signals across all replicates, which 
was apparent visually, amongst those relatively high signals, and quantifiably, across the majority of all 
signals above the noise threshold. Furthermore, as a means of assuring that only highly reproducible 
data was obtained for each protein of interest, a robustly low replicate CV threshold of 20% was also 
defined. Thus, thereafter, if any three protein-specific replicates varied more than 20%, these were 
excluded from analysis.  Even though this strict threshold was applied, the majority of all signals were 
retained, indicating that only a small number of protein-specific replicates had been discarded due to 
lack of signal reproducibility.  
Also, when comparing our pre- and post-optimized CT100+ array runs, although the initial runs resulted 
in a high repeat rate, when visually analysing the same sample it was very evident that the same 
relatively high signals were present in both runs, which is indicated in Fig. 3.29. This finding further 
implies uniformity amongst our data.   
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Figure 3.29: Pre- and Post-optimized arrays for a selected patient. This figure contains two scanned 
array images of a selected patient sample assayed on two different occasions, demonstrating consistent 
results: above: pre-optimized patient CT100+ array; below: post-optimized patient CT100+ array. Red 
boxes highlight triplicate CTAG2 (above) and NY-ESO-1 (below) positive signals. 
 
 
 
Hence, these studies verified that our array data is highly reproducible, with the ability to generate 
consistently robust ad high quality data.  The ability to obtain high inter- and intra-assay reproducibility 
highlights the feasibility and applicability of our protein microarray platform, a high-throughput tool 
used for the screening of immune responses in cancer patients. The protein microarray approach 
described here has the advantage of providing data on cancer-associated antigen expression through 
direct quantitation of autoantibody titres in serum, which are elicited relatively early in tumourigenesis 
and bind to their target autoantigens with high affinities and specificities (Anderson & LaBaer 2005b). 
Hence, the detection of cancer-specific autoantibodies is possible in principle at significantly lower 
serum concentrations than is routinely possible for detection of the cancer antigens themselves, 
 
 
 
 
 
 
CTAG2 
NY-ESO-1 
CTAG2 
NY-ESO-1 
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thereby leading to the potential for pre-symptomatic cancer diagnosis. Furthermore, when this array 
was originally created (CT100), ELISAs were performed as a means of validating the obtained antibody 
responses. These data suggested that our microarray platform was more sensitive than the ELISA 
(currently the gold standard for measuring antibody-antigen interactions), with an even higher capacity 
of multiplexing.  
 
 
    111 
4 PROFILING PATIENT AUTOIMMUNE 
RESPONSES 
4.1 Introduction 
This Section intends to explore the potential of our CT100+ protein microarray platform identifying 
novel cancer biomarkers, which could aid in the detection and management of cancer. The main 
objective of this Chapter is to attempt to comprehend and shed light on the interplay between 
chemotherapy, radiotherapy or immunotherapy and anti-cancer autoimmune responses.  
The quantitative study of antibodies that recognize cancer antigens in patients could in principle enable 
early detection of tumours, patient stratification, personalized patient treatment, development of 
improved therapies, and more efficient monitoring of therapeutic response and disease progression 
(Tan et al. 2009; Anderson & LaBaer 2005a).  
Although much progress has been made regarding comprehending the key hallmarks of cancer, effective 
diagnostic, predictive and therapeutic strategies are still yet to be discovered and implemented in a 
clinical setting. Profiling autoimmune patient responses towards tumour-specific and –associated 
antigens across several cancer types and treatments holds great promise and potential regarding the 
discovery of potential novel biomarkers. Similar assays have been performed by others, with promising 
results. For instance, (Wang et al. 2005) assessed autoantibody levels of prostate cancer patients and 
obtained evidence of a potential novel screening test, whilst more recently (Xu et al. 2014) assessed 
these levels across esophageal squamous cell carcinoma patients and obtained evidence of a potential 
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biomarker for early detection of disease. Furthermore, the latter study reported that these 
autoantibody titres were found to precede manifestations of symptomatic cancers, which further 
highlights the clinical applicability of this tool. 
 
4.2 Methodology 
4.2.1 CT100+ protein microarrays with patient sera 
4.2.1.1 CT100+ assay 
Following printing, slides were immersed in blocking buffer (50 µM biotin in PBST) and incubated on ice 
for 1 h, in a plastic chamber wrapped in foil. Slides were then washed three times for 5 min in PBST, and 
placed in slide holders and centrifuged at 240 x g for 2 min at RT to dry. Individual arrays were each 
incubated with a unique serum sample (100 µL at 1:800 dilution, dilution based on the results obtained 
for the initial linearity assay indicated in Section 3.3.5) for 1 h at RT, washed in PBST and dH20, and 
incubated with 100 µL of 20 µg/mL (concentration based in the results obtained for the additional 
linearity assay also indicated in Section 3.3.5) of Alexa Fluor 647 (Cy5 equivalent) Goat anti-Human IgG 
(H+L) (Invitrogen, Life Technologies, 2 mg/mL, #A21445; 1:100 dilution in PBST) for 30 min at RT. The 
individual arrays were then washed, dried and scanned using a Tecan LS Reloaded fluorescence 
microarray scanner in automatic gain control (AGC) mode. All liquid handling steps were performed on a 
Tecan HS4800 Pro automated hybridization station (Tecan Group Ltd., Switzerland), using 
QuadChambers. These chambers permitted each slide to have four separate segments, which 
eliminated the risk of cross-contamination between subarrays per slide. The complete assay design is 
summarized in the flowchart indicated below in Fig. 4.1.   
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Figure 4.1: Flowchart of CT100+ assay design. 
 
4.2.1.2 CT100+ data extraction 
All raw image files were visually inspected to assess spot morphology and background signal. Any arrays 
showing high background, excessive speckling, the presence of interfering dust particles or fibres, or 
evidence of coalescing protein spots were re-assayed in a subsequent new print and assay run. Typically, 
< 10% of assays were repeated for these reasons. In ArrayPro Analyzer software, a grid was autoaligned 
over the individual spots on each scanned image file and a constant area feature finder was used across 
the array surface. Following automatic spot finding using a fixed spot size, manual curation of the grid 
alignment was performed. A .gal file containing information on the sample identity in each spot was 
read into ArrayPro and the raw data was extracted from each spot as well as the local background – 
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using the local corners approach (see Fig. 4.2) – in batch processing mode using a 200 RFU pixel 
threshold, yielding the median foreground and background pixel intensities per sample spot.  
 
Figure 4.2: Local background setting used on ArrayPro Analyzer software. The mean intensity of the 
pixels located in the local corners of each spot was used as the local background, a setting commonly 
used in dense arrays. [Adapted from the ArrayPro Analyzer user guide.] 
 
 
4.2.1.3 CT100+ data processing and analysis 
The extracted data was then processed using a bioinformatic pipeline automated in a Java script for pre-
processing and quality control of custom protein microarray data – the CT100+.jar bioinformatic tool – 
which is described in detail in Section 3.2.5.  Briefly, the local background signal for each spot was 
replaced by its neighbourhood background. A corrected net intensity was then calculated for each spot 
by subtracting its neighbourhood background from its foreground signal. A user-defined noise threshold 
(nSD of Background) was applied, and all spots containing a net intensity below that threshold were 
removed from analysis.  The mean net intensities for each set of replicates were calculated, and 
replicates above the user-defined CV were removed. Similarly, whole array CVs were calculated using a 
chosen Cy5-bioin-BSA control, and arrays above the user-defined CV were removed. Sub-arrays within 
each array were normalized with respect to each other to minimize any effects of pin-to-pin variation. 
Whole arrays were then normalized with respect to each other to minimize any effects of slide-to-slide 
variation. Both normalization steps were performed using all Cy5-biotin-BSA controls. A novel composite 
normalization method combining both quantile and total intensity normalization modules was used for 
these purposes, as described previously. Any resulting whole arrays with unsatisfactory CV values were 
discarded and repeated. The processed and normalised triplicate data for each control/antigen was 
averaged, and only the final average net intensity per control/antigen was used further. Finally, each 
resulting data file – corresponding to an array – was consolidated, generating a single file containing the 
average net intensity values of each analysed array across all antigens.  
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Hence, data and statistical analyses were performed utilising only good quality robust data. To facilitate 
data analysis and interpretation, data analysis was performed using Excel. Statistical analysis was 
performed using Excel and GraphPad Prism, such as non-parametric one-way ANOVA (Friedman) and t-
tests (Mann-Whitney), to compare intensities of different time points for the same patient, and scatter 
plots (mean + 95% confidence intervals) to verify the distribution of signals across patients and antigens. 
4.2.2 In vitro T-cell re-stimulation assays using patient derived PBMCs 
As a means of validating our array results, secondary immune responses to treatment using a selected 
subset of patients was assessed. This was done with T-cell re-stimulation assays using patient derived 
peripheral blood mononuclear cells (PBMCs) at previously assayed matching time points, followed by 
fluorescent activated cell sorting (FACS). This work was conducted during a 3-month research visit to the 
CIBL.  
4.2.2.1 T-cell re-stimulation assay design 
PBMCs from protein microarray-tested matched patients and time points were collected from liquid 
nitrogen storage and thawed in a bead bath at 38 °C, along with T-cell-RPMI media (450 mL RPMI 1640 
medium, 25 mM HEPES (Life Technologies, 500 mL, #22400-089), 60 mg/L penicillin, 12.5 mg/L 
streptomycin (Life Technologies, 10000 U/L, #15140-122), 2 mM GlutaMAX (L-glutamine) (Life 
Technologies, 100 mL, #35050-038), 100% human sera (Australian Red Cross, Melbourne), 1% MEM-
NEAA (non-essential amino acids) (Life Technologies, 100 x, #11140-050) and 1 mM sodium pyruvate 
(Life Technologies, 100 mM, #11360070) stored at 4 °C). When thawed, the content of each vial was 
transferred to a respective 15 mL tube, and 10 mL of media was added to each tube. These tubes were 
centrifuged at 688 x g for 5 min at 4 °C, and supernatants were carefully aspirated, assuring that pellets 
were not lost. A 5 mL volume of media was added to each tube, followed by gentle but thorough mixing 
until the pellet had completely dissociated. The content of each tube was then transferred into a 
respective well in a 6-well plate. Each well was mixed further, as a means of breaking up any potential 
cell clusters. Each well was viewed using a standard microscope, to confirm the presence of cells, and 
the plate was stored in the incubator at 37 °C overnight. Selected peptide pools (NY-ESO-1, MART-
1/Melan-A, ROPN, MAGEA3, MAGE4, GAGE1, and TYR) (Mimotopes) were prepared to a final 
concentration of 1 mg/mL in PBS, as details regarding epitope specificity were not relevant for this 
study, and stored until use at -30 °C. Each peptide pool consisted of overlapping 18mer peptides, which 
spanned the full amino acid sequence of the relevant antigen. 
The following day, the 6-well plate was removed from the incubator, and cells were viewed. After gently 
mixing each well, 10 µL of each was transferred to a well in a 96-well plate. An equal amount of 10 µL of 
Trypan blue dye (Bio-Rad, 0.4% solution, #145-0013) was added to each well, and after gently mixing, 
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half of that volume was pipetted under the coverslip of a haemocytometer. Live translucent bright 
round cells were counted following the defined counting technique using a standard microscope. After 
gentle mixing, cells were transferred from each well in the 6-well plate to a respective 50 mL tube. A 10 
mL volume of PBS was added to each empty well, as an additional washing step to capture any 
remaining cells, and after further mixing was also added to the previous 50 mL tubes. These were 
centrifuged as above and supernatants were carefully aspirated. Each tube was then resuspended with 
media to allow 106 cells per well, based on the previous cell counting calculations. A 1:4000 dilution (25 
U/mL) of human IL-2 (Miltenyi biotech, 50 µg, #130-093-903) was added to each tube, and mixed gently. 
Each tube volume was then divided by the number of peptides tested, and this respective volume was 
added to respective wells of 12-well plates. According to the number of peptides in each antigen pool, a 
final volume of 1 µg/mL of each was added to the respective well, with gentle swirls (primary 
stimulation). After confirming the presence of cells in each well, the plates were stored in the incubator. 
Our intention was to stimulate cells for 10 days, after which secondary stimulation and FACS analysis 
could follow. Cells were checked daily, with IL-2 re-additions every second day and only up to day 8, to 
avoid interference with results. Media was changed and cells were passaged in the process, if needed.  
On day 11 after stimulation, wells were mixed gently, and each well was transferred to their respective 
15 mL falcon tube. Each well was washed out with an additional 1 mL of PBS, to assure that little to no 
cells were lost. Tubes were centrifuged as above and supernatants were aspirated. The assay 96-well 
plate layout was planned and the required sample volume, 100 µL per well, was calculated. Cell pellets 
were resuspended in 10% more volume than required of warmed media, with gentle mixing to allow 
complete dissociation. A 1:1000 dilution of GolgiPlug (BD Biosciences, 1 mL, #555029) was added to 
each tube, as a means of preventing cytokine release from the cell interior. After gentle mixing, cells 
were transferred according to planned layout to a 96-well U-bottom plate. Peptide pools were then re-
added to the respective wells, with exception of the negative and positive control cells (secondary 
stimulation). A mix of EBV (Mimotopes, 1 mg/mL), Influenza (Mimotopes, 333 µg/mL) and Hep. B 
(Mimotopes, 333 µg/mL) peptides were added to the positive control wells (one for each patient time 
point) at final concentrations of 1 µg/ml. No peptides were added to the negative control wells (one for 
each patient time point). The assay plate was then stored in the incubator for 3 h. After this incubation 
period, 100 µL of PBS was added to each well, and the plate was centrifuged at 300 x g for 5 min at 4 °C. 
The plate was decanted with one swift movement to remove supernatants, but retain pellets, and mixed 
on a shaker at 500 rpm for approximately 15 s. Cells were then ready for FACS fluorescent antibody 
staining to occur, which required all work from this step onwards to be conducted in the dark. The anti-
CD antibody cocktail was aimed to stain helper T-cells (CD3+, CD4+) and Cytotoxic T lymphocytes (CD3+, 
CD8+), and therefore consisted of a mix of APC mouse anti-human CD3 (BD Biosciences, 100 tests, 
#555335, 1:50 dilution), V450 mouse anti-human CD4 (BD Horizon, 300 tests, #561838, 1:150 dilution), 
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AmCyan mouse anti-human CD8 (BD Biosciences, 100 tests, #339188, 1:50 dilution) prepared in PBS, in 
the sufficient final volume required to add 30 µL per well. The anti-CD antibody cocktail was added to 
each well (surface staining), and the plate was incubated in a dark fridge at 4 °C for 15 min. Following 
this incubation step, 170 µL of PBS was added to each well, and the plate was centrifuged, decanted and 
shaken as indicated above. A 100 µL volume of 1 x fixation/permeabilization solution (BD Biosciences, 
125 mL, #554722) was added to each well, as a means of opening the cell pores to allow entry of anti-
cytokine antibodies, and plates were incubated in a dark fridge for 20 min. Next, 100 µL of 1 x 
permeabilization/wash buffer (BD Biosciences, 125 mL, #554722) was added to each sample well. The 
plate was centrifuged at 500 x g for 5 min at 4 °C, and then decanted and shaken as before. An anti- 
cytokine antibody cocktail was prepared in PBS, which consisted of a mix of FITC mouse anti-human IFN-
γ (eBioscience, 100 µg, #11-7319-82, 1:50 dilution), PE-Cy-7 mouse anti-human TNF-α (eBioscience, 100 
µg, #25-7349-82, 1:50 dilution), in the sufficient final volume required to add 30 µL per well. The anti-
cytokine antibody cocktail was added to each well (intracellular staining), and the plate was incubated in 
a dark fridge for 25 min. The plate was then washed, centrifuged, decanted and shaken, as indicated in 
the previous step. Finally, pellets were resuspended in either 100 µL of PBS (if FACS analysis would occur 
within 3 h of staining) or 4% PFA (Science Supply Associates, 16%, #15710) ((if FACS analysis would only 
occur between 3 h and 3 days later), and the plate was wrapped in foil and stored in a dark fridge at 4 °C 
until the FACS assay.  
This assay design is summarized in the flowchart indicated below in Fig. 4.3.  
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Figure 4.3: Flowchart of T-cell re-stimulation assay design. 
 
As a means of performing fluorophore calibration for FACS, a stain control plate was also prepared. 100 
µL of stain control cells – unstimulated and unstained patient PBMCs – were added to respective wells 
(according to the number of individual stains that require calibration) in a 96-well U-bottom shaped 
plate, followed by 100 µL of PBS. This plate was then centrifuged at 500 x g for 5 min at 4 °C, decanted 
and shaken as mentioned above. 50 or 150 µL (depending on the antibody dilution) of PBS, followed by 
1 µL of each stain, was added to each respective well (no stain, APC, V450, AmCyan, FITC, PE-Cy7), and 
the plate was incubated in a dark fridge for 15 min. 150 or 50 µL of PBS was added to each well, and the 
plate was then centrifuged, decanted and shaken, as indicated above. Finally, pellets were resuspended 
in either 100 µL of PBS or 4% PFA, and the plate was wrapped in foil and stored in a dark fridge at 4 °C 
until the FACS assay. 
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4.2.2.2 T-cell re-stimulation assay image capture 
Throughout the T-cell re-stimulation assay, cell images were captured every second day using an 
Olympus IX81 Motorized Inverted Microscope. The objective here was to record the evolution of cell 
responses towards the specific stimulus, and to measure how these differ between and within patients 
and among stimuli.  
4.2.2.3 Fluorescent activated cell sorting analysis 
Prior to analysing our stimulated patient T-cells, instrument setup was required, which entailed 
fluorophore compensation and voltage optimization steps.  
The previously prepared stain plate was assayed first using the BD FACSCanto II instrument and 
associated BD FACSDiva software, after the fluidics start-up was performed. This plate was collected 
from the fridge, shaken at 500 rpm for approximately 15 s, and placed on the plate holder after 
confirming that pellets had completely dissociated. The instrument’s front and side doors were closed, 
and the experimental plan and plate layout was setup as required. The fluorophores used were specified 
and the corresponding antibody was indicated (APC: CD3, V450: CD4, AmCyan: CD8, FITC: IFN-γ, PE-Cy7: 
TNF-α) to allow for specific scatter plots to be constructed. The loading settings selected for the setup 
unstained control are indicated below in Table 4.1.  
 
Table 4.1 FACS loading settings used for analysis of the setup unstained control. 
Sample flow rate 0.5 µL/s 
Sample volume  80 µL 
Mixing volume 40 µL 
Mixing speed  180 µL/s 
Number of mixes  5 
Wash volume  400 µL 
Events to record  2500000 
Throughput mode  standard 
 
All other controls and sample wells were assayed using different settings, as indicated in Table 4.2. 
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Table 4.2 FACS loading settings used for analysis of each control and sample. 
Sample flow rate 2.0 µL/s 
Sample volume  80 µL 
Mixing volume 40 µL 
Mixing speed  200 µL/s 
Number of mixes  5 
Wash volume  200 µL 
Events to record  2500000 
Throughput mode  standard 
 
On the global sheet, our intended scatter plots were constructed (SSC-A vs. FSC-A: population 1 of T-
cells, CD3-APC-H vs. CD4-V450-H: population 2 of CD3+ and CD4+ helper T-cells, CD3-APC-H vs. CD8-
AmCyan-H: population 3 of CD3+ and CD8+ cytotoxic T lymphocytes; IFN-γ-FITC-H vs. TNF-α-PE-Cy7-H: for 
both populations 2 and 3).  The setup unstained control was run, and voltage optimization was carried 
out, which entailed adjusting each fluorophore’s voltage until complete bell curves were seen below the 
103 threshold. Next, the individual stained control wells were run, which would allow for compensation 
to be performed during data extraction and analysis.  
The patient stimulated T-cells assay plate was collected and shaken, and a new experimental plan and 
plate layout was created indicating patient and peptide-specific relevant information. The fluorophore 
and loading settings were maintained, as well as the global sheet and scatter plots. The negative control 
wells, which did not undergo secondary stimulation, were assayed first for each patient sample, 
followed by the positive controls and all sample wells. Once the run was complete both plates were 
discarded, and the resulting data was exported as .fcs files to a selected destination folder. An HTS clean 
was performed using a cleaning plate containing a FACS clean solution (BD Biosciences, 5L, #340345) 
and Millipore water, followed by a fluidics shut down. Sheath fluid (BD Biosciences, 2L, #342003) was 
refilled and waste was emptied accordingly.  
4.2.2.4 FACS data extraction, processing and analysis 
FlowJo (version 7.6.5, LLC), the leading flow cytometry data viewer and analysis software, was used for 
the resulting data extraction, processing and analysis.  The above-mentioned resulting data was dragged 
onto FlowJo, and the column heading was adjusted to include all relevant parameters, such as samples 
IDs. Before proceeding, fluorophore compensation was required, which entailed selecting each 
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individual stain, and creating two separate range gates for the negative and positive peaks. Once this 
was done for each stain, the compensation editor was opened, and the specific negative and positive 
subsets were selected, and this compensation was applied to all samples, to account for any possible 
peak overlap or proximity that might have occurred.  
For each patient-specific negative control, a SSC-A vs. FSC-A graph was viewed and the T-cell population 
cluster was gated and defined. Within that population, a CD3-APC-H vs. CD4-V450-H graph was viewed, 
and the helper T-cell population located in the upper right quadrant (CD3+ and CD4+ cells) was selected, 
and within it both the CD4-V450-H vs. IFN-γ-FITC and the CD4-V450-H vs. TNF-α-PE-Cy7-H graphs were 
viewed. A gate was created close to the right of each viewed cluster, as a means of defining a baseline 
level prior to stimulation. This process was also conducted for the cytotoxic T lymphocyte population, a 
CD3-APC-H vs. CD8-AmCyan-H graph, located within the T-cell original population and also in the upper 
right quadrant (CD3+ and CD8+ cells). This gating was applied to all samples of this specific patient, and 
repeated accordingly for each distinct patient. Once this was done, it was then possible to visualize a 
percentage relative to baseline of increased T-cell response across all samples.   
The resulting data could then be exported to Microsoft Excel for further analysis, using the table editor 
function while defining the relevant columns of interest, and the FlowJo worksheet was saved for 
potential re-analysis or storage purposes. Each resulting Excel spreadsheet per assay plate was further 
analysed and graphed using standard graphing and statistical tools.  
 
4.3 Results and discussion 
Serum or plasma samples from each treatment cohort, along with the 3 additional quality control 
standards (c-Myc, healthy control pool, cancer control pool), were assayed using the CT100+ microarray 
platform as discussed in Section 4.2.1. The resulting arrays were scanned and extrapolated accordingly, 
after which the raw data was processed, filtered and normalized using our bioinformatic tool, the 
CT100+.jar. The results presented in this Chapter have undergone a strict downstream analysis pipeline, 
thus permitting confidence when comparing autoantibody levels of a given patient towards a specific 
antigen at different time points.  
In regards to the settings used, the selected specific whole array filtering control (5/10/15 ng/µL Cy5-
biotin-BSA) might differ between cohorts, as well as the whole array CV threshold (between 20 and 
25%), but consistent settings were used within any given cohort. Besides from the standard user-defined 
noise threshold (nSD of Background), an additional threshold stipulated as the median of all negative 
controls per array (usually below 1000 RFU) was measured for each assay, and autoantibody intensities 
were only considered if above this value. Repeats were conducted as needed, after which each 
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complete cohort was analysed, to allow for data interpretation to occur. The resulting data is indicated 
below for each treatment cohort. It is essential to note that as each treatment type, cohort size, sample 
numbers and clinical information availability is distinct, the data analysis process differed for each 
group.  
Furthermore, when the term ‘immune response’ is used, it refers to either an autoantibody (protein 
array generated) or a T-cell (T-cell assays generated) response, without the implication of an associated 
clinical response. Similarly, the term ‘clinical response’ is only used when significant evidence indicates 
that clinical benefit was achieved, usually determined by RECIST measurements. Understanding 
antibody production in a cancer setting is extremely complex, and thus any preliminary evidence 
indicating that these titres may reflect immune responses that are important in controlling cancer 
progression or regression is merely speculative, warranting further larger focused studies. Patient titres 
may be affected by a large amount of variables, such as age, clinical interventions or treatment-related 
adverse events, which cannot be controlled in a retrospective analysis of this sort.   
4.3.1 Malignant melanoma patients who underwent kinase inhibitor-based 
treatments 
A total of 96 serum samples, corresponding to thirty-six malignant melanoma patients before and 
several time points after kinase inhibitor treatment, were assayed, processed and analysed according to 
our pre-established CT100+ microarray pipeline. The following settings were used for the CT100+.jar 
processing and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations 
of the background, replicate CV threshold = 20%, whole array filtering control = 15 ng/µL Cy5-biotin-BSA 
and whole array CV threshold = 23%. The initial stipulated research question was whether the observed 
autoantibody responses correlated with the reported clinical responses, based on tumour size evolution 
for the kinase inhibitor treatment in question. For this cohort, data analysis was conducted according to 
the available clinical information, which permitted the attribution of a disease status per time point, 
allowing for an optimal direct comparison between the patient’s clinical and immune responses towards 
treatment.  Furthermore, based on sample number-based power calculations indicated in Chapter 2, 
this cohort includes sufficient patient and sample numbers to be able to report statistically relevant 
results (power = 0.83). A significant (> 1000 RFU) autoantibody response to treatment (increase in 
autoantibody titres above baseline) was present in all patients (n = 36/36, 100%), in at least one titre for 
at least one time point after treatment. However, when considering the overall complete array profile, it 
was evident that whilst some autoantibody responses were seen for some cases, others were not, with 
some profiles showing either a stable or decreasing response. Furthermore, within the same patient and 
across multiple time points, different responses were also seen over time, with many cases of patients 
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showing an initial response to treatment, but then a later lack of response. The strongest increase in 
autoimmune response (~120000 RFU) was seen for patient WMD-015 (see Fig. 4.4).  
 
Figure 4.4: Strongest increase in autoimmune response of the kinase inhibition treatment cohort. This 
graph indicates the autoimmune profile of patient WMD-015 across four distinct time points 
(represented by different colours). As a means of clarifying the visualization of relevant titres, an insert 
of the magnified relevant data is indicated within this figure. *Statistically significant difference, P < 0.05 
or **P < 0.01. D0: day 0; PR: partial response. 
 
 
Patient WMD-015, a 24 year old female with malignant melanoma undergoing a combination of BRAF + 
MEK treatment, showed a statistically significant increase from baseline (D0) to the first post-treatment 
time point (2010/05/18) for CTAG2 (from ~26000 RFU to ~90000 RFU, P < 0.01), CTAG2/LAGE-1b/LAGE-
1L (from ~3000 RFU to ~10000 RFU, P < 0.01) and NY-ESO-1 (from ~22000 RFU to ~97000 RFU, P < 0.01). 
An additional increase is also seen when comparing the latter time point to the second post-treatment 
time point (2010/08/24) for CTAG2/LAGE-1b/LAGE-1L (from ~10000 RFU to ~15000 RFU, P < 0.05) and 
NY-ESO-1 (from ~97000 RFU to ~119000 RFU, P < 0.01). Although autoantibody titres are also increasing 
for CTAG2 from ~90000 RFU to ~103000 RFU), this difference is not statistically significant. After these 
consistently gradual increases from time points 1 to 3, when comparing the latter with the third and 
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final post-treatment time point for this patient (2010/10/28), it was evident that CTAG2, its isoform, and 
NY-ESO-1 all showed a statistically significant (P < 0.01) decrease in immune response (B-cell responses). 
It is also worth mentioning that these three antigens, all members of the CT antigen family, are quite 
homologous, with NY-ESO-1 (also referred to as CTAG1) and CTAG2 sharing 77% of sequence homology, 
and CTAG2/LAGE-1b/LAGE-1L being an isoform of the latter. This indicates that a shared epitope 
amongst the three might be the potential location of the responsible antigen/antibody binding site.  
By comparing the observed autoimmune profile for this patient with her matching temporal disease 
statuses, as a means of verifying if these responses were possibly indicative of temporal clinical 
responses (tumour size regression and patient clinical improvement), interpretation of this profile 
became possibly interesting. It appeared that in both instances where an immune response was present 
based on statistically significant increases in autoantibody titres, preliminary evidence of a clinical partial 
response was also seen. Specifically, from baseline to post-treatment time points 1 and 2, tumour size 
continuously decreased by 73%, which is certainly a very beneficial clinical response. When attempting 
to verify if disease progression occurred when this immune response was significantly decreasing, from 
post-treatment time point 2 to 3, this patient was indicated to have disease progression one day after 
the latter time point (2010/08/25), although no tumour size details were available. Therefore, once 
again, preliminary evidence of a matching decrease in immune response and lack of clinical response 
was seen. This patient was indicated to have an overall survival of ten months, having passed away 
three months after the last measured time point, potentially indicating that the drop in immune 
response may be as significant as the earlier increase and that disease progression may be correlated 
with this decline in immune response. These findings indicate that, for this particular patient, the time 
line of array measured immune responses show preliminary evidence of matching clinical responses, 
which may be of great importance. This early evidence suggests the possibility that our array data may 
serve as a rapid, non-invasive means to determine overall response, both immunological and clinical, as 
a result to treatment.  
As a means to verify what was occurring in patients without positive immune responses to treatment, 
the strongest decrease in autoimmune response was assessed and seen for patient WMD-022 (see Fig. 
4.5).  
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Figure 4.5: Strongest decrease in autoimmune response of the kinase inhibition treatment cohort. This 
graph indicates the autoimmune profile of patient WMD-022 across two distinct time points 
(represented by different colours). As a means of clarifying the visualization of relevant titres, an insert 
of the magnified relevant data is indicated within this figure. *Statistically significant difference, P < 0.05 
or **P < 0.01. D0: day 0; PD: progressive disease. 
 
 
Patient WMD-022, a 41 year old male with malignant melanoma also undergoing a combination of BRAF 
+ MEK treatment, showed a statistically significant decrease from baseline (D0) to the post-treatment 
time point (2011/01/25) for CTAG2 (from ~21000 RFU to 0 RFU, P < 0.01) and NY-ESO-1 (from ~71000 
RFU to ~1100 RFU, P < 0.01).  
When comparing the observed autoimmune profile for this patient with his matching temporal disease 
status, as a means of assessing whether there was preliminary evidence of a matching clinical response, 
it appeared that the lack of an immune response, statistically significant decrease in autoantibody titres, 
showed evidence of a matching clinical disease progression. Specifically, from baseline to post-
treatment, tumour size increased by 10%, which may indicate no clinical efficacy of this treatment for 
this particular patient. This patient was indicated to have an overall survival of only three months, 
having passed away one month after the last measured time point, potentially indicating that the drop 
in immune response was gradual, and that disease progression may be correlated with this lack of an 
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immune response. Contrary to what occurred for patient WMD-015, this patient had no evident 
response to kinase inhibition treatment, with no signs of even an initial increase in autoantibody titres, 
potentially indicating some sort of immune suppression or resistance, warranting further investigation. 
Once again, patient WMD-022 showed preliminary evidence that the lack of an array measured immune 
response may indicate the lack of a clinical response, consistent with our initial early evidence 
mentioned above.   
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 19 leading antigens. These 
were detected in at least twenty-three or more instances across all patient time points (baseline or post-
treatment) in this cohort, and most abundantly towards NY-ESO-1 and MAGEB1, as indicated below in 
Fig. 4.6.  
 
Figure 4.6: Most prevalent autoantibody titres detected across the kinase inhibition treatment cohort. 
This graph indicates the summed number of times autoantibody levels were detected towards the 19 
leading antigens at titres above 1000 RFU, with distinction between D0: day 0 and Dn: post-treatment 
(pooled post-treatment time points). 
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Based on this graph, it was evident that initially, when comparing baseline to post-treatment time 
points, all prevalent autoantibody responses towards these leading antigens were increasing (n = 19/19, 
100%), suggesting that if preliminary evidence of matching clinical responses are seen, these antigens 
may somehow be involved in this response. Along with the most abundant autoantibody responses to 
the NY-ESO-1 antigen, fellow CT antigen members are amongst this set, including high sequence 
homologous CTAG antigens CTAG2, CTAG2/LAGE-1b/CTAG2-1L and CAMEL, melanoma (cancer type of 
this cohort) antigen (MAGE) family members, MAGEB1, MAGEA4v3, MAGEB5 and MAGEA11, as well as 
ROPN1, SPANXA1, SPO11, SYCE1 and CXorf48.1 (CTdatabase: www.cta.lncc.br). The remaining four 
antigens were either non-CT antigens, CEACAM 1 Isoform 1, SPATS1 (isoform a), CSAG2 and ITGB1, 
protein kinases, CALM1, or p53 mutants, p53 Q136X (www.uniprot.com).  
NY-ESO-1, also known as CT antigen 1, is a member of the CT antigen family, antigens with restricted 
expression to cancer tissue and limited expression to normal tissue (placenta and testis), with potential 
uses as cancer immunotherapeutic targets (Simpson et al. 2005; Caballero & Chen 2009; Scanlan et al. 
2002). Being an extremely attractive immunotherapeutic target overexpressed across a wide range of 
distinct cancers, NY-ESO-1 has been tested as a cancer therapeutic in a variety of clinical trials in a 
variety of cancer types, including melanoma (Scanlan et al. 2002; Cebon 2010; Nicholaou et al. 2006). 
Furthermore, studies have reported associations with clinicopathological parameters such as tumour 
thickness and metastasis (Scanlan et al. 2002; Li et al. 2005). When focussing on our research question, 
studies have shown that NY-ESO-1 expression has been associated with NY-ESO-1+ tumours and even 
disease evolution in malignant melanoma patients  (Stockert et al. 1998; Jäger et al. 1999). With this in 
mind, the available data for NY-ESO-1 across all patients was inspected, and those patients exhibiting a 
relevant (> 1000 RFU) signal were as indicated below in Fig. 4.7. This data was isolated from the general 
array data, which included technical triplicates for each antigen and biological replicates for a subset of 
patients. However, it is essential to note that the latter were not true biological replicates, as patients 
differ genetically, and in disease status and progression. 
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Figure 4.7: Anti-NY-ESO-1 immunoglobulin titres across relevant patients in the kinase inhibition 
treatment cohort. This graph indicates anti-NY-ESO-1 immunoglobulin titres across all patients and time 
points, highlighting those with statistical significance. D0: day 0; PR: partial response. D0: day 0, PR: 
partial response, PD: progressive disease, SD: stable disease. *Statistically significant difference, P < 0.05 
or **P < 0.01. 
 
 
It was apparent that 22/36 (61%) patients showed relevant signals towards NY-ESO-1, without any 
particular exclusivity for a disease status (PR, PD and SD). Amongst these, six patients showed signals 
above 20000 RFU, and these were patients EB, WMD-008, WMD-012, WMD-015 and WMD-020. 
Patients EB, WMD-015 and WMD-020, all showed statistically significant increasing autoantibody titres 
with preliminary evidence of possible matching partial response temporal disease statuses, based on 
tumour size reductions of 16%, 73% and 35%, respectively, whilst patient WMD-022 showed a 
statistically significant decrease in autoantibody titres with equal evidence of possible matching 
progressive disease temporal status, based on a tumour size increase of 11%. However, although the 
remaining patients WMD-008 and WMD-012 showed a slight but still significant decrease in 
autoantibody titres, their partial response temporal disease statuses did not correlate, based on tumour 
size reductions of 22% and 14%, respectively. This might indicate that the autoantibody titres towards a 
single antigen may not be enough to possibly infer clinical efficacy of a specific treatment. Alternatively, 
it may indicate that slight increases or decreases in autoantibody titres may not be sufficient to 
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potentially infer matching clinical responses, but rather much larger significant difference are required, 
indicating a better estimation inference with smaller P-values.  
MAGEB1, another member of the CT antigen family also known as melanoma-associated antigen B1, is a 
MAGE protein, as mentioned above, with known tumour antigen molecular function 
(www.uniprot.com). The MAGE antigens are known to bind to and activate RING E3 ubiquitin ligases, 
and studies have shown that MAGEB1 was expressed in a variety of cancer types, with evidence of 
spontaneous humoral responses (CT antigen database: www.cta.lncc.br). This cancer-specific expression 
has led to several studies which have identified MAGE family members as potential therapeutic targets 
and diagnostic markers, as well as  prognosis markers (Scarcella et al. 1999; Germano et al. 2012). 
Therefore, similarly to NY-ESO-1, MAGE members have been highly considered as potential 
immunotherapeutic against melanoma, and several clinical trials have and continue to test its clinical 
efficiency, with many showing beneficial patient clinical responses (Marchand et al. 1999; Thurner et al. 
1999). With this in mind, the available data for MAGEB1 across all patients was inspected, and those 
patients exhibiting a relevant (> 1000 RFU) signal were analysed as indicated below in Fig. 4.8.  
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Figure 4.8: Anti-MAGEB1 immunoglobulin titres across relevant patients in the kinase inhibition 
treatment cohort. This graph indicates anti-MAGEB1 immunoglobulin titres across all patients and time 
points, highlighting those with statistical significance.  D0: day 0, SD: stable disease, PD: progressive 
disease, PR: partial response. **Statistically significant difference, P < 0.01. 
 
 
It was apparent that 20/36 (56%) patients showed relevant signals towards MAGEB1, without any 
particular exclusivity for a disease status (PR, PD and SD). Amongst these, four patients showed signals 
above 2000 RFU, and these were patients WMD-010, WMD-016, WMD-020 and WMD-024. Patient 
WMD-020 showed a statistically significant (P < 0.01) increasing autoantibody titre with preliminary 
evidence of possible matching partial response temporal disease statuses, based on a tumour size 
reduction of 35%, whilst patient WMD-024 showed a statistically significant (P < 0.01) decrease in 
autoantibody titres with evidence of a non-matching partial response temporal status, based on a 
tumour size decrease of 50%. In regards to patients WMD-010 and WMD-016, although both of these 
showed increasing autoantibody titres with early evidence of matching partial response temporal 
disease statuses, these differences were not statistically significant. Hence, we estimate that 
autoantibody titres towards multiple antigens may need to be taken into consideration when 
attempting to speculate about possible clinical inference, as some statistically significant increases or 
decreases in autoantibody titres may not necessarily show evidence of correlation with temporal clinical 
responses, whilst others may.  
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Both NY-ESO-1 and MAGEB1 have been highly cited in the literature, with both antigens currently being 
tested as potential cancer immunotherapeutics, implying the potential utility of our findings in this 
particular cohort for patient stratification in a new therapeutic trial. These findings further indicate that 
this array platform may be a useful new tool with which to identify novel cancer therapy targets across a 
variety of cancer types.  
Based on these findings and the potential biological significance of our array platform, the complete 
cohort was assessed further to verify if potential clinical efficacy could be speculated across all patients. 
Formal statistics were conducted with GraphPad Prism (version 5.02), using a non-parametric 2-tailed T-
test known as Mann-Whitney for patients with two time points, and a one way non-parametric ANOVA 
known as Friedman for patients with three or more time points. These tests, which were well suited for 
this data given a non-normal distribution and unequal variances, were done with the intent of assessing 
whether the observed patient time points were statistically significantly different from one another, as a 
means of allowing preliminary clinical assumptions to be made. In total, statically significant (P < 0.05) 
time points were present amongst twenty-nine patients (n = 29/36, 81%), with P-values varying 
between 0.0001 and 0.0230. When visually inspecting each patient’s autoantibody profile and temporal 
disease statuses, eighteen patients (n = 18/34, 53%) showed evidence of a direct correlation between 
increase or decrease in autoantibody titres and presence or lack of clinical response, which indicated 
that for this subset clinical speculative inference could be made with basis on our immunological 
findings. Within the latter subset of possible visual correlation (n = 18/34, 53%), twelve of those patients 
(n = 12/18, 67%) had a corresponding statistical significance. For these twelve patients, the 
corresponding scatter plots across all antigens were combined and were indicated below in Fig. 4.9.  
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Figure 4.9: Scatter plots across relevant patients across the kinase inhibition treatment cohort. This 
figure indicates scatter plots for a selected subset of relevant patients, generated using GraphPad Prism, 
of the resulting statistical analysis using either a non-parametric 2-tailed T-test known as Mann-Whitney 
for patients with two time points, or a one way non-parametric ANOVA known as Friedman for patients 
with three or more time points. D0: day 0, SD: stable disease, PD: progressive disease, PR: partial 
response. Outliers have been removed to allow visual interpretation of this data. 
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It is essential to note that the following 33 outliers have been automatically removed by the statistical 
method used to allow visual representation of the data: DR: MAGEA4v3 (2701 RFU, TP2); GD: MAGEA10 
(4821 RFU, D0); TL: ACVR2B (2426 RFU, TP2), TKTL1 isoform a (2544 RFU, TP2), TSGA10 (2191 RFU, TP2); 
DD: CTAG2 (7000 RFU, TP1); KD: CT62 (2011 RFU, TP2), DDX53 (2735 RFU, D0), NXF2 (2692 RFU, TP2), 
p53Q136x (2331 RFU, TP2), SILV (2965 RFU, D0); DM: NY-ESO-1 (4716 RFU, TP4); WMD-013: cytochrome 
P450 3A4 (3885 RFU, TP1), TPTE (3252 RFU, TP1); WMD-015: CTAG2 (25628 RFU, D0; 89604 RFU, TP1; 
102930 RFU, TP2; 48247 RFU, TP3), CTAG2/LAGE-1b/LAGE-1L (10109 RFU, TP1; 14771 RFU, TP2), NY-
ESO-1 (22001 RFU, D0; 96965 RFU, TP1; 119280 RFU, TP2; 39954 RFU, TP3); WMD-016: ITGB1 (3209 
RFU, D0); WMD-019: CTAG2 (4352 RFU, TP1), NY-ESO-1 (6578 RFU, TP1); WMD-020: CTAG2 (7181 RFU, 
D0; 50231 RFU, TP1), CTAG2/LAGE-1b/LAGE-1L (6116 RFU, TP1), NY-ESO-1 (11864 RFU, D0; 48442 RFU, 
TP1); WMD-021: TKTL1 isoform a (6445 RFU, TP1).  
Based on the scatter plots indicated above, it was evident that across the majority of patients when a 
partial response is obtained, autoantibody titres are grouped above the previous time point, and when 
progressive disease is occurring, autoantibody titres are grouped below the previous time point, 
consistent with our preliminary observations described above. Furthermore, although 67% of the 
patients with evidence of a potential visual correlation had a statistically valid one, when comparing 
these to the complete patient cohort, only twelve out of thirty-four patients (two patients were lacking 
temporal disease statuses) (n = 12/34, 35%) presented with an autoimmune profile that could 
statistically significantly speculate a matching clinical response.  
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of metastatic malignant melanoma patients undergoing kinase inhibition, and observed a large 
number (81% of the cohort) of autoantibody responses – statistically significant changes in autoantibody 
titres – to treatment. The main intent of this study was to assess whether the induction of an 
autoantibody response may correlate with clinical improvements post-treatment amongst these 
patients, or whether other immunological features would provide preliminary evidence of correlation 
with a therapeutic response. In this regard, it is interesting that our CT antigen array data suggests 
preliminary evidence of a possible correlation between our observed autoantibody responses and the 
clinically reported ones across a subset of patients (35% of the cohort). The fact that this speculative 
finding is present across approximately a third of this complete cohort suggests that patient-specific 
autoantibody profiles may correlate with treatment responses. However, it appears plausible that other 
factors, which we have yet to determine, may be contributing towards this lack of suggested correlation 
amongst the remaining cohort. Such factors may include patient-specific differences amongst tumour-
induced systemic immune suppression, common amongst patients presenting with advanced 
melanoma, as well as undesirable suppression of anti-tumour T-cell immunity by Tregs, amongst other 
common immune evasion mechanisms (Nicholaou et al. 2009). Additionally, it is plausible that several 
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melanoma-specific subtypes are present amongst these patients, and that the above-mentioned 
possible correlation may only be present across a given subtype, warranting additional genomic studies. 
This data also suggests preliminary evidence of immune suppression or resistance to therapy in 
individual patients post-treatment, evident by a drastic decrease in autoantibody titres after an initial 
evident increase in response to the first dosage of treatment. The possibility of detecting immune 
suppression or therapeutic resistance is of great interest in the therapeutic management of disease, and 
thus warrants further investigation.   
In this kinase inhibition treatment cohort, we have successfully demonstrated that there are measurable 
differences in the autoantibody repertoires towards tumour-specific and –associated antigens between 
pre- and post-treated malignant melanoma patients, with preliminary evidence of possible correlation 
to the likelihood of clinical response. Furthermore, we have successfully identified well-established 
therapeutic targets – NY-ESO-1 and MAGEB1 – which were the two antigens towards which the most 
abundant autoantibody titres were detected amongst those tested, present across 61% and 56% 
patients, respectively. When considering patient sample numbers and relevant power calculations, 
although this cohort is quite diverse regarding patient demographics (age and gender) and treatments 
undergone (single vs. dual kinase inhibition treatment), the achieved statistical power is above 
recommended (power > 0.8), supporting the findings obtained in this cohort.   
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage in future cancer research in monitoring patient responses to treatment, identifying immune 
suppression and/or therapy resistance, and identifying novel therapeutic targets, warranting 
confirmation using a pre-stipulated specifically focussed study and homogeneous cohort design using 
sufficient patient numbers according to an a priori power calculation estimate. 
As a means of verifying how well the above-mentioned autoantibody profiles correlate with T-cell 
responses in these same patients, T-cell assays were conducted amongst a subset of eight patients of 
this treatment cohort, across a matching timeline. These time points were temporally matched with the 
samples used for the array data, to allow for a direct comparison between temporal B- and T-cell data. 
Furthermore, the T-cell assay investigated IFN-γ and TNF-α cytokine release of helper T-cells and 
cytotoxic T-cells against NY-ESO-1 and MART-1/Melan-A.  
For a selected T-cell assay which included patients AB and DM, images were captured microscopically 
across the 10-day cell re-stimulation, as a means of verifying morphologically visual changes towards 
treatment. It was rapidly evident that visual changes were quite evident amongst wells, which generally 
correlated to quantifiable T-cell responses to re-stimulation. Two distinct visual responses were seen, 
the first been a lack of visually evident morphological changes, as indicated below in Fig. 4.10.  
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Figure 4.10: Representative images depicting visually non-responding wells. This figure indicates four 
distinct microscope images captured after T-cell re-stimulation, showing no visual evidence of response 
defined by the lack of morphological changes after stimulation. 
  
   
 
In the images indicated above, it was clear that the majority of the cells maintained a round healthy 
appearance throughout the 10-days of re-stimulation. These images were consistent with what was 
seen for each patient time point at day 0, prior to T-cell stimulation, indicating that a T-cell response was 
unlikely. On the contrary, the second type of visual responses seen was the clear presence of visually 
evident morphological changes, as indicated below in Fig. 4.11.  
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Figure 4.11: Representative images depicting visually responding wells. This figure indicates four 
distinct microscope images captured after T-cell re-stimulation, showing visual evidence of response 
defined by the presence morphological changes after stimulation. Red arrow: example of immature DC; 
Green arrow: example of maturing DC; Blue arrow: example of fibroblast. 
  
  
 
Amongst these images, it was evident that although healthy round cells were seen in high numbers, 
other cell types were also evident. These included the presence of DCs, immature and mature, and 
fibroblasts. These morphological changes were very distinct from the matching day pre-stimulation 
wells, and were generally indicative of a quantifiable T-cell response.  
T-cell assays with NY-ESO-1 and MART-1/Melan-A were conducted across time lines for patients GD, TL, 
AB, DM, DD, EL, DBr and KD, using matching array tested temporal samples. The majority of the 
resulting FACS data was negligible, with patients TL, GD, DD and EL all showing T-cell responses below 
1%. Of the remaining four patients showing responses above 1%, AB, DM, EL and KD, half of those (DM 
and KD) were amongst the statistically significant array profiles with preliminary evidence of clinical 
efficacy, and therefore, those data will be shown. Patient DM, a male malignant melanoma patient 
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undergoing BRAF +/- MEK, was assayed across three time points, day 0, week 28 (27/02/2013) and week 
52 (17/07/2013), and the resulting data is indicated below in Fig. 4.12.  
 
Figure 4.12: T-cell responses towards NY-ES0-1 and MART-1/Melan-A for patient DM at three distinct 
time points. Above: graph for NY-ESO-1; Below: graph for MART-1/Melan-A. Th cells: helper T-cells; 
CTLs: cytotoxic T-cells. 
 
 
 
It was evident that all but one time point responses, IFN-γ+ cytotoxic T-cells towards MART-1/Melan-A, 
were below 1%. This particular response initially declined from day 0 to week 28, and then increased 
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from week 28 to week 52. To further comprehend how these cells were responding, the relevant 
corresponding scatter plots and gating are indicated below in Fig. 4.13.  
 
Figure 4.13: IFN-γ+ cytotoxic T-cells scatter plots and gating towards MART-1/Melan-A for patient DM 
at three distinct time points. Left: graph for day 0; Middle: graph for week 28; Right: graph for week 52. 
CTLs: cytotoxic T-cells. 
   
 
Based on the scatter plots indicated above, it was evident that very few cells were in fact responsible for 
the observed responses. When consulting the total percentage of cytotoxic T-cells relative to the 
complete T-cell population across this patient’s time points, the obtained proportions were 6.71% at day 
0, 7.01% at week 28, and 8.28% at week 52. As a means of verifying if this T-cell response correlated to 
an array generated B-cell response, the matching MART-1/Melan-A responses were assessed. This data 
showed baseline titres of ~400 RFU, below our significantly expressed threshold, which maintained 
stable at week 28, and then decreased to zero at week 52. When comparing these findings to the graph 
indicated above right in green, these did not match, indicating that in this instance a B-cell response was 
not indicative of a T-cell one. Moreover, when including the temporal disease status of a partial 
response at week 28, and progressive disease at week 52, the cytotoxic T-cells appeared to respond in a 
completely opposite manner, showing evidence of decreasing titres during a clinical response, and 
increasing titres during progressive disease. Therefore, specifically for patient DM, no preliminary 
evidence of a correlation was found between the generated B-cell, T-cell and clinical efficiency data. 
 Additionally, patient KD, a female malignant melanoma patient also undergoing BRAF +/- MEK, was 
assayed across three time points, day 0, week 8 (06/02/2013) and week 32 (23/07/2013), and the 
resulting data is indicated below in Fig. 4.14.  
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Figure 4.14: T-cell responses towards NY-ES0-1 and MART-1/Melan-A for patient KD at three distinct 
time points. Above: graph for NY-ESO-1; Below: graph for MART-1/Melan-A. Th cells: helper T-cells; 
CTLs: cytotoxic T-cells. 
 
 
 
It was evident that all but two time point responses, IFN-γ+ helper T-cells and cytotoxic T-cells towards 
MART-1/Melan-A, were below 1%. The helper T-cells steadily declined from day 0 to week 8 and to 
week 32, whilst the cytotoxic T-cells initially increased from day 0 to week 8, and then decreased from 
week 8 to week 32. To further comprehend how these cells were responding, the relevant 
corresponding scatter plots and gating are indicated below in Fig. 4.15.  
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Figure 4.15: IFN-γ+ helper and cytotoxic T-cells scatter plots and gating towards MART-1/Melan-A for 
patient KD at three distinct time points. Above: helper T-cells; Below: cytotoxic T-cells Left: graph for 
day 0; Middle: graph for week 8; Right: graph for week 32. 
   
   
 
Based on the scatter plots indicated above, it was evident that when comparing helper T-cells with 
cytotoxic T-cells, the latter contained a reduced amount of cells responsible for the observed responses. 
When consulting the total percentage of helper T-cells and cytotoxic T-cells relative to the complete T-
cell population across this patient’s time points, the obtained proportions were 81.1% and 13.4% at day 
0, 79.9% and 13.1% at week 8, and 74.8% and 17.7% at week 32, respectively. It was certainly apparent 
that as for patient DM, there was a much higher proportion of helper T-cells when compared to 
cytotoxic T-cells. As a means of verifying if these T-cell responses showed preliminary evidence of 
correlation to the array generated B-cell response, the matching MART-1/Melan-A responses were 
assessed. This data showed baseline titres of ~500 RFU, which gradually increased to ~600 RFU (week 8) 
and then ~950 RFU, with all titres below our significantly expressed threshold. When comparing these 
early findings to the graph indicated above right in green, these only match for the cytotoxic T-cells from 
day 0 to week 8, and no not match in the 3 additional instances, indicating that in this instance a B-cell 
response was somewhat indicative of a T-cell one, although this was not consistent across time points 
and cell types. Moreover, when including the temporal disease status of a partial response at week 8 
and week 32, cytotoxic T-cells from day 0 to week 8 also respond in a similar manner, showing evidence 
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of increasing titres during a clinical response. However, the subsequent time point no longer matches 
the speculated titre increase with clinical efficacy.  Therefore, specifically for patient KD, speculative 
evidence of a correlation was found between the generated B-cell, T-cell and clinical efficiency data for 
IFN-γ+ cytotoxic T-cells, but only between day 0 and week 8.  
Kinase inhibition – the specific treatment under investigation in this cohort – was designed to elicit both 
T-cell and antibody responses against melanoma-associated antigens in melanoma patients. Given that 
T-cell and B-cell responses are coordinated to some degree at the level of helper T-cells, agreement 
between these antigen-specific responses was expected. Yet, only two out of the eight tested patients 
presented with matching autoantibody responses. Amongst these, early evidence of  a limited 
correlation was seen between T-cell and clinical data. However, due to the reduced number of array 
assayed temporal matching samples, this study was only conducted on a small subset of patients. 
Unfortunately, to be able to make accurate assumptions, larger patient numbers and possibly a longer 
stimulation period is required, limiting our possible data interpretation. Additionally, only 2 (NY-ESO-1 
and MART-1/Melan-A) of our 123 antigens tested were available and functional for these assays, further 
limiting this assay.  
4.3.2 Colorectal cancer patients who underwent pre- or post-operative 
chemotherapy/radiotherapy  
A total of 62 serum samples, corresponding to sixty-two colorectal cancer patients undergoing pre- or 
post-operative chemotherapy/radiotherapy treatment were assayed, processed and analysed according 
to our pre-established CT100+ microarray pipeline. The following settings were used for the CT100+.jar 
processing and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations 
of the background, replicate CV threshold = 20%, whole array filtering control = 10 ng/µL Cy5-biotin-BSA 
and whole array CV threshold = 21%. The initial stipulated research question was whether a pre- or post-
operative therapy significantly altered the pattern of cancer-associated autoantibody titres in these 
patients, thereby potentially influencing the outcome of any subsequent treatment, which would 
provide us with a greater understanding of the interplay between chemotherapy/radiotherapy and anti-
cancer autoimmune responses. For this cohort, data analysis was conducted based on the collected 
clinical information and each patient’s resulting autoimmune profile, permitting the comparison 
between several of these parameters, as a means of possibly identifying diagnostic or prognostic 
biomarkers, or discovering that a therapy induced antigen expression deregulation might stimulate a 
beneficial cancer-specific autoimmunological effect post-therapy. However, it is important to note that 
only a single blood sample was available for each patient, signifying that no autoantibody responses 
progression across a time course may be measured, but rather a single profile for each patient. Hence, 
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our data analysis pipeline is distinct from those mentioned above. Furthermore, based on sample 
number-based power calculations indicated in Chapter 2, this cohort includes sufficient patient and 
sample numbers to be able to report statistically relevant results (power = 0.97). 
Significant (> 1000 RFU) autoantibody titres were present in all 62 patients (n = 62/62, 100%), with 
signals ranging from 0 to ~23000 RFU. The majority of these patients (n = 40/62, 65%) displayed medium 
(between 2000 and 10000 RFU) signals, followed by 17/62 (27%) patients with low (between 1000 and 
2000 RFU) signals, and 5/62 (8%) patients with high (above 10000 RFU) signal. In an attempt to verify if 
autoantibody levels were increased as a result of pre-operative chemotherapy/radiotherapy, patient 
distribution was assessed and no evident pattern was seen, with an equally divided pre- and post-
operative subset of patients in each low (7 vs 7), medium (20 vs 19) and high (2 vs 2) signal group, 
respectively. Unfortunately, this finding did not infer any clarification in regards to whether higher 
autoantibody signals were associated with the presence of pre-operative chemotherapy/radiotherapy. 
When considering the presence or absence of recurrence, it was evident that the patients were 
distributed unequally across these same low (3 vs 11), medium (8 vs 29) and high (2 vs 2) autoantibody 
titre groups, respectively.  This indicated that the majority of the recurring patients had medium 
autoantibody signals when tested. It seems unlikely therefore that this autoimmune profile would 
provide relevant information regarding likelihood of recurrence, due to the latter occurring at a much 
later temporal time point, and in a variable manner across patients. Additionally, in regards to cancer 
stage and site of disease, patient distribution was also assessed, with the majority of patients being 
stage II (n = 7/14, 50%) in the low group, stage III (n = 17/37, 46%) in the medium group, and both stage 
I (n = 2/4, 50%) and III (n = 2/4, 50%) in the high group.  Cancer stage seemed to cluster quite randomly 
across signal groups, with lower autoimmune signals belonging to mainly stage II patients, medium 
signals to stage III, and higher signals to stages I and III. The main cancer types accumulating in each 
group were rectum (n = 8/14, 57%) and recto-sigmoid junction (n = 4/14, 29%) for low, rectum (n = 
27/39, 69%) and caecum (n = 4/39, 10%) for medium, and rectum (n = 2/4, 50%) for high. Rectum was 
the main cancer site in each autoantibody signal group, which was most likely related to the fact that it 
is the most abundant cancer type of this cohort (65%), rather than an actual site-signal association.  
Interestingly, the patient displaying the highest autoantibody titres (~23000 RFU), CRC038, was a stage I 
rectum patient with pre-operative therapy. However, this patient also had disease recurrence, indicating 
that no likelihood of recurrence inference should be made, based on early array data.   
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 14 leading antigens. These 
were detected in at least 10 or more instances across all patients in this cohort, and most abundantly 
towards SILV/gp100 (n = 19/62, 31%) and p53 Q136X (n = 13/62, 21%), as indicated below in Fig. 4.16. 
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Figure 4.16: Most prevalent autoantibody titres detected across the pre- or post-operative therapy 
treatment cohort. This graph indicates the summed number of times autoantibody levels were detected 
towards the 14 leading antigens at titres above 1000 RFU. 
 
 
Based on this graph, it was evident that the most prevalent autoantibody titres towards a very 
interesting subset of leading antigens were present in at least ten patients. Besides from p53 Q136X, 
autoantibody titres towards an additional four p53 mutants were also amongst the top signals, thus 
arguing for upregulation of one form that shares a common epitope amongst these mutants. This 
finding strengthens a potential use for these, either diagnostic or therapeutic related. Additionally, the 
remaining prevalent titres were towards either CT antigens (MAGEA5, CTAG2/LAGE-b/LAGE-1L, 
ROPN1A), protein kinases (CDK4, PRKCZ, MAPK1) or other cancer-associated antigens (5T4/TPBG, 
CREB1).  
As a means of defining whether the antigens with the most abundant autoantibody titres could be 
potential diagnostic or prognostic biomarkers, or even therapeutic targets, SILV/gp100 and p53 Q136X 
were investigated further.  
SILV, also known as lineage-specific antigen gp100, is a type I transmembrane glycoprotein that plays a 
crucial role in the biogenesis of melanosomes (www.uniprot.com, www.ncbi.nlm.nih.gov/ 
pubmedhealth). This protein is usually referred to as a melanoma or tumour-associated antigen, due to 
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its wide expression in melanomas, with early studies showing associated between an anti-SILV/gp100 
response and cancer regression which is linked to the specific recognition by HLA-A2-restricted CD8+ 
cytotoxic T-cells (Kawakami et al. 1994; Bakker et al. 1994). Hence, this protein was rapidly considered 
as an attractive melanoma diagnostic marker due to its restricted expression in melanocytes, and as a 
potential target for cellular immune responses against melanoma (Adema et al. 1994; Bakker et al. 
1994; de Vries et al. 1997). A vast number of clinical trials followed this discovery, testing the efficacy of 
using a variety of SILV/gp100 peptides, either alone, or in combination with MART-1/Melan-A or IL-2, as 
a targeted melanoma immunotherapeutic, with promising results and continued testing to date (Zhai et 
al. 1996; Rosenberg et al. 1998; Di Pucchio et al. 2006; Schwartzentruber et al. 2011). However, all of 
the above and easily accessible literature is referent to melanoma, and this treatment cohort included 
solely colorectal cancer patients. When attempting to verify if a SILV/gp100-derived therapeutic vaccine 
had been tested in colorectal cancer, no records were found, indicating that this therapy has not yet 
been considered for colorectal cancer (Tartaglia et al. 2001; Xiang et al. 2013). This finding is of 
particular importance, as SILV/gp100 might be a potential novel therapeutic target for colorectal cancer, 
which has previously not been reported or tested. Therefore, the available data for SILV/gp100 across all 
patients was inspected, and an autoantibody titre trendline across this whole cohort was constructed, as 
indicated below in Fig. 4.17. 
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Figure 4.17: Anti-SILV/gp100 immunoglobulin titre trendline across all patients of the pre- or post-
operative therapy treatment cohort. Threshold on graph indicates ~1000 RFU, as a means of facilitating 
view of most significant signals. 
 
 
Visual inspection of this anti-SILV/gp100 immunoglobulin titre trendline indicates that autoantibody 
titres against SILV/gp100 are quite variable across our cohort, with two spikes for patients CRC038 
(~23000 RFU, rectum, stage I, pre-operative therapy, and no disease recurrence) and CRC048 (~4500 
RFU, rectum, stage IV, no pre-operative therapy, and no disease recurrence). In an attempt to verify if 
any particular disease site or stage, as well as presence or absence of pre-operative therapy and 
recurrence, was most prevalent across significant (> 1000 RFU) titres, these were accounted for.  The 
most prevalent site and stage of disease was the rectum (n = 11/18, 61%) and stage II (n = 8/16, 50%), 
respectively. The latter seems to indicate that these titres don’t seem to be related to a more advanced 
cancer type, but rather variably between stages I to IV. If this protein was in fact considered as a novel 
colorectal cancer therapeutic, the fact that it is expressed across all disease stages is certainly beneficial, 
as it implies a wider applicability. When considering pre-operative therapy, these patients were equally 
divided, with exactly half of them (n = 9/18, 50%) not having pre-operative therapy. Lastly, in regards to 
recurrence, it seemed that the majority of these patients did not have recurring disease (n = 13/17, 
76%). This finding is of particular interest, as it might potentially indicate that the presence of 
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SILV/gp100 might be associated with a reduced likelihood of recurrent disease, warranting further 
studies.   
In regards to the other most abundantly expressed protein, p53 Q136X, a similar analysis was 
conducted. The tumour suppressor p53 is known to play a crucial role in cell cycle regulation and 
induction of apoptosis, and common cancer-related mutations have been implicated with 
carcinogenesis, cancer progression, as well as possible diagnostic, prognostic and therapeutic uses. In 
regards to colorectal cancer in particular, the overexpression and mutation of p53 is also a known 
phenomenon, which validates our finding within this specific cancer type, amongst the several ones 
included in this treatment cohort (Rodrigues et al. 1990; Liu & Bodmer 2006). Additionally, p53 mutant 
overexpression has been linked to a poorer prognosis, decreased survival and even likelihood of tumour 
relapse, and therefore be considered an immunotherapeutic (Starzynska et al. 1992; Houbiers et al. 
1995; Hammel et al. 1997; Kressner et al. 1998). Understandingly, p53 has been tested in a clinical trial 
setting across a variety of distinct cancer types, including colorectal cancer (www.clinicaltrials.gov). 
Therefore, the available data for p53 Q136X (a frame-shifted, inactivated mutant of p53) across all 
patients was inspected, and an autoantibody titre trendline across this whole cohort was constructed, as 
indicated below in Fig. 4.18. 
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Figure 4.18: Anti-p53 Q136X immunoglobulin titre trendline across all patients of the across pre- or 
post-operative therapy treatment cohort. Threshold on graph indicates ~1000 RFU, as a means of 
facilitating view of most significant signals. 
 
 
Visual inspection of this anti-p53 Q136X immunoglobulin titre trendline indicates that autoantibody 
titres against p53 Q136X are also variable across our cohort, with a spike for patient CRC050 (~14000 
RFU, rectum, stage I, pre-operative therapy, and disease recurrence). In an attempt to verify if any 
particular disease site or stage, as well as presence or absence of pre-operative therapy and recurrence, 
was most prevalent across significant (> 1000 RFU) titres, these were accounted for.  The most prevalent 
site and stage of disease was the rectum (n = 8/13, 62%) and stage III (n = 7/12, 58%), respectively. The 
latter seems to indicate that these autoantibody titres might be related to a more advanced cancer 
type, with gradually increasing patient numbers from stages I to III (no stage IV patient were present in 
this subset), which might indicate a potential use in identifying a more advanced cancer stage, 
warranting further studies. Remarkably, both this higher prevalence in rectum cancers and this increase 
in autoantibody titres related to increasing disease stage has been reported previously, which highly 
validates this finding (Starzynska et al. 1992). When considering pre-operative therapy, these patients 
were quite equally divided, with just over half of them (n = 7/13, 54%) not having pre-operative therapy. 
Lastly, in regards to recurrence, it seemed that the majority of these patients did not have recurring 
disease (n = 8/12, 67%). This finding might potentially indicate that the presence of p53 Q136X might 
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also be associated with a reduced likelihood of recurrent disease, however, this is contrary to what has 
been reported in the literature, and therefore warrants further study (Starzynska et al. 1992).   
As a means of identifying the most interesting patient autoantibody titres across these most abundant 
antigens, a 3-D plot was constructed with all patients, and is indicated below in Fig. 4.19. 
 
Figure 4.19: Most abundant autoantibody titres across pre- or post-operative therapy treatment 
cohort. This 3-D graph indicates the autoimmune profile of all patients across the most abundant 
antigens of this treatment cohort. Each antigen is indicated in a different colour, and each patient 
sample is indicated in the x-axis.  
 
 
This data representation indicates that the majority of these patient signals are below 5000 RFU, with 
only five patients displaying signals between 5000 and 25000 RFU. These high signals were seen for p53 
S6A (CRC002, rectum, stage II, pre-operative therapy, and no disease recurrence), ROPN1A (CRC037, 
proximal descending colon, stage III, no pre-operative therapy, and no disease recurrence), SILV/gp100 
(CRC038, rectum, stage I, pre-operative therapy, and no disease recurrence), and MAGEA5 (CRC050, 
rectum, stage I, pre-operative therapy, and disease recurrence).  It is particularly interesting to visualize 
that even amongst the same cancer type, stage and therapy, each patient’s autoimmune profile and 
most commonly detected autoantibodies vary greatly, highlighting that each patient is a unique case, 
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and aiding in comprehending the distinct responses to treatment across a given cancer type. Thus, both 
variable genomic and proteomic profiles highlight the need for a personalised treatment approach for 
each patient.   
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of colorectal cancer patients who either underwent or not pre-operative chemotherapy or 
radiotherapy, and observed significant autoantibody titres across all patients. The main intent of this 
study was to assess whether pre-operative therapy altered patterns of autoantibody titres, thereby 
potentially influencing the outcome of subsequent therapy. In this regard, this cohort data showed that 
no apparent difference in autoantibody profiles was evident between patients who had undergone pre-
operative therapy and those who hadn’t, contrary to what was expected. However, it may be plausible 
that other factors, which we have yet to determined, may be contributing towards this lack of 
distinction. Such factors may include the presence of distinct cancer subtypes amongst this cohort, some 
of which may be immune suppressive in character, and thus potentially influencing the resulting 
autoimmune profiles (Sadanandam et al. 2013; Sanz-García et al. 2014). Although previous studies have 
demonstrated benefits when combining cancer therapeutics, we are unable to infer influences on 
subsequent treatment outcome of this specific cohort, due to the lack of evident differences amongst 
patients who underwent pre-operative therapy and those who did not (Hodi et al. 2010).  
In this pre- or post-operative chemotherapy/radiotherapy cohort, we have successfully demonstrated 
that there are measurable differences in the autoantibody repertoires towards tumour-specific and –
associated antigens amongst colorectal cancer patients. However, there was no evidence that these 
were potentially augmented or not by prior therapy. Furthermore, we identified SILV/gp100 – potential 
novel therapeutic target for colorectal cancer – and p53 Q136X – potential indicator of disease 
progression – as the two most abundantly detected autoantibodies amongst those tested, present 
across 31% and 21% patients, respectively. However, unlike with the kinase inhibition cohort, these 
titres are much less prevalent than desired to be considered as viable colorectal cancer biomarkers or 
cancer therapeutic targets with broad applicability. When considering patient sample numbers and 
relevant power calculations, although this cohort is quite diverse regarding age, the achieved statistical 
power is above recommended (power > 0.8), supporting the findings obtained in this cohort.   
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage in determining whether or not previous systemic therapy may aid in the efficacy of 
subsequent therapeutics, warranting confirmation using a pre-stipulated specifically focussed study and 
homogeneous cohort design using sufficient patient numbers according to an a priori power calculation 
estimate. 
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4.3.3 Myelodysplasia patients who underwent dual epigenetic modification  
A total of 30 serum samples, corresponding to twelve MDS and AML patients before and after cycles 3 
and 4 of treatment with panobinostat and azacitidine, were assayed, processed and analysed according 
to our established CT100+ microarray pipeline. The following settings were used for the CT100+.jar 
processing and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations 
of the background, replicate CV threshold = 20%, whole array filtering control = 15 ng/µL Cy5-biotin-BSA 
and whole array CV threshold = 22%. The initial stipulated research question was whether the 
deregulation of the cancer-provoked epigenetic instability would create neo-antigens and subsequent 
expanded autoantibody responses. For this cohort, data analysis was conducted according to the 
available clinical information, which permitted the attribution of a disease status per time point, 
allowing for an optimal direct comparison between the patients clinical and immune responses towards 
the treatment.  Furthermore, based on sample number-based power calculations indicated in Chapter 2, 
this cohort does not include sufficient patient and sample numbers to be able to report statistically 
relevant results (power = 0.35). 
A significant (> 1000 RFU) autoantibody response was present in 11/12 (92%) patients, with the 
strongest response (~9000 RFU) seen, both quantifiably and visually, for patient 001-0002 (see Fig. 4.20 
and 4.21). 
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Figure 4.20: Strongest patient autoimmune profile of the epigenetic modifier treatment cohort. This 
graph indicates the autoimmune profile of patient 001-0002 across two distinct time points 
(represented by different colours). As a means of clarifying the visualization of relevant titres, an insert 
of the magnified relevant data is indicated within this figure. *Statistically significant difference, P < 0.05 
or **P < 0.01. D0: day 0; PR: partial response. 
 
 
Figure 4.21: Strongest patient corresponding scanned array image of the epigenetic modifier 
treatment cohort. This figure indicates scanned array images of patient 001-0002 before (image on left 
at screening) and after (image on right at cycle 4, day 25) treatment, with visual evidence of an 
autoantibody response towards PRKCZ. Red box highlights triplicate PRKCZ positive signals. 
  
 
 
 
PRKCZ 
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Patient 001-0002, diagnosed with AML-MRC, showed a statistically significant increase above 2000 RFU 
in CREB1 (P < 0.05) and PRKCZ (P < 0.01) in response to treatment. The fact that this patient shows such 
a drastic increase in autoimmune response to PRKCZ is of particular interest. PRKCZ, known as protein 
kinase C-zeta, is an atypical calcium- and diacylglycerol-insensitive isozyme of the protein kinase C 
family, a family of serine/threonine kinases that regulate several cell functions, such as proliferation, 
gene expression, cell cycle, differentiation, cytoskeletal organization cell migration and apoptosis 
(Teicher 2006; Way et al. 2000). Protein kinase C has been broadly targeted as a potentially attractive 
cancer therapy due to its potential role in carcinogenesis, being the receptor for tumour-promoting 
phorbol esters, with several studies aiming to understand how it regulates apoptosis and 
chemoresistence, as a means of reversing the latter (Bosco et al. 2011; Marengo et al. 2011; Pearson & 
Fabbro 2004; Teicher 2006). PRKCZ expression has been specifically linked to multiple myeloma and 
leukaemia, cancer types included in this treatment cohort, showing direct involvement in modulating 
hematopoietic neoplasms, which indicates a direct association and validation of this finding with the 
literature (Teicher 2006). Additionally, PRKCZ has recently shown to be essential for the regulation of 
cell motility, with direct involvement in the regulation of cancer cell migration and invasion, which may 
explain why an autoimmune response towards this protein was present for this patient (Xiao & Liu 
2013).  
When comparing the observed autoimmune profile for this patient with the overall disease status, PR, 
both showed preliminary evidence of agreement. However, to understand whether this response was 
indicative of a temporal clinical response (tumour regression and patient improvement), one must 
consider the disease status of the matched time point in question, rather than the patient’s best or 
overall response, as this information will be more relevant. For that purpose, this particular question will 
be assessed further below. Additionally, to verify if this PRKCZ response was restricted to this patient 
(PR), all resulting autoimmune profiles were inspected, and three additional patients were found with a 
much lower (between 1000 and 2000 RFU) but relevant response, patients 001-00003 (CR), 001-0007 (R) 
and 001-0013 (SD), all of which presented with distinct overall disease statuses. Both patients 001-0002 
and 001-0007 were diagnosed with AML-MRC, but the remaining two patients were diagnosed with 
MDS-Int2. 
 As a means to assist in comprehending the reason why some patients have a stronger immune 
response than others, the weakest response (~1500 RFU) was also of importance, and was seen for 
patient 001-0016 (see Fig. 4.22).   
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Figure 4.22: Weakest patient autoimmune profile of the epigenetic modifier treatment cohort. This 
graph indicates the autoimmune profile of patient 001-0016 across three distinct time points 
(represented by different colours). As a means of clarifying the visualization of relevant titres, an insert 
of the magnified relevant data is indicated within this figure. *Statistically significant difference, P < 0.05 
or **P < 0.01. 
 
 
On the contrary to patient 001-0002, patient 001-0016, diagnosed with MDS-Int2, showed only a slight, 
but also statistically significant, increase above 1000 RFU in DSCR8/MMA1 (P < 0.01) and MART-
1/Melan-A (P < 0.05) in response to treatment. When comparing this finding with the patient’s overall 
disease status, PD, once again evidence of corroboration was made, as although a very weak response 
to treatment was present, the majority of these were below 1000 RFU, which was potentially indicative 
of a likely disease progression, rather than a suggested response.  
Of this cohort, 12/12 (100%) patients showed autoantibody responses to treatment, although these 
responses were minor and below 2000 RFU for two patients, patient 001-0016 (see Fig. 4.22 above) and 
patient 001-0013 (see Fig. 4.23).   
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Figure 4.23: Patient with minor autoimmune responses of the epigenetic modifier treatment cohort. 
This graph indicates the autoimmune profile of patient 001-0013 across three distinct time points 
(represented by different colours). 
 
 
Patient 001-013, also diagnosed with MDS-Int2, showed several but minor increases in autoantibody 
signals in response to treatment, with overall stable titres across each time point. This patient’s overall 
disease status was SD, which speculatively agreed with the observed autoimmune profile, as no major 
change was seen from screening to cycles 3 or 4 of treatment. However, when directly compared to 
patient 001-016, far more of these signals were above the 1000 RFU threshold (32 versus 2), which may 
account for the overall disease status difference (SD versus PD) between these two patients with 
seemingly similar autoimmune profiles. 
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 19 leading antigens. These 
were detected in at least six or more instances across all patient time points (screening or cycles of 
treatment) in this cohort, and most abundantly towards cytochrome P450 reductase and DSCR8/MMA1, 
as indicated below in Fig. 4.24.  
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Figure 4.24: Most prevalent autoantibody titres detected across the epigenetic modifier treatment 
cohort. This graph indicates the summed number of times autoantibody levels were detected towards 
the 19 leading antigens at titres above 1000 RFU, with distinction between S: screening; C3: cycle 3 of 
treatment; and C4: cycle 4 of treatment.  
 
 
Based on this graph, it was evident that initially, when comparing screening to cycle 3 of treatment, the 
majority of these prevalent autoantibody responses towards these leading antigens were decreasing (n 
= 11/19, 58%), whilst the rest were either stable (n = 6/19, 32%) or increasing (n = 2/19, 10%). However, 
when comparing cycle 3 to cycle 4 of treatment, there was a clear shift in the opposite direction, with 
the majority of the prevalent autoantibody responses towards these leading antigens increasing (n = 
15/19, 79%), whilst the remaining few were either stable (n = 3/19, 16%) or decreasing (n = 1/19, 5%). 
Based on the initially established research question, our interest was towards those that were 
augmented, as a result of treatment. Incidentally, the two most abundant autoantibodies of this set, 
when considering the cycle 3 and 4 comparison, both fell within this increasing responses subgroup, 
validating their potential. 
Radar plots are typically used to represent a large number of variables in a two-dimensional chart, as a 
means of providing the viewer with a broad overview of the complete dataset. These plots can therefore 
be used to provide an overview of the distribution of autoantibody titres across a patient subset. 
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Therefore, for visual interpretation purposes, a radar plot of the detected autoantibody titres was 
constructed for all patients across the above-mentioned leading 19 antigens, to allow for a facilitated 
view of how patient responses are clustering across these antigens, and shown below in Fig. 4.25. 
 
Figure 4.25: Radar plot of the prevalent autoantibody titres detected towards the leading 19 antigens 
across the epigenetic modifier treatment cohort. Each antigen is indicated by an axis, and each patient 
sample is indicated in a different colour. PRKCZ (~9000 RFU) for patient 001-0002, C4D25 and 
DSCR8/MMA1 (~8000 RFU) for patient 001-0006, C4D25 data points are omitted in this plot (outliers), 
due to an above average high intensity, to permit a better visualization of the majority of the signals. 
 
 
This radar plot provides a clear representation of why autoantibody titres towards these antigens are 
the most relevant of those tested, with multiple patients showing responses towards each of them. In a 
scenario where one would be seeking specific candidate biomarkers for a particular study, this finding 
would indicate that a potential biomarker would be amongst these 19 antigens, warranting further 
studies with a larger cohort. 
As a means of interpreting these findings, and verifying their biological significance, the most abundant 
autoantibody titres detected, towards Cytochrome P450 reductase and DSCR8/MMA1, were 
investigated further. Cytochrome P450s can mediate the metabolism of several cancer therapeutic 
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drugs, being key enzymes in cancer treatment and even formation (Rodriguez-Antona & Ingelman-
Sundberg 2006). Studies have shown that the polymorphic nature of the P450 genes affects an 
individual’s drug response, highlighting the importance of considering this variability in cancer 
treatment (Ingelman-Sundberg et al. 2007). Cytochrome P450 reductase is a membrane bound protein 
that catalyses electron transfer from NADPH to all known cytochrome P450s, which is responsible for 
the oxidative metabolism of endogenous (fatty acids, steroids and prostaglandins) and exogenous 
(therapeutic drugs, environmental toxicants and carcinogens) compounds (Wang et al. 1997). Some 
P450 forms are selectively expressed in tumours, which could potentially aid the understanding of drug 
resistance mechanisms, or even indicate prospective therapeutic targets (Rodriguez-Antona & 
Ingelman-Sundberg 2006). To comprehend the presence of this enzyme in our cohort, it was essential to 
understand if these enzymes have an essential role in metabolizing the treatment undergone 
(azacitidine and panobinostat). Recent in vitro studies have shown that the metabolism of azacitidine is 
not mediated by P450s, as this drug is activated by intracellular phosphorylation, and although the exact 
metabolic fate of this drug is unknown, it is stated that clinically significant inhibitory or inductive effects 
on these enzymes is unlikely (Derissen et al. 2013; Chen et al. 2010).  Panobinostat, on the other hand, is 
metabolized via multiple pathways (reduction, hydrolysis, oxidation and glucuronidation), with an 
oxidative metabolism mediated mainly by human cytochrome P450 CYP3A4 (70–98%) (with minor 
involvement of CYP2D6 and CYP2C19), indicating that if this drug was administered in combination with 
a CYP3A4 inhibitor, the end result would likely be clinical toxicity, as the anti-cancer therapeutic drug 
may not be metabolized (Hamberg et al. 2011). Moreover, it has been shown that the expression of 
some P450s may be affected  by DNA methylation changes, which should occur when treating patients 
with the hypomethylating agent azacitidine, occurring mainly in genes of importance for the  
metabolism of endogenous compounds (Ingelman-Sundberg et al. 2007). With this in mind, the available 
data for cytochrome P450 reductase and 3A4 across all patients was inspected, and those patients 
exhibiting a relevant (> 1000 RFU) signal were plotted along with their overall disease status and OS, as 
indicated below in Fig. 4.26.  
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Figure 4.26: Anti-cytochrome P450 (reductase and 3A4) immunoglobulin titres across relevant 
patients. This graph indicates anti-cytochrome P450-3A4 (in blue) and -reductase (in red) 
immunoglobulin titres across all patients and time points, highlighting those with statistical significance. 
CR: complete response, PR: partial response, PD: progressive disease, R: resistant, SD: stable disease. 
 
 
It was apparent that 9/12 (75%) patients showed relevant signals towards these two antigens, without 
evidence of any particular exclusivity for a disease status (CR, PR, PD, R and SD) or average survival 
(ranging from 5 to 34+ months). Although there is a known link between P450s and cancer treatment 
resistant mechanisms, as mentioned above, a clear link was not seen in this cohort, possibly related to 
the limited number of patients. However, further studies using a larger cohort may be able to verify this 
assumption.    
DSCR8/MMA1, known as Down syndrome critical region protein 8/malignant melanoma-associated 
protein 1, is another member of the CT antigen family, CT25, with unknown function (www.uniprot.org) 
(De Wit et al. 2002). Although DSCR8/MMA1 expression was initially found in melanoma, it has been 
specifically linked to other tumour types, such as lung, liver, bladder, sarcoma, uterus, and multiple 
myeloma, the latter being a cancer type closest to this treatment cohort (De Wit et al. 2002; Risinger et 
al. 2007; van Duin et al. 2011). Therefore, the available data for DSCR8/MMA1 across all patients was 
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inspected, and those patients exhibiting a relevant (> 1000 RFU) signal were plotted along with their 
overall disease status and OS, as indicated below in Fig. 4.27.  
 
 Figure 4.27: anti-DSCR8/MMA1 immunoglobulin titres across relevant patients. This graph indicates 
anti-DSCR8/MMA1 immunoglobulin titres across all patients and time points, highlighting those with 
statistical significance. CR: complete response, R: resistant, PR: partial response, SD: stable disease, PD: 
progressive disease. 
 
 
It was apparent that 8/12 (67%) patients showed responses towards this protein, without any particular 
exclusivity for a disease status (CR, R, PR, SD and PD) or average survival (ranging from 7 to 32 months). 
Although no clear evidence was apparent between DSCR8/MMA1 and disease status, this could possibly 
related to the limited number of patients. Hence, it may be of interest to conduct further studies using a 
larger cohort, as a means of verifying a potential use for this protein.    
As a means of further understanding how DSCR8/MMA1 interacts with other proteins, which could 
potentially infer details regarding its unknown function, a STRING (search tool for the retrieval of 
interacting genes/proteins v9.1, http://string-db.org) analysis was performed, and the resulting network 
is indicated in Fig. 4.28 (Franceschini et al. 2013).  
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Figure 4.28: Network of STRING resulting associations with DSCR8/MMA1. This network is the 
evidence view using Homo sapiens, and each line colour represents the types of evidence for the 
association. Black line: coexpression; Green line: textmining. 
 
 
When visually inspecting this association, interestingly two other proteins that appeared as the 19 most 
significantly and abundantly expressed in this cohort, SPANXD (SPANX family, member E, unknown 
specific function) and DPPA4 (developmental pluripotency associated 4, may play a role in maintaining 
cell pluripotentiality) appear here as predicted functional partners (scores: 0.856 and 0.661, 
respectively). This prediction strengthens our findings made above for this treatment cohort, but does 
not necessarily clarify the function of DSCR8/MMA1.  
Additionally, a BLAST (basic local alignment search tool) analysis against the Homo sapiens database 
using UniProtKB was conducted, with the intent of verifying which proteins shared a similar sequence 
with DCSR8 (Altschul et al. 1990; Altschul et al. 1997). The resulting alignments were ordered by E-value 
and score, and the best alignment, after excluding protein isoforms, was for Actin-related protein 10, 
with an E-value of 3e-6, a score of 110 and an identity of 68%. This protein has been reported to be 
involved in microtubule-based movement. When ordering the resulting alignments by identity, the best 
alignment was for Zinc finger matrin-type protein 1, with an E-value of 8e-3, a score of 81, and an 
identity of 82%. This protein has been reported to have a possible role in the p53-dependent growth 
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regulatory pathway, which is of particular interest, as p53 mutant autoantibody titres are also amongst 
the 19 most significantly detected of this cohort, possibly implying that p53 might also be a component 
of a network with DSCR8/MMA1 (Hellborg et al. 2001).  
As mentioned above, to understand whether the observed autoimmune responses were speculatively 
indicative of temporal clinical responses, a matched disease status per time point must be assessed. For 
this purpose, on a patient-by-patient basis, each autoimmune profile was directly compared to the 
patient’s clinical status at that time point, as a means of suggesting a biological significance of our 
generated data. When observing the autoimmune profile of patient 001-0002, which is mentioned 
above in Fig. 4.20 (and corresponding array images indicated in Fig. 4.21), it was indicated that at C4D25 
(cycle 4, day 25), the patient was responding to treatment. This is in agreement with the array data 
which shows a statistically significant increase in CREB1 and PRKCZ autoantibody levels from screening 
to cycle 4 of epigenetic modification, whilst other signals remain more or less stable, which shows 
evidence of a matching partial response measured by bone marrow assessment. For patient 001-0016, 
whose immune profile is mentioned above in Fig. 4.22, clinical notes indicated a slight deterioration at 
C3D25 (cycle 3, day 25), followed by disease progression at C4D25 (cycle 4, day 25) of treatment, which 
is somewhat in agreement with the observed autoimmune responses. Although a slight – but 
statistically significant – increase (although below 1500 RFU) in MART-1/Melan-A levels is observed from 
screening to cycle 3, these levels drop below our noise threshold at cycle 4 of treatment and all other 
responses are below 1000 RFU. Hence, at the latter time point, the observed autoimmune profile 
suggests a complete lack of significant autoantibody level for this patient, which is in agreement with 
the matching reported disease progression. Lastly, when considering patient 001-013, whose 
autoimmune profile is indicated in Fig 4.23,  clinical notes are not available for C3D25 (cycle 3, day 25), 
but indicate stable disease/no deterioration at C4D25 (cycle 4, day 25). This patient’s autoantibody 
levels remain stable across all time points, including from screening to cycle 4 of treatment, showing 
evidence of a matching reported stable disease after epigenetic modification. Hence, in these three 
instances, the preliminary data suggests that temporal clinical statuses were in partial or complete 
agreement with observed autoimmune responses, which may indicate that the presence or absence of 
an autoimmune response might suggest the presence or absence of a clinical response.   
When assessing the agreement between our array data and the temporal clinical data for the remaining 
nine patients of this treatment cohort, four patients (001-0001, 001-0003, 001-0006 and 001-0018) 
showed evidence of a complete agreement and one additional patient (001-0012) of partial agreement, 
indicating speculative evidence of partial or complete matching data across 8/12 (66.7 %) patients in this 
cohort. By contrast, the autoantibody levels observed for the remaining four patients (001-0004, 001-
0007, 001-0008 and 001-0011) suggested no agreement with temporal clinical responses, or lack 
thereof, indicating no agreement across 4/12 (33.3%) patients.  Interestingly, all patients that were 
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deemed clinically resistant to treatment (001-0007, 001-0008 and 001-0011) showed no evidence of 
agreement between array and temporal clinical data, whilst all patients that were indicated as complete 
responders (001-0001, 001-0003 and 001-0006) showed evidence of complete agreement. Hence, it is 
plausible that the patients that are deemed resistant to treatment, may be displaying some sort of 
immune evasion and associated suppression, and are thus displaying autoimmune profiles with limited 
possible inferences regarding immune efficacy. These findings suggest potential biological significance of 
our generated CT100+ array data, as well as its prospective utility as a tool to monitor clinical responses 
to treatment. However, it is essential to note that all measurements require a baseline reference, as 
relative and not absolute changes are being assessed.  Furthermore, these findings require further 
studies using a larger cohort, as the limited patient numbers do not allow for statistically significant 
inferences to be made. 
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of myelodysplasia patients undergoing epigenetic modification, and observed a large number 
(92% of the cohort) of autoantibody responses – statistically significant changes in autoantibody titres – 
to treatment. The main intent of this study was to assess whether epigenetic modification created neo-
antigens and subsequent expanded antibody responses. In this regard, we identified autoantibody titres 
towards 19 potential antigens abundantly detected across this cohort. However, amongst these, no 
specific autoantibody titre appeared to be exclusively induced as a result to treatment. An expanded 
immune response after epigenetic treatment was evident across the majority of all patients, of which 
67% of the cohort presented with preliminary evidence of a matching array and clinically reported 
responses. Furthermore, evidence of the lack of agreement between array and clinical data across all 
resistant patients suggests that immunoevasion – an emerging cancer hallmark – may be occurring, and 
thus possibly contributing towards cancer progression in these cases (Hanahan & Weinberg 2011).  
In this epigenetic modification treatment cohort, we have successfully demonstrated that there are 
measurable differences in the autoantibody repertoires towards tumour-specific and –associated 
antigens between pre- and post-treated myelodysplasia patients, with preliminary evidence of possible 
correlation to the likelihood of clinical response. When considering patient sample numbers and 
relevant power calculations, the achieved statistical power is well below recommended (power > 0.8), 
which does not support the findings obtained in this cohort. Therefore although these results provide 
preliminary insight into this cohort, these warrant further confirmation across a larger group of patients.  
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage once again in monitoring patient responses to treatment, with potential therapy resistance 
inferences, warranting confirmation using a pre-stipulated specifically focussed study and homogeneous 
cohort design using sufficient patient numbers according to an a priori power calculation estimate. 
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4.3.4 Variable cancer type patients who underwent survivin treatment 
A total of 103 serum samples, corresponding to forty-eight variable cancer patients with advanced solid 
tumours undergoing survivin treatment were assayed, processed and analysed according to our 
established CT100+ microarray pipeline. The following settings were used for the CT100+.jar processing 
and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations of the 
background, replicate CV threshold = 20%, whole array filtering control = 10 ng/µL Cy5-biotin-BSA and 
whole array CV threshold = 20%. The initial stipulated research question was whether the observed T-
cell responses against survivin peptides were indicative of an expanded B-cell response, an autoantibody 
response detected by our CT100+ array. For this cohort, data analysis was conducted according to the 
available clinical information, which permitted the attribution of a best overall tumour response to 
treatment and presence of a post-vaccination immunological response for each patient, allowing for a 
comparison between our generated array data (B-cell responses) and the reported tumour and T-cell 
responses towards survivin. However, it is important to note that both the tumour and immunological 
data was sourced from the complete study, whilst the generated array data is based only on either 
baseline only, baseline and one post-vaccination time point or baseline and two post-vaccination time 
points, with no temporal data available, indicating that the provided blood samples could be from 
anytime between weeks 0 and 24. Therefore, comparison between these is not as direct as desired, as it 
is unknown what tumour or T-cell response was present at the matching array data time point. 
Nonetheless, these data were compared, based in the assumption that the array data represents 
baseline, 1st vaccination and 2nd vaccination. Furthermore, based on sample number-based power 
calculations indicated in Chapter 2, this cohort includes sufficient patient and sample numbers to be 
able to report statistically relevant results (power =  0.92). 
A significant (> 1000 RFU) autoantibody response to treatment (increase in autoantibody titres above 
baseline) was present in 29/44 (66%) patients, with the remaining 4 patients having only a baseline 
blood sample. The strongest autoimmune response (~35000 RFU) was seen, both quantifiably and 
visually, for patient C05P005 (see Fig. 4.29 and 4.30).  
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Figure 4.29: Strongest patient autoimmune profile of the survivin cohort. This graph indicates the 
autoimmune profile of patient C05-P005 across two distinct time points (represented by different 
colours). As a means of clarifying the visualization of relevant titres, an insert of the magnified relevant 
data is indicated within this figure. *Statistically significant difference, P < 0.05 or **P < 0.01. 
 
 
Figure 4.30: Strongest patient corresponding scanned array images of the survivin cohort. This figure 
indicates scanned array images of patient C05P005 before (image on left at baseline) and after (image 
on right at post-vaccination 1) treatment, with visual evidence of an autoantibody response towards 
many different p53 forms, either wild-type or mutant. Red boxes highlight triplicate p53 S392A, p53 
K382R, p53 S46A, p53 S6A, p53 T18A, p53 S15A and p53 L344P positive signals. 
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Patient C05P005, diagnosed with ovarian cancer, showed a statistically significant increase above 2000 
RFU in CDC25A (P < 0.01) and in p53 (P < 0.01), p53 S6A (P < 0.01), p53 C141Y (P < 0.01), p53 S15A (P < 
0.01), P53 T18A (P < 0.01), p53 Q136X (P < 0.01), p53 S46A (P < 0.01), p53 K382R (P < 0.01), p53 S392A 
(P < 0.01), p53 L344P (P < 0.01) in response to treatment. The fact that this patient shows autoimmune 
responses to nearly all p53s (with exception of p53 M133T), wild type and mutants, is most likely 
indicative of one form – most simply, wild type p53 – that shares a common epitope amongst these 
mutants. p53, also known as cellular tumour antigen p53, acts as a tumour suppressor in many distinct 
tumour types, with specific functions related to cell cycle regulation and induction of apoptosis 
(www.uniprot.org) (El-Deiry et al. 1993). p53 mutations are common in cancer, which has led to the 
extensive study of these abnormalities in regards to carcinogenesis and the ability to potentiate cancer 
progression, as well as their possible diagnostic, prognostic and therapeutic implications (Greenblatt et 
al. 1994; Risch 1998). In regards to ovarian cancer in particular, the overexpression and mutation of p53 
is a known phenomenon, which is consistent with our finding within this specific cancer type, amongst 
the several ones included in this treatment cohort (Kupryjaoczyk et al. 1993; Marks et al. 1991). It has 
also been shown that in ovarian cancer these mutations are linked to chemotherapy resistance, early 
relapse and shortened overall survival (Reles et al. 2001).  
A comparison between the observed autoimmune profile and the best observed clinical response for 
this patient was not possible, as the latter was non-evaluable. However, when assessing this patient’s 
immunological response, no T-cell response against survivin as a result of treatment was detected.  
When comparing the obtained autoimmune profile for this patient with the overall reported clinical and 
T-cell responses, these are not in agreement, as these latter data seem to indicate no response towards 
treatment. This lack of preliminary correspondence may be due to the lack of temporal matching of the 
array data with the reported clinical and T-cell responses. As a means to verify if the p53 autoimmune 
responses were restricted to this patient, all other autoimmune profiles were inspected, and two 
additional patients were found with a similar response, C01P028 (PD) and C01P0029 (PD). Interestingly, 
these two patients were also diagnosed with ovarian cancer, which supports this finding, yet neither 
patient presented a clinical response to treatment. However, patient C01P028 did have a T-cell response 
to treatment, which could be explained by either a younger age (44) or the presence of 3 HLA types 
(A01, A03 and B07), when compared to patients C05P005 (63 years of age, HLA type A01) and C01P029 
(67 years of age, HLA types A02 and A03), respectively. Due to the limited amount of ovarian cancer 
patients in this cohort, an additional study using a larger patient cohort should be performed, as a 
means of verifying if these findings hold true across a significant number of patients.  
Of the remaining 15 patients, a significant decrease in autoantibody response to treatment (decrease in 
autoantibody titres above baseline) was present in 7/44 (16%) patients, whilst 8/44 (18%) patients 
presented with stable autoimmune levels.  A decrease in autoantibody titres was seen for patients 
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C01P007 (colorectal cancer, PD, survivin T-cell response), C01P012 (colorectal cancer, PD, survivin T-cell 
response), C01P040 (mesothelioma, PD, no survivin T-cell response), C03P009 (melanoma, PD, survivin 
T-cell response), C03P012 (colorectal cancer, NE, no survivin T-cell response), C03P020 (melanoma, PD, 
no survivin T-cell response) and C05P017 (neuroendocrine tumour, SD, survivin T-cell response). Once 
again, no evidence of a correlation is seen between the reported overall patient characteristics and the 
autoimmune profile, probably due to the lack of comparison between temporal clinical and 
immunological responses. The patients who presented with stable autoantibody titres across all assayed 
array time points included C01P013 (sarcoma, PD, survivin T-cell response), C01P024 (colorectal cancer, 
SD, no survivin T-cell response), C02P003 (melanoma, PD, no survivin T-cell response), C02P008 
(outstanding clinical information), C03P002 (NSCLC, PD, survivin T-cell response), C03P005 (NSCLC, SD, 
survivin T-cell response), C03P014 (breast cancer, PD, survivin T-cell response) and C04P013 (melanoma, 
PD, no survivin T-cell response). As indicated above, no correlation is seen between the reported overall 
patient characteristics and the autoimmune profile. 
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 20 leading antigens. These 
were detected in at least nine or more instances across all patient time points (baseline or post-
treatment) in this cohort, and most abundantly towards NY-ESO-1 and CTAG2/LAGE-1b/LAGE-1L, as 
indicated below in Fig. 4.31.  
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Figure 4.31: Most prevalent autoantibody titres detected across the survivin treatment cohort. This 
graph indicates the summed number of times autoantibody levels were detected towards the 20 leading 
antigens at titres above 1000 RFU , with distinction between B: baseline; V1: post-vaccination 1; and V2: 
post-vaccination 2. 
 
 
Based on this graph, it was evident that initially, when comparing baseline to post-vaccination 1, half of 
these prevalent autoantibody responses towards these leading antigens were increasing (n = 10/20, 
50%), whilst the rest were either decreasing (n = 9/20, 45%) or stable (n = 1/20, 5%). When comparing 
post-vaccination 1 to 2, all prevalent autoantibody responses towards these leading antigens decrease 
(n = 20/20, 100%), however, this is most likely a function of only 10/48 (21%) patients possessing the 
post-vaccination 2 time point, as the majority of the patients included in our cohort have only two time 
points. Based on the initially established research question, our interest was towards those 
autoantibody titres that were both augmented and decreased as a result to treatment, as we wanted to 
assess whether the observed T-cell responses were indicative of an autoantibody response. The two 
most abundant autoantibody titres of this set are decreasing from baseline to post vaccination time 
points 1 and 2.  
As a means of defining whether these most abundant autoantibody titres were clustering within a 
specific cancer type, radar plots were constructed for the three most abundant cancer types in this 
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cohort, melanoma (n = 9/46, 20%), colorectal cancer (n = 8/46, 17%) and ovarian cancer (n = 7/46, 15%), 
and are indicated below in Fig. 4.32, 4.33 and 4.34. 
 
Figure 4.32: Radar plot of the prevalent autoantibody titres detected towards the leading 20 antigens 
across melanoma patients of the survivin cohort. Each antigen is indicated by an axis, and each patient 
sample is indicated in a different colour. 
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Figure 4.33: Radar plot of the prevalent autoantibody titres detected towards the leading 20 antigens 
across colorectal cancer patients of the survivin cohort. Each antigen is indicated by an axis, and each 
patient sample is indicated in a different colour. NY-ESO-1 (˜45000 RFU) for patient C01P007 at baseline 
was omitted in this plot (outlier), due to an above average high intensity, to permit an equal axis range 
amongst cancer type radar plots. 
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Figure 4.34: Radar plot of the prevalent autoantibody titres detected towards the leading 20 antigens 
across ovarian cancer patients of the survivin cohort. Each antigen is indicated by an axis, and each 
patient sample is indicated in a different colour. 
 
 
In regards to melanoma (see Fig. 4.32), it was evident that this cancer type presented the overall lowest 
autoantibody signals in comparison to colorectal and ovarian cancer, with the highest intensity being 
only 6000 RFU. The highest autoantibody titres were towards LIP1 (~6000 RFU), PRKCZ (~5000 RFU) and 
NY-ESO-1 (~3500 RFU), along with the expected melanoma antigens, MAGEA2, MAGEA3 and MAGEB5 
(~3000 RFU). When assessing the resulting radar plot for the colorectal cancer patients (see Fig. 4.33), it 
was clear that this cancer type presented the overall highest signals, with intensities reaching ~45000 
RFU. The antigens that presented with the highest autoantibody titres were NY-ESO-1 (~45000 RFU) and 
CTAG2 (~4500 RFU), as well as LIP1 (~2500 RFU). The NY-ESO-1 and CTAG2 pair usually appears together 
due to their high sequence homology (77%). In regards to ovarian cancer (see Fig. 4.34), the highest 
autoantibody titre reached ~21500 RFU, with evidence of accumulative p53 mutant (p53 C141Y, p53 
K382R and p53 S46A) autoantibody titres ranging from ~2000 to ~21500 RFU. Whether or not these 
mutant forms correspond to multiple mutations or simply a shared epitope of one form remains to be 
determined, warranting further genomic testing. Besides from these, NY-ESO-1 (~5500 RFU) and 
CDC25A (~4000 RFU) were also amongst the highest titres. When combining these findings, it seems 
that only NY-ESO-1 was present in all three cancer types, which interestingly coincide with the most 
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abundant protein of this treatment cohort. The second most abundant protein, CTAG2/LAGE-1b/LAGE-
1L, was a CTAG2 isoform, which also explains why this pair arose as the most abundant amongst the 20 
antigens reported here.  
As a means of interpreting these findings, and verifying their biological significance, the most abundant 
autoantibody titres towards NY-ESO-1 and CTAG2/LAGE-1b/LAGE-1L, were investigated further. 
NY-ESO-1, a CT antigen member broadly described in Section 4.3.1 in regards to the kinase inhibition 
treatment cohort, has once again appeared as one of the most significant autoantibody titres.  
CTAG2/LAGE-1b/LAGE-1L, a CTAG2 (NY-ESO-2) isoform usually reported as LAGE-1b, is evidently yet 
another member of the CT antigen family. LAGE-1b has also been reported as an attractive 
immunotherapeutic target, mainly due to similarities with NY-ESO-1, and has been reported to have 
both prognostic and predictive value in cancers (Lethé et al. 1998; Odunsi et al. 2003; Dyrskjøt et al. 
2012). Furthermore, survivin cancer treatment, as the one administered to the patient in this treatment 
cohort, has been reported to induce frequent, robust and multifunctional CD4+ T-cell responses amongst 
vaccinated patients, which have been shown to be essential for the induction and maintenance of 
cytotoxic T-cell responses (Widenmeyer et al. 2012). Therefore, the available data for NY-ESO-1 and 
CTAG2/LAGE-1b/LAGE-1L across all patients was inspected, and those patients exhibiting relevant (> 
1000 RFU) signals were plotted along with their presence or absence of T-cell and clinical response, as 
indicated below in Fig. 4.35.  
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Figure 4.35: Anti-NY-ESO-1 and -CTAG2/LAGE-1b/LAGE-1L immunoglobulin titres across relevant 
patients. This graph indicates anti-NY-ESO-1 (in red) and -CTAG2/LAGE-1b/LAGE-1L (in blue) 
immunoglobulin titres across all patients and time points, highlighting those with statistical significance. 
PD:  progressive disease; SD: stable disease. 
 
 
It was apparent that 17/48 (35%) patients showed responses towards NY-ESO-1, with the majority of 
these presenting clinically as stable disease (n = 9/17, 53%), followed by progressive disease (n = 7/17, 
41%) and one non-evaluable case (n = 1/17, 6%). After treatment, these responses mainly decreased (n 
= 13/17, 76%), with only a few increases (n = 3/17, 18%), and a patient with a single time point (n = 
1/17, 6%). Amongst the three patients who showed an increase in autoantibody titres after survivin 
treatment, all three were deemed as clinically stable throughout the clinical trial. However, although an 
additional six patients were also stable, their titres decreased as a result to treatment, which is difficult 
to explain without further clinical studies, but may suggest that either the anti-NY-ESO-1 antibody 
response is not clinically relevant here, or that there are distinct subtypes of cancer, some of which may 
be immune suppressive in character (Sadanandam et al. 2013; Sanz-García et al. 2014; The Cancer 
Genome Atlas Reserach Network 2013; Konecny et al. 2014).  
In regards to CTAG2/LAGE-1b/LAGE-1L, responses were seen towards 12/48 (25%) patients, with the 
majority of these presenting clinically with progressive disease (n = 8/12, 67%), the remaining patients 
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remaining stable (n = 4/12, 33%). Once again, the majority of these are decreasing as a result of 
treatment (n = 8/12, 67%), with only a few increases (n = 3/12, 25%), and one patient with a single time 
point (n = 1/12, 8%). Amongst the three patients with increasing titres, two are classified as having 
progressive disease, and solely one as stable. By contrast, the additional three stable patients presented 
a decrease in autoantibody titres. 
It is difficult to compare the resulting autoimmune profiles with the clinical and immunological reported 
findings of this clinical trial, due to lack of temporal and peptide match between the latter and the array 
data. However, an attempt to compare these might still provide some relevant information. Based on 
the array data, it was clear that complete agreement between clinical and survivin T-cell responses was 
also not obtained.  
When considering the clinical responses, amongst the 14/46 (30%) patients classified as having stable 
disease, 10/14 (71%) of those presented with autoantibody responses to treatment. An equal number of 
10/14 (71%) of these patients also presented with survivin T-cell responses post-vaccination, although of 
these only 7/10 (70%) patients presented with matching expanded B-cell and survivin T-cell responses. 
Amongst the 27/46 (59%) patients classified as progressive disease, 14/27 (52%) of those presented 
with elevated autoantibody responses to treatment, while 4/27 (15%) could not be evaluated (single 
time point). A slightly higher number of 15/27 (55%) of those patients also presented with survivin T-cell 
responses post-vaccination, although only 9/15 (60%) of these presented with matching expanded B-cell 
and survivin T-cell responses. This indicates that 9/27 (33%) patients classified as progressive disease 
also did not present elevated autoantibody responses to treatment.  
In regards to the survivin T-cell responses, amongst the 29/46 (63%) patients classified as having a 
survivin T-cell response post-vaccination, 17/29 (59%) of those presented with autoantibody responses 
to treatment, while 4/29 (14%) could not be evaluated (single time point). Amongst the 17/46 (40%) 
patients classified as non- survivin-T-cell responders post-vaccination, 11/17 (65%) of those presented 
with autoantibody responses to treatment. This indicates that 6/17 (35%) patients classified as non-
survivin-T-cell responders also did not present autoantibody responses to treatment.  
Hence, it appeared that the array generated data showed speculative evidence of 71% (SD) and 33% 
(PD) agreement with the reported clinical data, and 59% (survivin T-cell responders) and 35% (non-
survivin-T-cell responders) agreement with the reported T-cell data. The lack of correspondence in the 
lower percentages may be related to lack of temporal equality of the array generated data. However, it 
is of note that 52% of the patients presenting with progressive disease and 65% of the patients classified 
as non-survivin-T-cell responders presented an expanded B-cell responses to treatment. Unfortunately, 
survivin was not present on our CT100+ array, but it would be interesting to verify if a matching anti-
survivin B-cell response was present in the patients reported as having a T-cell response against survivin. 
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Nonetheless, these results indicate that a possible expanded B-cell immunological response towards 
cancer-associated antigens might be occurring as a result of survivin vaccination in 29/44 (66%) patients 
in this cohort, most likely due to survivin therapy leading to tumour lysis, which in turn leads to an 
increase in circulating cancer antigens, and therefore resulting in an increase in detected autoantibody 
responses towards those antigens. Whether such increases actually signify a clinical efficient immune 
response to therapy or are simply symptomatic remains to be determined.  
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of variable cancer type patients undergoing survivin treatment, and observed a defined number 
(66% of the cohort) of autoantibody responses – statistically significant increases in autoantibody titres 
– to treatment. The main intent of this study was to assess whether the induction of an autoantibody 
response correlated with reported induced survivin-specific T-cell responses post-treatment amongst 
these patients. In this regard, it is interesting that our CT antigen array data suggests evidence of direct 
correlation between our observed autoantibody responses and the survivin-specific T-cell reported ones 
across a subset of patients (59% of the cohort). Hence, this proposes that a potential expanded B-cell 
immunological response may be occurring as a result to treatment, as although a survivin-specific 
therapeutic is administered a variety of autoantibody responses towards other cancer-associated 
antigens are observed. Furthermore, a direct correlation between our data the reported clinical benefit 
was also observed, across a larger subset of patients (71%). Nonetheless, these findings warrant further 
investigation due to the lack of exact temporal matching between antibody, T-cell and clinical 
responses.  
In this survivin treatment cohort, we have successfully demonstrated that there are measurable 
differences in the autoantibody repertoires towards tumour-specific and –associated antigens between 
pre- and post-treated patients, with preliminary evidence of possible correlation to the likelihood of 
clinical and T-cell response. Furthermore, we have successfully identified a well-established therapeutic 
target – NY-ESO-1 – and an isoform of its homologous pair (CTAG2), CTAG2/LAGE-1b/LAGE-1L, which 
were the two most abundant antigens toward which autoantibody titres were detected, present across 
35% and 25% patients, respectively. The fact that both these antigens share the majority of their 
sequence and have common epitopes suggests that autoantibody responses are probably towards one 
of these forms in particular (most likely NY-ESO-1). When considering patient sample numbers and 
relevant power calculations, although this cohort is quite diverse regarding patient age and tumour type 
, the achieved statistical power is above recommended (power > 0.8), supporting the findings obtained 
in this cohort. 
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage in future cancer research in monitoring patient expanded autoantibody responses to 
treatment and identifying novel therapeutic targets, warranting confirmation using a pre-stipulated 
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specifically focussed study and homogeneous cohort design using sufficient patient numbers according 
to an a priori power calculation estimate. 
4.3.5 Colorectal cancer patients with unresectable liver metastasis who 
underwent SIRT treatment 
A total of 25 serum samples, corresponding to eleven colorectal cancer patients with unresectable liver 
metastasis undergoing selective internal radiotherapy were assayed, processed and analysed according 
to our pre-established CT100+ microarray pipeline. The following settings were used for the CT100+.jar 
processing and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations 
of the background, replicate CV threshold = 20%, whole array filtering control = 10 ng/µL Cy5-biotin-BSA 
and whole array CV threshold = 20%. The initial stipulated research question was to assess the effect of 
selective internal radiotherapy on a patient’s autoimmune profile, thereby potentially inferring a 
successful clinical response to treatment. For this cohort, data analysis was conducted based on the 
available clinical trial and sample information, which permitted comparison between patient 
autoimmune profiles before and after SIRT treatment, as a means of verifying the immunological 
efficacy of this treatment. However, it is important to note that due to the absence of basic clinical 
information and the resulting clinical efficacy or inefficacy, speculative clinical inference and correlation 
with immunological data may not be made, therefore limiting this analysis. Furthermore, based on 
sample number-based power calculations indicated in Chapter 2, this cohort does not include sufficient 
patient and sample numbers to be able to report statistically relevant results (power =  0.32). 
A significant (> 1000 RFU) autoantibody response to treatment (increase in autoantibody titres above 
baseline) was present in 6/11 (55%) patients, while the remaining four patients showed a decrease in 
autoantibody titres as a response to treatment.  As previous studies have reported a clinical efficacy of 
up to 90%, a relatively high clinical response rate is predicted (Stubbs et al. 2001; Stubbs & 
Wickremesekera 2004). However, if that clinical response is suggested to be correlated with an immune 
one, a much lower speculated response rate is seen here for this treatment cohort. The highest 
autoantibody titres detected both quantifiably and visually were for patient SIRT027 (~60000 RFU), 
although these decrease from baseline to each successive time points after treatment (see Fig. 4.36 and 
4.37). 
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Figure 4.36: Strongest patient autoimmune profile of the SIRT cohort. This graph indicates the 
autoimmune profile of patient SIRT027 across three distinct time points (represented by different 
colours). As a means of clarifying the visualization of relevant titres, an insert of the magnified relevant 
data is indicated within this figure. **Statistically significant difference, P < 0.01. 
 
 
Figure 4.37: Highest autoantibody titres patient’s corresponding scanned array images of the SIRT 
cohort. This figure indicates scanned array images of patient SIRT027 before (image on left at baseline) 
and after treatments (image in middle at cycle 1, and image on right at cycle 2), with visual evidence of a 
decreasing autoantibody response towards DDX53. Red boxes highlight triplicate DDX53 positive signals. 
   
 
Patient SIRT027 showed a statistically significant decrease in DDX53 (P < 0.01) from an initial high signal 
of ~60000 RFU at baseline, to ~37000 RFU at cycle 1 of treatment, and then to ~21000 RFU at cycle 2 of 
treatment, showing a progressive decrease in autoantibody titres as a response to treatment. DDX35, a 
DDX53 
   
DDX53 DDX53 
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known CT antigen also known as CAGE, has a known catalytic function involved in both ATP and RNA 
binding (www.uniprot.com). This decrease in autoantibody titres could either signify that antibody-
antigen complexes have formed resulting in less free circulating antibodies available for detection using 
our array platform (which seems unlikely), or that there is a possible decrease in clinical efficacy. It is 
essential to note that due to the nature of this treatment, it is unknown whether a cancer-specific 
immune response is expected, as this treatment consists of radiotherapy rather than immunotherapy. 
Furthermore, a study has reported that immediate levels of serum CEA (carcinoembryonic antigen) after 
treatment might be a misleading indication of clinical efficacy, as these levels only gave the best and 
most indicated information only 2-3 months after treatment administration (Stubbs & Wickremesekera 
2004). However, due to the lack of clinical efficacy information, the true reasoning as to whether an 
immune response may be indicative of a clinical one remains to be determined.    
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 12 leading antigens. These 
were detected in at least six or more instances across all patient time points (baseline or cycles of 
treatment) in this cohort, and most abundantly towards CSAG2, as indicated below in Fig. 4.38. 
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Figure 4.38: Most prevalent autoantibody titres detected across the SIRT treatment cohort. This graph 
indicates the summed number of times autoantibody levels were detected towards the 12 leading 
antigen at titres above 1000 RFUs, with distinction between D0: baseline; C1: cycle 1; and C2: cycle 2. 
 
 
Based on this graph, it was evident that initially, when comparing baseline to cycle 1 of treatment, the 
majority of these prevalent autoantibody responses towards these leading antigens were stable (n = 
5/12, 42%), whilst the rest were either decreasing (n = 4/12, 33%) or increasing (n = 3/12, 25%). When 
comparing cycle 1 to 2, the majority of the prevalent autoantibody responses decrease (n = 10/12, 83%), 
while the remaining two (n = 2/12, 17%) remain stable. This is most likely a function of only 3/12 (25%) 
patients possessing the cycle 2 time point, as the majority of the patients included in our cohort have 
only two time points. Based on the initially established research question, our interest was towards 
those autoantibody titres that were both augmented and decreased as a result to treatment, as we 
wanted to assess the effect of selective internal radiotherapy on a patient’s autoimmune profile, 
thereby potentially inferring a successful clinical response to treatment. The most abundant 
autoantibody of this set, towards the CT antigen CSAG2, was initially stable from baseline to cycle 1 of 
treatment, but then decreased from cycles 1 to 2. Interestingly, both CSAG2 and the remaining eleven 
(CEP290, CT62, DSCR8/MMA1, MAGEA3, MAGEA4v4, MAGEA5, NXF2, SGY-1, SPAG9, SPANXB1 and 
ZNF165) most abundantly detected autoantibody titres of this treatment cohort were all CT antigens 
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(CTdatabase: www.cta.lncc.br). The fact that the most relevant antigens in this cohort were all CT 
antigens serves as a validation of our vast CT antigen selection for this array platform.  
As a means of comprehending what role CSAG2 plays in this advanced cancer type or therapy, it was 
investigated further. Chondrosarcoma-associated gene 2/3 protein (CSAG2), also known as taxol-
resistant-associated gene 3 protein (TRAG-3), is a drug resistance related protein, with its expression 
being associated with chemotherapy resistant, neoplastic and possibly malignant phenotype 
(www.uniprot.com).  CSAG2 expression was first reported in ovarian carcinoma cell lines, but a study 
using colorectal cancer cell lines also confirmed its expression in the cancer type of this treatment 
cohort (Duan et al. 1999; Nimmrich et al. 2000). The clinical impact of this overexpression was studied in 
ovarian carcinoma patients, and it was demonstrated that an overall progression-free survival was 
increased for those who expressed a weak CSAG2 signal, making this protein a prognostic factor for the 
prediction of clinical outcome after chemotherapy (Materna et al. 2007). Furthermore, this protein has 
been found to be co-expressed with the fellow CT antigen MAGE family (Lin et al. 2002). This finding 
validates the fact that three distinct members of the MAGE family, MAGEA3, MAGEA4v4 and MAGEA5, 
were alongside with CSAG2 amongst the antigens towards which autoantibody titres were most 
abundantly detected in the SIRT treatment cohort. As a means to further assess the levels of CSAG2 
autoantibodies in this cohort, the available data for CSAG2 across all patients was inspected, and an 
autoantibody trendline across this whole cohort was constructed, as indicated below in Fig. 4.39. 
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Figure 4.39: Anti-CSAG2 immunoglobulin titre trendline across SIRT treatment cohort. Threshold on 
graph indicates ~1000 RFU, as a means of facilitating view of most significant signals. 
 
 
Visual inspection of this anti-CSAG2 immunoglobulin titre trendline indicated that autoantibody titres 
against CSAG2 were quite variable across our cohort, with two spikes above 2000 RFU for patients 
SIRT007 at cycle 2 and SIRT030 at baseline. Oddly, these spikes occurred at opposite time points, with 
the first being induced as a result of treatment, and the second being present at baseline, but then 
drastically reduced. Therefore, one might assume that the potential clinical effect were contrary in these 
two patients, although this has not been confirmed.  When comparing these two patient’s complete 
autoimmune profiles, it was evident that patient SIRT007 presented an overall autoimmune response to 
treatment, with an increase in autoantibody titres from baseline to cycle 1, whilst patient SIRT030 did 
not, showing a drop in autoantibody titres from baseline to cycle 1 of treatment. This further adds to 
our assumption of clinical efficacy on regards to patient SIRT007. As mentioned above, high levels of this 
protein prior to therapy are indicative of a poorer overall and progression free survival, indicating a poor 
prediction of clinical outcome after therapy (Materna et al. 2007). Hence, this further verifies our 
assumption regarding poor predicted clinical efficacy in patient SIRT030. However, this prediction 
cannot be verified due to restricted access to clinical efficacy results, and most importantly, due to the 
limited patient numbers in this cohort. An additional study using a larger patient cohort may be relevant 
to assess if any clinical significance of this finding is true.   
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As a means of identifying the most interesting autoantibody titres across these 13 leading antigens, a 3-
D plot was constructed with all patients, and is indicated below in Fig. 4.40. 
 
Figure 4.40: Most abundant autoantibody titres towards antigens across SIRT treatment cohort. This 
3-D graph indicates the autoimmune profile of all patients across the most abundant antigens of this 
treatment cohort. Each antigen is indicated in a different colour, and each patient sample is indicated in 
the x-axis.  D0: baseline; C1: cycle 1; C2: cycle 2. 
 
 
This data representation indicates that the majority of these patient signals are below 2500 RFU, with 
only one patient displaying a very above average signal of ~14000 RFU. This was seen for patient 
SIRT007 at cycle 1 of treatment against the DSCR8/MMA protein. This protein was discussed previously 
for the epigenetic modification cohort (Section 4.3.3), highlighting its immunotherapeutic potential, as 
well as a possible role in conferring a complete clinical response in patients when previously absent 
titres are greatly induced as a response to treatment. Based on this, one might assume that a possible 
highly beneficial clinical response for this patient was present, although this has not been confirmed for 
the reasons given above.  
As mentioned above, although previously studies have reported clinical responses of up to 90%, the 
limited access to patient characteristics and clinical responses to treatment of this particular cohort, and 
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the limited patient numbers, meant that no further analysis or data interpretation could be conducted 
here.   
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of metastatic colorectal cancer patients who presented with liver metastasis and are undergoing 
SIRT. The main intent of this study was to assess the effect of SIRT on autoantibody levels, and if these 
changes were able to speculatively infer successful clinical response to treatment. In this regard, it is 
interesting that our CT antigen array data suggests evidence of observed autoantibody responses – 
statistically significant increases in autoantibody titres – across 55% of the cohort to treatment, an 
immune response rate much lower than clinical responses previously reported in other studies. Once 
again, due to the fact that all patients present with metastatic disease, tumour-induced systemic 
immune suppression may be occurring, which could in turn lead to lower autoantibody responses to 
treatment than expected (Nicholaou et al. 2009). Additionally, it may also be likely that this specific 
therapy does not necessarily induce a cancer-specific autoantibody response, but rather a distinct 
response that might be mediating clinical improvement.  
In this SIRT treatment cohort, we have successfully demonstrated that there are measurable differences 
in the autoantibody repertoires towards tumour-specific and –associated antigens between pre- and 
post-treated metastatic colorectal cancer patients, with speculative preliminary evidence of possible 
correlation to the likelihood of clinical response. Furthermore, we have successfully identified CSAG2 – a 
well reported indicator of chemotherapeutic resistance - as the most abundantly expressed protein 
amongst those tested, present across 73% of patients. This clinical trial in particular tested the efficacy 
of combining chemotherapy with SIRT, which indicates the need to potentiate chemotherapeutic 
responses to therapy, and is thus in agreement with the suggested lack of chemotherapeutic efficacy 
associated with anti-CSAG2 immunoglobulin titres. However, when considering patient sample numbers 
and relevant power calculations, the achieved statistical power is well below recommended (power > 
0.8), which does not support the findings obtained in this cohort. Therefore although these results 
provide preliminary insight into this cohort, these warrant further confirmation across a larger group of 
patients.  
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage in monitoring patient responses to treatment, with potential therapy resistance inferences, 
warranting confirmation using a pre-stipulated specifically focussed study and homogeneous cohort 
design using sufficient patient numbers according to an a priori power calculation estimate. 
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4.3.6 Malignant melanoma patients who underwent standard or no treatment 
A total of 98 serum samples, corresponding to eighty-eight malignant melanoma patients undergoing a 
variety of distinct cancer treatments (surgery, chemotherapy, radiotherapy, immunotherapy or none), 
either in a clinical trial setting or not, were assayed, processed and analysed according to our pre-
established CT100+ microarray pipeline. The following settings were used for the CT100+.jar processing 
and filtering steps: mean or median values = mean, noise threshold = 2 standard deviations of the 
background, replicate CV threshold = 20%, whole array filtering control = 10 ng/µL Cy5-biotin-BSA and 
whole array CV threshold = 21%. The initial stipulated research question was whether this retrospective 
study could potentially identify diagnostic or prognostic biomarkers, as well as to assess whether and 
how different therapies significantly alter autoimmune titres. For this purpose, data analysis was 
conducted based on the collected clinical information and each patient’s resulting autoimmune profile, 
permitting the comparison between several of these parameters. However, although eight patients 
have multiple sample time points undergoing distinct treatments which may allow therapy efficacy 
comparisons, it is important to note that the majority of these patients only have a single blood sample, 
signifying that no autoantibody responses progression across a time course may be measured for these, 
but rather a single profile for each patient. Hence, our data analysis pipeline is distinct from those 
mentioned above. Furthermore, based on sample number-based power calculations indicated in 
Chapter 2, this cohort includes sufficient patient and sample numbers to be able to report statistically 
relevant results (power =  0. 996). 
Significant (> 1000 RFU) autoantibody titres were present in the majority of all samples (n = 93/98, 95%), 
with only five patients displaying titres below 1000 RFU, with signals ranging from 0 to ~289000 RFU. 
The latter were patients 581576 (male, surgery, stage III, not deceased), 568788 (female, no treatment, 
stage II, not deceased), 228343 (female, unknown treatment, stage III, deceased), 735678 (female, no 
treatment, stage III, deceased), 584655 (male, surgery, stage IV, not deceased), with no apparent 
consistent pattern. It is of note, however, that of the four of these five patients who had treatment 
information, none were undergoing chemotherapy, radiotherapy or immunotherapy, but rather had no 
treatment or surgery only. When grouping these patients based on treatment undergone, the highest 
autoantibody titres were observed for patients undergoing no treatment (~289000 RFU towards 
CTAG2), followed by those undergoing immunotherapy (~140000 RFU towards CTAG2), chemotherapy 
(~90000 RFU towards NY-ESO-1), and surgery (~26000 RFU towards NY-ESO-1), with the overall lowest 
titres seen for patients undergoing radiotherapy (~2500 RFU towards CTNNB1). These levels of 
autoantibody titres are quite peculiar, as they indicate that counterintuitively no therapy yields the 
highest autoimmune levels, even though this subset includes forty-seven patients. This may be due to 
the fact that many of the patients in this subset have previously undergone some previous therapy at an 
earlier time point, although the captured information is limited to the specific treatment each patient 
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was having at the time of the sample collection. Alternatively, as many cancer treatments suppress the 
immune system, these patients may be displaying a more responsive immune system due to not having 
undergone any previous harsh treatment. On the other hand, patients undergoing radiotherapy 
presented the lowest autoantibody titres, although this data was limited to only three patients, and 
therefore not allowing an adequate representation of this treatment type. In regards to the antigens 
indicating highest autoantibody titres, both CTAG2 and NY-ESO-1 appear twice in these treatment 
subsets. However, further analysis is required to verify if these might have a larger significance in this 
cohort. As a means of further interpreting the largest and most interesting subset of patients 
undergoing no treatment, a radar plot was constructed displaying autoantibody titres across all 
antigens, and is indicated below in Fig. 4.41. 
 
Figure 4.41: Radar plot of the autoantibody titres detected towards all antigens across patients 
undergoing no treatment of the other treatments cohort. Each antigen is indicated by an axis, and each 
patient sample is indicated in a different colour. 
 
 
Based on this radar plot, it was evident that patient autoantibody titres are repeatedly clustering against 
both CTAG2 and NY-ESO-1 for matching patient samples. A paired response towards NY-ESO-1 and 
CTAG2 is certainly expected, due to the high sequence homology between them, as previously 
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mentioned above. It would certainly be informative to verify if the seven patients displaying the 
extremely high autoantibody signals (between 50000 and 300000 RFU) towards these two antigens 
were in fact undergoing some form of immunotherapy at a previous time-point. As one of the 
immunotherapies includes NY-ESO-1 vaccination, it seems as if this might be the most likely previous 
therapy undergone. Alternatively, those instances could be patients with naturally occurring high 
autoantibody titres, independent of any therapy. These seven included patients 773298 (female, stage 
III, deceased), 825325-2 (female, stage IV, deceased), 574971 (female, stage IV, deceased), 760422 
(male, stage IV, deceased), 739555 (male, stage IV, deceased), 702850 (male, stage IV, deceased), and 
574184 (female, stage IV, unknown). The most prevalent characteristic of these seven patients were 
disease stage IV (n = 6/7, 86%), and deceased (n = 6/6, 100%). These are in line with a very advanced 
disease phase, where not much can be done except attempt to prolong the short predicted survival time 
for metastatic melanoma patients.  
Of the 123 cancer-associated antigens present on our CT100+ array, the most prevalent significant 
autoantibody titres (above 1000 RFU) detected in this cohort were towards 17 leading antigens. These 
were detected in at least 27 or more instances across patient samples in this cohort,  and most 
abundantly towards NY-ESO-1 (n = 48/98, 49%) and CTAG2 (n = 45/98, 46%), as indicated below in Fig. 
4.42. 
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Figure 4.42: Most prevalent autoantibody titres detected across the other treatments cohort. This 
graph indicates the summed number of times autoantibody levels were detected towards the 17 leading 
antigens at titres above 1000 RFU. 
 
 
Based on this graph, it was evident that a very interesting subset of prevalent autoantibody titres was 
present in at least 27/98 (28%) patient samples. Besides from prevalent titres towards the NY-ESO-1 and 
CTAG2 common leading antigen pair, as well as CTAG2/LAGE-1b/LAGE-1L, a CTAG2 isoform, many 
autoantibody titres were towards CT antigens, such as members of the expected melanoma antigen 
(MAGE) family, MAGEB1, MAGEB6, MAGEB5, MAGEA3, MAGEA11, as well as NY-CO45, TSSK6 and 
SYCE1. Additionally, a few protein kinases are also present, such as FES, MAPK3, MAPK1 and PRKCZ, and 
other non-CT antigens such as SOX1 and TYR, which are quite a wide range of distinct antigen groups. As 
a means of defining whether abundant titres towards these leading antigens could be potential 
diagnostic or prognostic biomarkers, or even therapeutic targets, the NY-ESO-1 and CTAG2 pair was 
investigated further.  
NY-ESO-1 has been broadly discussed above in Sections 4.3.1 and 4.3.4, as abundant autoantibody titres 
were detected towards this antigen in both the kinase inhibition and the survivin treatment cohorts. The 
high level of sequence homology (77%) between the NY-ESO-1/CTAG2 pair has also been mentioned, 
which justifies the matching titres towards these two antigens mentioned above. Particularly, in 
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melanoma, NY-ESO-1 has received a great deal of interest as an attractive immunotherapeutic target 
(NY-ESO-1 ISCOMATRIX vaccine), and has also been tested in a clinical trial setting, with initial promise 
due to a treatment triggered induction of immune responses (Davis et al. 2004; Maraskovsky 2004). 
However, although strong vaccine-induced responses were shown in early disease stages, advanced 
melanoma patients showed little to no clinical responses to vaccination, which was possible due to a 
tumour-induced systemic immune suppression driven by regulatory T-cells (Nicholaou et al. 2009). 
Hence, NY-ESO-1 therapies have been somewhat overshadowed by kinase inhibitors, due to more 
beneficial clinical responses to treatment, even amongst advanced melanoma patients (Vanneman & 
Dranoff 2012). Nonetheless, the available data for both NY-ESO-1 and CTAG2 across all patients was 
inspected, and a dual autoantibody titre trendline across this whole cohort was constructed, as 
indicated below in Fig. 4.43. 
 
Figure 4.43: Anti-NY-ESO-1 and -CTAG2 immunoglobulin titre trendlines across other treatments 
cohort. Anti-NY-ESO-1 immunoglobulin titres are indicated in red, and anti-CTAG2 immunoglobulin 
titres are indicated in blue, with both trendlines showing nearly complete overlap.  
 
 
Visual inspection of these anti-NY-ESO-1 and -CTAG2 immunoglobulin titre trendlines indicate a nearly 
complete overlap and paired NY-ESO-1/CTAG2 autoantibody titre across this cohort, which serves as a 
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very robust validation of our array platform, methodology, data analysis pipeline, and reported 
autoantibody responses. Additionally, this indicates autoantibody responses amongst these patients are 
certainly occurring in NY-ESO-1/CTAG2 shared epitope regions. When inspecting the three most intense 
autoantibody titres above 100000 RFU, these occur for patients 825325-2/3 (female, stage IV, 
undergoing no treatment (2) or immunotherapy (3), deceased), 773298-2 (female, stage II, undergoing 
no treatment, deceased) and C 6/3/1996 (no available information). The first two patients were 
certainly enrolled in immunotherapeutic trials in between no-treatment breaks, which might explain the 
presence of such high titres. Due to such a high number of patient samples (n = 48/98, 49%) expressing 
significantly high autoantibody titres towards NY-ESO-1, this protein certainly has diagnostic biomarker 
potential. Previous studies have identified this protein as a predictive biomarker of response, showing 
an improved clinical benefit prediction for seropositive NY-ESO-1 melanoma patients (Yuan et al. 2011). 
However, due to the lack of complete clinical information, and available temporal sample information 
instead, it is unknown whether these patients did in fact have an improved clinical response to 
immunotherapy, although this prediction is likely. Furthermore, due to the high levels of NY-ESO-1 
amongst our mostly advanced malignant melanoma cohort, perhaps researchers should re-focus 
interest in understanding why vaccination with this protein was not effective in advanced cases, and 
attempt to change that.  
We have applied our CT antigen microarray platform to the investigation of autoantibody profiles in a 
cohort of metastatic malignant melanoma patients undergoing a variety of different treatments, and 
observed significant autoantibody titres across 95% of this cohort. The main intent of this study was to 
retrospectively assess whether potential diagnostic or prognostic biomarkers could be identified, and 
whether distinct therapeutic options generated specific autoantibody titres or patterns. In this regard, it 
is interesting that our CT antigen array data successfully identified a melanoma-specific well-established 
therapeutic target – NY-ESO-1– and its homologous pair, CTAG2, which were the two antigens towards 
which the most abundant autoantibody titres were detected, present across 49% and 46% patients, 
respectively. Once again, due to the increased sequence homology amongst this pair, it remains to be 
determined whether the observed responses are towards a shared epitope. However, the nearly 
complete overlap of autoantibody responses of this pair across this cohort are most likely indicative of 
such. Additionally, when considering treatment specific autoantibody patterns, the highest 
autoantibody levels were observed for patients undergoing no treatment, which may be due to the 
absence of immune-aggressive previous therapeutics leading to more responsive immune systems. 
However, clinical history is not available amongst these patients, and thus inferences may not be made.  
In this variable treatment cohort, we have successfully demonstrated that there are measurable 
differences in the autoantibody repertoires towards tumour-specific and –associated antigens between 
malignant melanoma patients. Furthermore, we have successfully identified a melanoma-specific well-
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established therapeutic target – NY-ESO-1– and its homologous pair, CTAG2, which were the two 
antigens towards which the most abundant autoantibody titres were detected, present across 49% and 
46% patients, respectively. The fact that both these antigens share the majority of their sequence and 
have common epitopes suggests that autoantibody responses are probably towards one of these forms 
in particular (most likely NY-ESO-1). When considering patient sample numbers and relevant power 
calculations, although this cohort is quite diverse regarding demographics (age and gender) and 
treatment undergone , the achieved statistical power is above recommended (power > 0.8), supporting 
the findings obtained in this cohort. 
We therefore anticipate that our novel, quantitative, customizable CT antigen microarray platform may 
find usage in identifying diagnostic or prognostic biomarkers, as well as novel therapeutic targets, 
warranting confirmation using a pre-stipulated specifically focussed study and homogeneous cohort 
design using sufficient patient numbers according to an a priori power calculation estimate. 
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5 CONCLUSIONS 
  
5.1 Conclusions 
In this work, we have developed and validated a novel protein microarray platform, the CT100+, 
containing CT antigens, and other cancer-associated antigens of interest. Our microarray is mainly 
composed of CT antigens due to their attractive and highly reported potential as cancer biomarkers and 
their restricted overexpression in a variety of distinct cancer types with potential applications in many 
cancers. Initially, slide coating and cloning procedures were improved, resulting in a much more 
homogenous assay surface as a result of the newly developed immersion technique, and reduced non-
specific binding following transfer of all protein expression to insect cells. The array layout was 
developed to include additional cancer-related antigens, as well as incorporating a means to measure 
total IgG levels per array. Printing and assaying procedures were optimized with the intent of obtaining 
consistently reproducible and robust data. Printing settings involving the number of stamps, buffer 
standardization and pin washing procedures were adjusted to obtain equal-sized and spaced spots, 
excluding the usual printing-associated issues such as pin sticking, spot running, carryover, and non-
specific binding. Post-printing slide storage was altered to improve storage time and slide viability, and 
consisted of using a dry storage refrigerated method.  
Once an optimal process was in place, the platform was assessed to verify its linear range and detection 
limit, as a means of inferring potential applications and best assaying concentrations, obtaining a 
previously unreported low detection limit in the pg/mL range, with linearity over at least three orders of 
magnitude. Hence, only 1 µL amount of patient serum was required for each assay, which is 
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advantageous when dealing with precious and limited patient samples, which is usually the case, and 
suggesting that in the future assays could be run on a pin prick of blood. Quality control steps were 
developed as a means of assuring robust and highly reproducible results amongst repeatedly generated 
data. These included verifying that printing was successful, and that both patient serum and detection 
antibody were added to each array, as well as testing for array specificity towards cancer using pooled 
cancer and healthy samples, and were required to be as stipulated in order to accept with high 
confidence the resulting data of that print run. Reproducibility studies were also performed with the 
intent of verifying that consistent resulting data was obtained repeatedly, even when amongst different 
sample dilution preparations. Additionally, a new bioinformatic tool, the CT100+.jar, was developed to 
enable robust pre-processing and objective quality control of raw data files.  
Once this complete, optimized, thorough and robust pipeline was in place, serum based immune 
responses could be assessed, which was done across six distinct cohorts undergoing different 
treatments, and including several cancer types, with the intent of either supporting or refuting our 
original hypothesis. We thus aimed to verify whether or not there were measurable differences in 
autoantibody repertoires towards tumour-specific and –associated antigens between pre- and post-
treated cancer patient samples, which could potentially correlate with associated T-cell or clinical 
responses, thus exploring different potential uses of this platform.  
The resulting data of the first cohort including thirty-six malignant melanoma patients undergoing 
kinase inhibition, identified abundant autoantibody titres towards two antigens, NY-ESO-1 and MAGEB1, 
that were present in 61% (n = 22/36) and 56% (n = 20/36) of all patients, respectively, both of which 
have been identified previously as cancer therapeutic targets and are currently being tested in a clinical 
trial setting. In regards to the stipulated research question – whether the induction of an autoantibody 
response correlated with T-cell responses and clinical improvements post-treatment amongst these 
patients – our CT antigen array data suggests limited evidence of correlating T-cell responses, but 
preliminary evidence of correlation between our observed autoantibody responses and the clinically 
reported ones across a subset of patients (35% of the cohort). Although this cohort was quite diverse 
regarding patient demographics (age and gender) and treatments undergone (single vs. dual kinase 
inhibition treatment), the achieved statistical power was above recommended (power > 0.8), supporting 
the findings obtained in this cohort.   
The resulting data of the second cohort included sixty-two colorectal cancer patients undergoing pre- or 
post-operative chemotherapy/radiotherapy treatment, identified abundant autoantibody titres towards 
two antigens, SILV/gp100 and p53 Q136X, across 31% (n = 19/62) and 21% (n = 13/62) of all patients, 
identifying potential novel therapeutic targets for colorectal cancer and a possible indicator of advanced 
disease stage, respectively. In regards to the main intent of this study – to assess whether pre-operative 
therapy altered patterns of autoantibody titres, thereby potentially influencing the outcome of 
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subsequent therapy – this cohort data showed that no difference in autoantibody profiles was evident 
between patients who had undergone pre-operative therapy and those who hadn’t, contrary to what 
was expected, thus limiting subsequent inferences to be made. Although this cohort was quite diverse 
regarding age, the achieved statistical power was above recommended (power > 0.8), supporting the 
findings obtained in this cohort.   
The third cohort included twelve myelodysplasia patients undergoing dual epigenetic modification 
treatment, and identified abundant autoantibody titres towards two antigens, cytochrome P450 
reductase and DSCR8/MMA1, that were present in 75% (n = 9/12) and 67% (n = 8/12) of all patients. 
However, due to the limited number of patients in this cohort, no inferences could be made regarding a 
potential link to resistance and a possible novel therapeutic target, respectively.  In regards to the main 
intent of this study – to assess whether epigenetic modification created neo-antigens and subsequent 
expanded autoantibody responses – we identified abundant autoantibody titres towards 19 potential 
antigens with expanded autoantibody response towards cancer-associated antigens as a result to 
treatment, but no specific responsible neo-antigen. Furthermore, preliminary evidence of an expanded 
immune response after epigenetic treatment was evident across the majority of all patients, of which 
67% of the cohort presented with matching array and clinically reported responses. Unfortunately, this 
cohort did not achieve the required statistical power (power > 0.8), and thus the findings obtained could 
not be statistically supported. Therefore although these results provide preliminary insight into this 
cohort, these warrant further confirmation across a larger group of patients. 
The data obtained on the fourth cohort including forty-eight variable cancer patients undergoing 
survivin treatment, identified a known potential link between p53 mutant-associated chemotherapy 
resistance, early relapse and shortened overall survival in ovarian cancer patients, warranting further 
genomic studies. However, this possible association requires verification using a larger dedicated 
ovarian cancer cohort, as a means of verifying significance. Additionally, abundant autoantibody titres 
towards two antigens, NY-ESO-1 and CTAG2/LAGE-1b/LAGE-1L, were identified. This homologous pair 
was present in 35% (n = 17/48) and 25% (n = 12/48) of all patients, respectively, and have been 
identified previously as cancer immunotherapeutic targets with potential prognostic and predictive 
value. In regards to the main intent of this study – to assess whether the induction of an autoantibody 
response correlated with reported induced survivin-specific T-cell responses post-treatment amongst 
these patients – our CT antigen array data suggests evidence of direct correlation between our observed 
autoantibody responses and the survivin-specific T-cell reported ones across a subset of patients (59% 
of the cohort). Furthermore, preliminary evidence of a correlation between our data and the reported 
clinical benefit was also observed, across a larger subset of patients (71%), warranting further 
investigation. Although this cohort was quite diverse regarding patient age and tumour type, the 
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achieved statistical power was above recommended (power > 0.8), supporting the findings obtained in 
this cohort. 
The fifth and smallest cohort included eleven colorectal cancer patients with unresectable liver 
metastasis undergoing selective internal radiotherapy, identified abundant autoantibody titres towards 
an antigen, CSAG2, across 73% (n = 8/11) of all patients. However, the limited patient numbers in this 
cohort, and lack of their clinical information, do not allow speculative inferences to be made regarding a 
potential link to poor clinical efficacy to treatment. In regards to the main intent of this study – to assess 
the effect of SIRT on autoantibody levels and to potentially infer clinical responses to treatment – our CT 
antigen array data suggests an immune response rate much lower than clinical responses previously 
reported in other studies. Unfortunately, this cohort did not achieve the required statistical power 
(power > 0.8), and thus the findings obtained could not be statistically supported. Therefore although 
these results provide preliminary insight into this cohort, these warrant further confirmation across a 
larger group of patients. 
The sixth and final cohort included eighty eight malignant melanoma patients undergoing a variety of 
distinct cancer treatments. In regards to the stipulated research question of this study - whether 
potential diagnostic or prognostic biomarkers could be identified, and whether distinct therapeutic 
options generated specific autoantibody titres or patterns – our CT antigen array data successfully 
identified abundant autoantibody titres towards two antigens, NY-ESO-1 and CTAG2, a homologous pair 
expressed across 49% (n = 48/98) and 46% (n = 45/98) of all patients, respectively, with reported 
diagnostic and clinical efficacy predictive biomarker potential. Additionally, when considering treatment 
specific autoantibody patterns, the highest autoantibody levels were observed for patients undergoing 
no treatment, which may be due to treatment-related, or lack thereof, more responsive immune 
systems. Furthermore, the overlap in autoantibody titres of this pair validated our array platform, 
showing consistency amongst our obtained results across patients. Although this cohort was quite 
diverse regarding demographics (age and gender) and treatment undergone, the achieved statistical 
power was above recommended (power > 0.8), supporting the findings obtained in this cohort. 
In sum, it was evident that some of the treatment cohorts assessed in this work were limited by low 
patient numbers and/or lack of access to clinical information, making robust statistically relevant 
conclusions difficult. Furthermore, inter- and intra-cohort variability was prevalent, even amongst the 
same cancer type and stage, , indicating that if patients are known to respond differently to treatment, a 
personalised treatment and disease management approach should also be used. However, the main 
objective of this thesis was to develop a protein microarray platform capable of robustly measuring 
differences in autoantibody repertoires using cancer patient serum, and to then explore its potential 
utility across a range of cancers and treatments; rather than attempting to identify robust clinically 
valuable and applicable findings, using pre-stipulated specifically focussed studies and homogeneous 
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cohort designs with adequate patient numbers. Additionally, our findings have successfully supported 
our research hypothesis, by demonstrating that there are in fact measurable differences in the 
autoantibody repertoires towards tumour-specific and –associated antigens amongst cancer patients, 
which usually differ between pre- and post-treatment time points. Although these autoantibody levels 
showed preliminary evidence of correlation with associated T-cell and clinical responses across some of 
the assayed pilot cohorts, larger focussed studies using sufficient patient numbers according to an a 
priori power calculation estimates are required to verify significant and clinically applicable findings.   
Additionally, it is essential to mention that amongst all treatment cohorts, a subset of patients 
presented with an overall lack of significant autoantibody titres towards the assessed tumour-specific 
and –associated antigens. The absence of these titres may be related to a number of 
immunosuppressive or immunoregulatory cancer mechanisms, as the majority of these patients have 
undergone numerous therapeutics and present with advanced cancers. As a result, these may 
potentially lead to a dysfunctional cellular immunity, which would negatively affect autoantibody 
production. Although this may be considered to be a limitation in the application of this method in the 
future, this overall lack of an autoimmune repertoire still provides essential information which may aid 
in comprehending a lack of clinical response to therapy, and thus guide alternative therapeutic planning, 
such as attempting to use an immunotherapeutic that may reverse regulatory pathways (e.g. immune 
checkpoint blockade therapy) instead.  
In conclusion, we have shown that our novel protein microarray platform thus represents a sensitive, 
high-throughput and readily customizable means to detect and quantify the presence of large panels of 
cancer-specific human autoantibodies in serum, obtaining consistently robust, high quality and 
reproducible data, and demonstrating its potential feasibility and inferred biological significance. 
Although patient-specific autoantibody profiles may correlate with treatment responses, further 
validation is required. Nonetheless, without doubt, these profiles do inform on patient-specific 
autoantibody titres towards antigens, which may be useful in stratification of treatment options in the 
future.  
5.2 Potential applications 
This work has shown that our robust, highly reproducible, sensitive and specific CT100+ protein 
microarray platform has great potential clinical applicability. Applications of this tool include the 
potential use to identify novel diagnostic, disease progression, prognostic, treatment resistant and even 
predictive biomarkers, which could aid in the detection and management of cancer. Most importantly, 
these could lead to the discovery of novel cancer therapeutic targets, which are certainly a topic of great 
importance and necessity in the cancer field. This biomarker discovery approach is applicable to a 
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variety of distinct cancer types, broadening its possible use. Additionally, the identification of novel 
biomarkers that could be used in patient stratification prior to chemotherapy, radiotherapy or 
immunotherapy, as a means to improve clinically efficacy of the therapeutic being tested, is also a 
possibility. In addition, this platform has the potential to serve as a means of monitoring cancer patient 
responses to chemotherapy, radiotherapy or immunotherapy, indicating a prospective and promising 
utility as an immune monitoring tool in a clinical trial setting, allowing for easily and rapidly obtainable 
patient clinical efficiency inferential information without use of laborious, costly and unpleasant medical 
tests.   
Based on the results obtained in this Thesis, the potential application that may hold the most promise is 
the biomarker discovery approach, specifically the identification of novel diagnostic or prognostic 
biomarkers. This assumption is based on the fact that amongst the four cohorts that contained an 
acceptable sample number and the recommended statistical power, we were able to detect abundant 
autoantibody titres towards previously well reported antigens, namely NY-ESO-1, CTAG2, CTAG2/LAGE-
1b/LAGE-1L, MAGEB1, SILV/gp100 and p53 Q136X. These antigens have been identified as potential 
diagnostic or prognostic biomarkers across specific cancer types, or have either been or continue to be 
used as potential cancer therapeutics in a clinical trial setting, thus validating our reported findings. 
5.3 Future work 
The CT100+ protein microarray platform could potentially be developed even further, mainly regarding 
the inclusion of additional cancer-associated antigens of interest, as our array layout and format allows 
for the triplicate printing of up to 170 individual protein types. These could be selected based on current 
literature in this field, or specific assays developed for this purpose. Additionally, our protein microarray 
bioinformatic tool, the CT100+.jar, could be enhanced to include an optional graphing and clustering 
tool, as well as the possibility to conduct varied statistical analysis, as a means of allowing a user-friendly 
standardized data analysis procedure for all users. Alternatively, this protein microarray principle could 
be applicable to other immune system diseases, such as tuberculosis, warranting further research.  
In addition, it is apparent from the work described in this Thesis that perhaps a more advanced 
approach is needed to understand the complexity of the observed cancer-specific autoimmune 
responses. In particular, genomic experiments are now revealing specific subtypes of cancer with very 
different inflammatory or immunosuppressive phenotypes; it remains to be seen though whether our 
serology data provides a non-invasive means to identify cancer subtypes. 
 196  
6 REFERENCES 
Adema, G.J. et al., 1994. Molecular characterization of the melanocyte lineage-specific antigen 
gp100. The Journal of biological chemistry, 269(31), pp.20126–33.  
Alberts, B. et al., 2002. B Cells and Antibodies. In Molecular Biology of the Cell. New York: 
Garland Science.  
Altieri, D.C., 2003. Validating survivin as a cancer therapeutic target. Nature reviews. Cancer, 
3(1), pp.46–54.  
Altschul, S.F. et al., 1990. Basic local alignment search tool. Journal of molecular biology, 
215(3), pp.403–10.  
Altschul, S.F. et al., 1997. Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs. Nucleic acids research, 25(17), pp.3389–402. 
Ambrosini, G., Adida, C. & Altieri, D.C., 1997. A novel anti-apoptosis gene, survivin, expressed 
in cancer and lymphoma. Nature Medicine, 3(8), pp.917–921.  
Andersen, B.M. & Ohlfest, J.R., 2012. Increasing the efficacy of tumor cell vaccines by 
enhancing cross priming. Cancer Letters, 325(2), pp.155–164. 
Anderson, K.S. & LaBaer, J., 2005a. The sentinel within: Exploiting the immune system for 
cancer biomarkers. Journal of Proteome Research, 4(4), pp.1123–1133. 
    197 
Anderson, K.S. & LaBaer, J., 2005b. The sentinel within: exploiting the immune system for 
cancer biomarkers. Journal of proteome research, 4(4), pp.1123–33. 
Atadja, P., 2009. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and 
challenges. Cancer letters, 280(2), pp.233–41.  
Athappilly, F.K. & Hendrickson, W. a, 1995. Structure of the biotinyl domain of acetyl-
coenzyme A carboxylase determined by MAD phasing. Structure (London, England : 
1993), 3(12), pp.1407–1419. 
Ausubel, F.M. et al., 1999. Short Protocols in Molecular Biology. In Current Protocols in 
Molecular Biology. Wiley, New York. 
Bakker, A.B. et al., 1994. Melanocyte lineage-specific antigen gp100 is recognized by 
melanoma-derived tumor-infiltrating lymphocytes. The Journal of experimental medicine, 
179(3), pp.1005–9.  
Balboni, I. et al., 2006. Multiplexed protein array platforms for analysis of autoimmune diseases. 
Annual review of immunology, 24, pp.391–418. 
Balch, C.M. et al., 2009. Final version of 2009 AJCC melanoma staging and classification. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 
27(36), pp.6199–206.  
Beeton-Kempen, N. et al., 2014. Development of a novel, quantitative protein microarray 
platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. 
International journal of cancer. Journal international du cancer, 135(8), pp.1842–51.  
Bendandi, M., 2009. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial 
failures. Nature reviews. Cancer, 9(SepTemBer), pp.675–681. 
Berrade, L., Garcia, A.E. & Camarero, J.A., 2011. Protein Microarrays : Novel Developments 
and Applications. Pharmaceutical Research, pp.1480–1499. 
Beyer, M. & Schultze, J.L., 2006. Regulatory T cells in cancer. Blood, 108(3), pp.804–811. 
 198  
Blackburn, J.M. & Shoko, A., 2011. Protein Function Microarrays for Customised Systems-
Oriented Proteome Analysis. In U. Korf, ed. Methods in Molecular Biology. Humana Press, 
pp. 305–330. 
Blackburn, J.M., Shoko, A. & Beeton-Kempen, N., 2012. Miniaturized, microarray-based assays 
for chemical proteomic studies of protein function E. D. Zanders, ed. Methods in Molecular 
Biology, 800, pp.133–162.  
Blank, C.U. et al., 2011. Combination of targeted therapy and immunotherapy in melanoma. 
Cancer Immunol Immunother, 60, pp.1359–1371. 
Bolstad, B.M. et al., 2003. A comparison of normalization methods for high density 
oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England), 
19(2), pp.185–93.  
Boni, A. et al., 2010. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma 
without affecting lymphocyte function. Cancer Research, 70(9), pp.5213–5219. 
Bosset, J.-F. et al., 2006. Chemotherapy with preoperative radiotherapy in rectal cancer. The 
New England journal of medicine, 355(11), pp.1114–23.. 
Boutell, J.M. et al., 2004. Analysis of the effect of clinically-relevant mutations on p53 function 
using protein microarray technology. Proteomics, 4, pp.1950–1958. 
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72, 
pp.248–54. 
Bray, F. et al., 2013. Global estimates of cancer prevalence for 27 sites in the adult population in 
2008. International journal of cancer. Journal international du cancer, 132(5), pp.1133–45.  
Büssow, K. et al., 2001. Protein Array technology: Potential Use in Medical Diagnostics. Am J 
Pharmacogenomics, 1(1), pp.1–7. 
Caballero, O.L. & Chen, Y., 2009. Cancer ⁄ testis ( CT ) antigens : Potential targets for 
immunotherapy. Cancer Science, 100(11), pp.2014–2021. 
    199 
Causton, H.C., Quackenbush, J. & Brazma, A., 2004. Microarray gene expression data analysis: 
a beginners guide. In Yeast. Blackwell Publishing, pp. 973–974.  
Cebon, J., 2010. Cancer vaccines: Where are we going? Asia-Pacific journal of clinical 
oncology, 6 Suppl 1, pp.S9–15.  
Chapman, P.B. et al., 2011. Improved survival with vemurafenib in melanoma with BRAF 
V600E mutation. The New England journal of medicine, 364(26), pp.2507–16.  
Chapman-Smith, A. & Cronan, J.E., 1999. The enzymatic biotinylation of proteins: a post-
translational modification of exceptional specificity. Trends in Biochemical Sciences, 24(9), 
pp.359–363. 
Chen, Y. et al., 2010. In vitro assessment of cytochrome P450 inhibition and induction potential 
of azacitidine. Cancer chemotherapy and pharmacology, 65(5), pp.995–1000.  
Choi-Rhee, E. & Cronan, J.E., 2003. The biotin carboxylase-biotin carboxyl carrier protein 
complex of Escherichia coli acetyl-CoA carboxylase. The Journal of Biological Chemistry, 
278(33), pp.30806–12. 
Cohen, J., 1988. Statistical Power Analysis for the Behavioral Sciences. In Psychology. pp. 273–
406.  
Curtin, J.A. et al., 2005. Distinct sets of genetic alterations in melanoma. The New England 
journal of medicine, 353(20), pp.2135–47.  
Danna, E.A. et al., 2004. Surgical Removal of Primary Tumor Reverses Tumor-Induced 
Immunosuppression Despite the Presence of Metastatic Disease. Cancer Research, 64, 
pp.2205–2211. 
Davies, H. et al., 2002. Mutations of the BRAF gene in human cancer. Nature, 417(6892), 
pp.949–54.  
Davies, M.A. et al., 2011. Prognostic factors for survival in melanoma patients with brain 
metastases. Cancer, 117(8), pp.1687–1696.  
Davis, I.D. et al., 2004. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces 
broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. 
 200  
Proceedings of the National Academy of Sciences of the United States of America, 101(29), 
pp.10697–702.  
Derissen, E.J.B., Beijnen, J.H. & Schellens, J.H.M., 2013. Concise Drug Review: Azacitidine 
and Decitabine. The Oncologist, 18, pp.619–624. 
Disis, M.L. et al., 2009. Concurrent trastuzumab and HER2/neu-specific vaccination in patients 
with metastatic breast cancer. Journal of Clinical Oncology, 27(4), pp.4685–4692. 
Dougan, M. & Dranoff, G., 2009. Immune therapy for cancer R. Wang, ed. Annu Rev Immunol, 
27, pp.83–117. 
Drake, C.G., Lipson, E.J. & Brahmer, J.R., 2014. Breathing new life into immunotherapy: 
review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology, 11(1). 
Dranoff, G., 2004. Cytokines in cancer pathogenesis and cancer therapy. Nature reviews. 
Cancer, 4(January), pp.11–22. 
Duan, Z. et al., 1999. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma 
cell line. Gene, 229(1-2), pp.75–81.  
Duarte, J. et al., 2013. Protein Function Microarrays: Design, Use and Bioinformatic Analysis in 
Cancer Biomarker Discovery and Quantitation. In X. Wang, ed. Bioinformatics of Human 
Proteomics, Translational Bioinformatics 3. Springer Netherlands, pp. 39–74. 
Van Duin, M. et al., 2011. Cancer testis antigens in newly diagnosed and relapse multiple 
myeloma: prognostic markers and potential targets for immunotherapy. Haematologica, 
96(11), pp.1662–9.  
Dyrskjøt, L. et al., 2012. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in 
urothelial carcinoma. British journal of cancer, 107(1), pp.116–22.  
Edge, S.B. & Byrd, D.R., 2010. AJCC Cancer Staging Manual 7th Editio., Springer SBM. 
El-Deiry, W.S. et al., 1993. WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 
pp.817–25.  
    201 
Esteller, M., 2008. Epigenetics in cancer. The New England journal of medicine, 358(11), 
pp.1148–59.  
Falchook, G.S. et al., 2012. Dabrafenib in patients with melanoma, untreated brain metastases, 
and other solid tumours: a phase 1 dose-escalation trial. Lancet, 379(9829), pp.1893–901.  
Fang, Y., Lahiri, J. & Picard, L., 2003. G protein-coupled receptor microarrays for drug 
discovery. Drug Discovery Today, 8(16), pp.755–61. 
Faul, F. et al., 2007. G*Power 3: a flexible statistical power analysis program for the social, 
behavioral, and biomedical sciences. Behavior research methods, 39(2), pp.175–191. 
Faul, F. et al., 2009. Statistical power analyses using G*Power 3.1: tests for correlation and 
regression analyses. Behavior research methods, 41(4), pp.1149–1160. 
Ferlay, J. et al., 2015. Cancer incidence and mortality worldwide: Sources, methods and major 
patterns in GLOBOCAN 2012. International journal of cancer. Journal international du 
cancer, 136(5), pp.E359–86.  
Flaherty, K.T. et al., 2012. Combined BRAF and MEK inhibition in melanoma with BRAF 
V600 mutations. The New England journal of medicine, 367(18), pp.1694–703.  
Franceschini, A. et al., 2013. STRING v9.1: protein-protein interaction networks, with increased 
coverage and integration. Nucleic acids research, 41(Database issue), pp.D808–15.  
Frank, R. & Hargreaves, R., 2003. Clinical biomarkers in drug discovery and development. 
Nature Reviews, 2(7), pp.566–580. 
Fukuda, S. & Pelus, L.M., 2006. Survivin, a cancer target with an emerging role in normal adult 
tissues. Molecular cancer therapeutics, 5(5), pp.1087–98.  
Garcia-lora, A., Algarra, I. & Garrido, F., 2003. MHC Class I Antigens , Immune Surveillance , 
and Tumor Immune Escape. Journal of Cellular Physiology, , 355, pp.346–355. 
Germano, S. et al., 2012. MAGE-D4B is a novel marker of poor prognosis and potential 
therapeutic target involved in breast cancer tumorigenesis. International journal of cancer. 
Journal international du cancer, 130(9), pp.1991–2002.  
 202  
Gibbs, P. et al., 2014. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin 
microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX 
alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the 
SIRFLOX study. BMC cancer, 14(1), p.897. 
Greenberg, P. et al., 1997. International Scoring System for Evaluating Prognosis in 
Myelodysplastic Syndromes. Blood, 89(6), pp.2079–2088. 
Greenblatt, M.S. et al., 1994. Mutations in the p53 tumor suppressor gene: clues to cancer 
etiology and molecular pathogenesis. Cancer research, 54(18), pp.4855–78.  
Halama, N. et al., 2011. Localization and density of immune cells in the invasive margin of 
human colorectal cancer liver metastases are prognostic for response to chemotherapy. 
Cancer Research, 71(17), pp.5670–5677. 
Hall, D.A., Ptacek, J. & Snyder, M., 2007. Protein microarray technology. Mechanisms of ageing 
and development, 128(1), pp.161–7. 
Hamberg, P. et al., 2011. Effect of ketoconazole  mediated CYP3A4 inhibition on clinical 
pharmacokinetics of panobinostat (LBH589 ), an orally active histone deacetylase inhibitor. 
Cancer Chemotherapy and Pharmacology, 68(3), pp.805–813. 
Hammel, P. et al., 1997. Detection and monitoring of serum p53 antibodies in patients with 
colorectal cancer. Gut, 40(3), pp.356–61.  
Hanahan, D. & Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell, 144(5), 
pp.646–74.  
Hanahan, D. & Weinberg, R.A., 2000. The hallmarks of cancer. Cell, 100(1), pp.57–70.  
Hardiman, G., 2003. Microarray technologies - an overview. In Pharmacogenomics. pp. 251–6. 
Hellborg, F. et al., 2001. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc 
finger protein. Oncogene, 20(39), pp.5466–74.  
Hodi, F.S. et al., 2010. Improved survival with ipilimumab in patients with metastatic 
melanoma., 
    203 
Holliday, R., 1987. The inheritance of epigenetic defects. Science, 238(4824), pp.163–170.  
Houbiers, J.G. et al., 1995. Antibodies against p53 are associated with poor prognosis of 
colorectal cancer. British journal of cancer, 72(3), pp.637–41.  
Houghton, A.N. & Guevara-Patiño, J.A., 2004. Immune recognition of self in immunity against 
cancer. The Journal of clinical investigation, 114(4), pp.468–71.  
Hunder, N.N. et al., 2008. Treatment of Metastatic Melanoma with Autologous CD4+ T Cells 
against NY-ESO-1. N Engl J Med, 358(25), pp.2698–2703. 
Ingelman-Sundberg, M. et al., 2007. Influence of cytochrome P450 polymorphisms on drug 
therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & 
therapeutics, 116(3), pp.496–526. 
Islam, A. et al., 2000. High expression of Survivin, mapped to 17q25, is significantly associated 
with poor prognostic factors and promotes cell survival in human neuroblastoma. 
Oncogene, 19(5), pp.617–23.  
Jäger, E. et al., 1999. Humoral immune responses of cancer patients against “Cancer-Testis” 
antigen NY-ESO-1: correlation with clinical events. International journal of cancer. 
Journal international du cancer, 84(5), pp.506–10.  
Jemal, A. et al., 2011. Global cancer statistics. CA: a cancer journal for clinicians, 61(2), pp.69–
90.  
Jones, P.A. & Laird, P.W., 1999. Cancer epigenetics comes of age. Nature genetics, 
21(february), pp.163–167. 
Kapiteijn, E. et al., 2001. Preoperative radiotherapy combined with total mesorectal excision for 
resectable rectal cancer. The New England journal of medicine, 345(9), pp.638–46.  
Kawakami, Y. et al., 1994. Identification of a human melanoma antigen recognized by tumor-
infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the 
National Academy of Sciences of the United States of America, 91(14), pp.6458–62.  
Kim, K.B. et al., 2013. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with 
metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF 
 204  
inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 31(4), pp.482–9.  
Klein, J.B. & Thongboonkerd, V., 2004. Overview of Proteomics. In Proteomics in Nephrology. 
pp. 1–10. 
Kodadek, T., 2001. Protein microarrays : prospects and problems. Chemistry & biology, 8(2), 
pp.105–115. 
Konecny, G.E. et al., 2014. Prognostic and Therapeutic Relevance of Molecular Subtypes in 
High-Grade Serous Ovarian Cancer. JNCI Journal of the National Cancer Institute, 106, 
pp.dju249–dju249.  
Koopmann, J.-O. & Blackburn, J., 2003. High affinity capture surface for matrix-assisted laser 
desorption/ionisation compatible protein microarrays. Rapid communications in mass 
spectrometry : RCM, 17(5), pp.455–62. 
Kressner, U. et al., 1998. Increased serum p53 antibody levels indicate poor prognosis in patients 
with colorectal cancer. British journal of cancer, 77(11), pp.1848–51. 
Kruit, W.H. et al., 2008. Immunization with recombinant MAGE-A3 protein combined with 
adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic 
cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma 
Group (16032- 18031). ASCO Meeting Abstracts, 25(15). 
Kufe, D.W. et al. eds., 2003. Holland-Frei Cancer Medicine 6th editio., Hamilton: BC Decker. 
Kupryjańczyk, J. et al., 1993. p53 gene mutations and protein accumulation in human ovarian 
cancer. Proceedings of the National Academy of Sciences of the United States of America, 
90(11), pp.4961–5.  
Lennerz, V. et al., 2014. Immunologic response to the survivin-derived multi-epitope vaccine 
EMD640744 in patients with advanced solid tumors. Cancer immunology immunotherapy, 
63(4), pp.381–94.  
Lesterhuis, W.J. et al., 2011. Route of administration modulates the induction of dendritic cell 
vaccine-induced antigen-specific T cells in advanced melanoma patients. Clinical Cancer 
Research, 17(3), pp.5725–5735. 
    205 
Lethé, B. et al., 1998. LAGE-1, a new gene with tumor specificity. International journal of 
cancer., 76(6), pp.903–8.  
Li, F. et al., 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 
396(December), pp.580–584. 
Li, M., Yuan, Y. & Han, Y., 2005. Expression Profile of Cancer-Testis Genes in 121 Human 
Colorectal Cancer Tissue and Adjacent Normal Tissue. Clinical Cancer Research, pp.1809–
1814. 
Lin, C. et al., 2002. Cancer/testis antigen CSAGE is concurrently expressed with MAGE in 
chondrosarcoma. Gene, 285(1-2), pp.269–78.  
Liu, M.A., 2011. DNA vaccines: an historical perspective and view to the future. Immunol Rev, 
239, pp.62–84.  
Liu, Y. & Bodmer, W.F., 2006. Analysis of P53 mutations and their expression in 56 colorectal 
cancer cell lines. Proceedings of the National Academy of Sciences of the United States of 
America, 103(4), pp.976–81.  
Long, G. V. et al., 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in 
melanoma. The New England journal of medicine, 371(20), pp.1877–88.  
MacBeath, G. & Schreiber, S.L., 2000. Printing Proteins as Microarrays for High-Throughput 
Function Determination, 
Madoz-Gúrpide, J. et al., 2008. Integral protein microarrays for the identification of lung cancer 
antigens in sera that induce a humoral immune response. Molecular & cellular proteomics : 
MCP, 7(2), pp.268–281. 
Maraskovsky, E., 2004. NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent 
Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and 
Protection against NY-ESO-1+ Tumors. Clinical Cancer Research, 10(8), pp.2879–2890.  
Marchand, M. et al., 1999. Tumor regressions observed in patients with metastatic melanoma 
treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. 
International journal of cancer. Journal international du cancer, 80(2), pp.219–30.  
 206  
Marks, J.R. et al., 1991. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer 
research, 51(11), pp.2979–84.  
Matarraz, S. et al., 2011. New technologies in cancer. Protein microarrays for biomarker 
discovery. Clin Transl Oncol, 13, pp.156–161. 
Materna, V. et al., 2007. Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is 
predictive for clinical outcome in ovarian carcinoma patients. Virchows Archiv : an 
international journal of pathology, 450(2), pp.187–94. 
McArthur, G.A. et al., 2014. Safety and efficacy of vemurafenib in BRAF(V600E) and 
BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, 
randomised, open-label study. The Lancet. Oncology, 15(3), pp.323–32.  
Merrell, K. et al., 2004. Analysis of low-abundance, low-molecular-weight serum proteins using 
mass spectrometry. Journal of biomolecular techniques : JBT, 15(4), pp.238–248. 
Michaud, G. et al., 2003. Analyzing antibody specificity with whole proteome microarrays. 
Nature Biotechnology, 21(12), pp.1509–12. 
Neller, M.A., López, J.A. & Schmidt, C.W., 2008. Antigens for cancer immunotherapy. 
Seminars in Immunology, 20, pp.286–295. 
Nicholaou, T. et al., 2006. Directions in the immune targeting of cancer: lessons learned from the 
cancer-testis Ag NY-ESO-1. Immunology and cell biology, 84(3), pp.303–17.  
Nicholaou, T. et al., 2009. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-
ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical 
cancer research : an official journal of the American Association for Cancer Research, 
15(6), pp.2166–2173. 
Nimmrich, I. et al., 2000. Seven genes that are differentially transcribed in colorectal tumor cell 
lines. Cancer letters, 160(1), pp.37–43.  
Nutt, S.L. et al., 2015. The generation of antibody-secreting plasma cells. Nature Reviews 
Immunology, 15(3), pp.160–171.  
    207 
O’Kane, S.L., O’Brien, J.K. & Cahill, D.J., 2011. Optimized Autoantibody Profiling on Protein 
Arrays. In U. Korf, ed. Methods in Molecular Biology. Methods in Molecular Biology. 
Humana Press, pp. 331–341. 
Odunsi, K. et al., 2003. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for 
immunotherapy in epithelial ovarian cancer. Cancer research, 63(18), pp.6076–83.  
Peled, N. et al., 2009. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy, 
1(1), pp.19–25. 
Perales, M.-A. et al., 2002. Strategies to overcome immune ignorance and tolerance. Seminars in 
cancer biology, 12(1), pp.63–71.  
Peyssonnaux, C. & Eychène, A., 2001. The Raf/MEK/ERK pathway: new concepts of activation. 
Biology of the cell / under the auspices of the European Cell Biology Organization, 93(1-2), 
pp.53–62.  
Predki, P.F., 2004. Functional protein microarrays: ripe for discovery. Current Opinion in 
Chemical Biology, 8(1), pp.8–13. 
Di Pucchio, T. et al., 2006. Immunization of stage IV melanoma patients with Melan-A/MART-
1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and 
monocyte/dendritic cell precursors. Cancer research, 66(9), pp.4943–51.  
Quackenbush, J., 2001. Computational Analysis of Microarray Data. Genetics, 2(June). 
Quoix, E. et al., 2011. Therapeutic vaccination with TG4010 and first-line chemotherapy in 
advanced non-small-cell lung cancer: A controlled phase 2B trial. The Lancet Oncology, 
12(12), pp.1125–1133.  
Reles, A. et al., 2001. Correlation of p53 mutations with resistance to platinum-based 
chemotherapy and shortened survival in ovarian cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research, 7(10), pp.2984–97.  
Restifo, N.P., Dudley, M.E. & Rosenberg, S.A., 2012. Adoptive immunotherapy for cancer: 
harnessing the T cell response. Nature reviews. Immunology, 12(4), pp.269–81. 
 208  
Rifai, N., Gillette, M.A. & Carr, S.A., 2006. Protein biomarker discovery and validation: the 
long and uncertain path to clinical utility. Nature Biotechnology, 24(8), pp.971–983. 
Risch, H.A., 1998. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning 
the role of androgens and progesterone. Journal of the National Cancer Institute, 90(23), 
pp.1774–86.  
Risinger, J.I. et al., 2007. Global expression analysis of cancer/testis genes in uterine cancers 
reveals a high incidence of BORIS expression. Clinical cancer research : an official journal 
of the American Association for Cancer Research, 13(6), pp.1713–9.  
Rodrigues, N.R. et al., 1990. p53 mutations in colorectal cancer. Proceedings of the National 
Academy of Sciences of the United States of America, 87(19), pp.7555–9.  
Rodriguez-Antona, C. & Ingelman-Sundberg, M., 2006. Cytochrome P450 pharmacogenetics 
and cancer. Oncogene, 25(11), pp.1679–91.  
Rodríguez-Paredes, M. & Esteller, M., 2011. Cancer epigenetics reaches mainstream oncology. 
Nature medicine, 17(3), pp.330–9.  
Roitt, I.M., Brostoff, J. & Male, D.K. eds., 2001. Immunology 6th editio., Mosby. 
Rosenberg, S.A. et al., 1998. Immunizing patients with metastatic melanoma using recombinant 
adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National 
Cancer Institute, 90(24), pp.1894–900.  
Rosenberg, S.A. et al., 1998. Immunologic and therapeutic evaluation of a synthetic peptide 
vaccine for the treatment of patients with metastatic melanoma. Nature medicine, 4(3), 
pp.321–7.  
Sadanandam, A. et al., 2013. A colorectal cancer classification system that associates cellular 
phenotype and responses to therapy. Nat Med, 19(5), pp.619–625. 
Safari Serufuri, J.-M., 2010. Development of computational methods for Custom protein arrays 
analysis . A case study on a 100  protein (“ CT100 ”) cancer / testis antigen array . 
    209 
Sanchez-Carbayo, M., 2011. Antibody Microarrays as Tools for Biomarker Discovery. In U. 
Korf, ed. Methods in Molecular Biology. Methods in Molecular Biology. Humana Press, pp. 
159–182. 
Sanz-García, E. et al., 2014. Prognosis and Therapeutic Implications for Emerging Colorectal 
Cancer Subtypes. Current Colorectal Cancer Reports, 10, pp.55–61.  
Sauer, R. et al., 2004. Preoperative versus postoperative chemoradiotherapy for rectal cancer. 
The New England journal of medicine, 351(17), pp.1731–40.  
Scanlan, M.J. et al., 2002. Cancer/testis antigens: an expanding family of targets for cancer 
immunotherapy. Immunological reviews, 188(3), pp.22–32.  
Scarcella, D.L. et al., 1999. Expression of MAGE and GAGE in high-grade brain tumors: a 
potential target for specific immunotherapy and diagnostic markers. Clinical cancer 
research : an official journal of the American Association for Cancer Research, 5(2), 
pp.335–41.  
Schlom, J., 2012. Therapeutic cancer vaccines: Current status and moving forward. Journal of 
the National Cancer Institute, 104, pp.599–613. 
Schwartzentruber, D.J. et al., 2011. gp100 peptide vaccine and interleukin-2 in patients with 
advanced melanoma. The New England journal of medicine, 364(22), pp.2119–27.  
Schweitzer, B., Predki, P. & Snyder, M., 2003. Microarrays to characterize protein interactions 
on a whole-proteome scale. Proteomics, 3(11), pp.2190–2199. 
Scott, A.M., Wolchok, J.D. & Old, L.J., 2012. Antibody therapy of cancer. Nature Reviews 
Cancer, 12(April), pp.278–287.  
Shiku, H. et al., 1977. Cell surface antigens of human malignant melanoma. III. Recognition of 
autoantibodies with unusual characteristics. The Journal of experimental medicine, 145, 
pp.784–789. 
Shin, S. et al., 2001. An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-
3 and -7. Biochemistry, 40(4), pp.1117–1123. 
 210  
Simpson, A.J.G. et al., 2005. Cancer/testis antigens, gametogenesis and cancer. Nature reviews. 
Cancer, 5(8), pp.615–25.  
Starzynska, T. et al., 1992. Prognostic significance of p53 overexpression in gastric and 
colorectal carcinoma. British journal of cancer, 66(3), pp.558–62.  
Stockert, E. et al., 1998. A survey of the humoral immune response of cancer patients to a panel 
of human tumor antigens. The Journal of experimental medicine, 187(8), pp.1349–54.  
Stubbs, R.S., Cannan, R.J. & Mitchell, A.W., 2001. Selective internal radiation therapy with 
yttrium-90 microspheres for extensive colorectal liver metastases. Journal of 
gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 
5(3), pp.294–302.  
Stubbs, R.S. & Wickremesekera, S.K., 2004. Selective internal radiation therapy (SIRT): a new 
modality for treating patients with colorectal liver metastases. HPB : the official journal of 
the International Hepato Pancreato Biliary Association, 6(3), pp.133–9.  
Sumimoto, H. et al., 2006. The BRAF-MAPK signaling pathway is essential for cancer-immune 
evasion in human melanoma cells. The Journal of experimental medicine, 203(7), pp.1651–
1656. 
Swana, H.S. et al., 1999. Tumor content of the antiapoptosis molecule survivin and recurrence of 
bladder cancer. The New England journal of medicine, 341(6), pp.452–3.  
Tabi, Z., 2009. Cancer Vaccines. In Y. Lu & R. I. Mahato, eds. Pharmaceutical Perspectives of 
Cancer Therapeutics. Springer US, pp. 365–397. 
Tamm, I. et al., 1998. IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis 
Induced by Fas (CD95), Bax, Caspases, and Anticancer Drugs. Cancer research, 58, 
pp.5315–5320. 
Tan, E.M., 2001. Autoantibodies as reporters identifying aberrant cellular mechanisms in 
tumorigenesis. Journal of Clinical Investigation, 108(10), pp.1411–1415. 
Tan, H.T. et al., 2009. Serum autoantibodies as biomarkers for early cancer detection. FEBS 
Journal, 276, pp.6880–6904. 
    211 
Tan, P. et al., 2014. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid 
leukemia and high-risk myelodysplastic syndrome. Blood cancer journal, 4(e170).  
Tartaglia, J. et al., 2001. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine, 
19(17-19), pp.2571–5. 
Terwilliger, T.C., Stuart, D. & Yokoyama, S., 2009. Lessons from Structural Genomics. Annu 
Rev Biophys, 38, pp.371–383. 
The Cancer Genome Atlas Reserach Network, 2013. Integrated genomic characterization of 
endometrial carcinoma. Nature, 497(53), pp.67–73.  
Thompson, C., 1995. Apoptosis in the pathogenesis and treatment of disease. Science, 
267(5203), pp.1456–1462.  
Thurner, B. et al., 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived 
dendritic cells expands specific cytotoxic T cells and induces regression of some metastases 
in advanced stage IV melanoma. The Journal of experimental medicine, 190(11), pp.1669–
78.  
Ueda, H. et al., 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to 
autoimmune disease. Nature, 423(6939), pp.506–511. 
Ulloa-Montoya, F. et al., 2013. Predictive gene signature in MAGE-A3 antigen-specific cancer 
immunotherapy. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology, 31(19), pp.2388–2395. 
Vanneman, M. & Dranoff, G., 2012. Combining immunotherapy and targeted therapies in cancer 
treatment. Nature Reviews \ Cancer, 12(April), pp.237–251. 
Vansteenkiste, J. et al., 2007. Final results of a multi-center, double-blind, randomized, placebo-
controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as 
adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol.25. 
ASCO Meeting Abstracts, 25(18), p.7554. 
Vigil, C., Martin-Santos, T. & Garcia-Manero, G., 2010. Safety and efficacy of azacitidine in 
myelodysplastic syndromes. Drug Design, Development and Therapy, pp.221–229.  
 212  
Vigneron, N. et al., 2013. Peptide database: T cell-defined tumor antigens. Cancer Immunity.  
Vivier, E. et al., 2012. Targeting natural killer cells and natural killer T cells in cancer. Nature 
Reviews Immunology, 12(4), pp.239–252.  
De Vries, T.J. et al., 1997. Heterogeneous expression of immunotherapy candidate proteins 
gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic 
lesions. Cancer research, 57(15), pp.3223–9.  
Wang, M. et al., 1997. Three-dimensional structure of NADPH – cytochrome P450 reductase : 
Prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA, 94(August), 
pp.8411–8416. 
Wang, X. et al., 2005. Autoantibody signatures in prostate cancer. The New England journal of 
medicine, 353(12), pp.1224–1235. 
Whitehurst, A.W., 2014. Cause and consequence of cancer/testis antigen activation in cancer. 
Annual review of pharmacology and toxicology, 54, pp.251–72. 
Widenmeyer, M. et al., 2012. Promiscuous survivin peptide induces robust CD4+ T-cell 
responses in the majority of vaccinated cancer patients. International journal of cancer. 
Journal international du cancer, 131(1), pp.140–9. 
De Wit, N.J.W. et al., 2002. Expression profiling of MMA-1a and splice variant MMA-1b: new 
cancer/testis antigens identified in human melanoma. International journal of cancer, 98(4), 
pp.547–53.  
Wolf-Yadlin, A., Sevecka, M. & MacBeath, G., 2009. Dissecting protein function and signaling 
using protein microarrays. Current Opinion in Chemical Biology, 13(4), pp.398–405. 
World Health Organization, 2002. National Cancer Control Programmes - Policies and 
managerial guidelines, 
Xiang, B. et al., 2013. Colorectal cancer immunotherapy. Discovery medicine, 15(84), pp.301–8.  
Xiang, R. et al., 2008. Oral DNA vaccines target the tumor vasculature and microenvironment 
and suppress tumor growth and metastasis. Immunological Reviews, 222, pp.117–128. 
    213 
Xu, Y.-W. et al., 2014. Autoantibodies as potential biomarkers for the early detection of 
esophageal squamous cell carcinoma. The American journal of gastroenterology, 109(1), 
pp.36–45.  
Yang, Y. et al., 1993. Construction of recombinant DNA by exonuclease recession. Nucleic 
Acids Research, 21(8), pp.1889–1893. 
Yuan, J. et al., 2011. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with 
clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the 
National Academy of Sciences of the United States of America, 108(40), pp.16723–8.  
Zhai, Y. et al., 1996. Antigen-specific tumor vaccines. Development and characterization of 
recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Journal of 
immunology (Baltimore, Md. : 1950), 156(2). 
Zhao, Y., Chapman, D.A.G. & Jones, I.M., 2003. Improving baculovirus recombination. Nucleic 
Acids Research, 31(2), pp.1–5. 
Zheng, J. et al., 2005. Strong repulsive forces between protein and oligo (ethylene glycol) self-
assembled monolayers: a molecular simulation study. Biophysical Journal, 89(1), pp.158–
66. 
Zhu, H. et al., 2000. Analysis of yeast protein kinases using protein chips. Nature Genetics, 
26(3), pp.283–9. 
Zhu, H. et al., 2001. Global analysis of protein activities using proteome chips. Science (New 
York, N.Y.), 293(5537), pp.2101–5. 
Zhu, X., Gerstein, M. & Snyder, M., 2006. ProCAT : a data analysis approach for protein 
microarrays. Genome Biology, 7(11), p.R110. 
Zou, W., 2006. Regulatory T cells, tumour immunity and immunotherapy. Nature reviews. 
Immunology, 6(April), pp.295–307. 
 
 
 
